0001641489-23-000070.txt : 20231109 0001641489-23-000070.hdr.sgml : 20231109 20231109163031 ACCESSION NUMBER: 0001641489-23-000070 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 70 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231109 DATE AS OF CHANGE: 20231109 FILER: COMPANY DATA: COMPANY CONFORMED NAME: vTv Therapeutics Inc. CENTRAL INDEX KEY: 0001641489 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473916571 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37524 FILM NUMBER: 231393066 BUSINESS ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 BUSINESS PHONE: 336-841-0300 MAIL ADDRESS: STREET 1: 3980 PREMIER DR STREET 2: SUITE 310 CITY: HIGH POINT STATE: NC ZIP: 27265 FORMER COMPANY: FORMER CONFORMED NAME: VTV Therapeutics Inc. DATE OF NAME CHANGE: 20150506 10-Q 1 vtvt-20230930.htm 10-Q vtvt-20230930
000164148912-312023Q3false0.500016414892023-01-012023-09-300001641489us-gaap:CommonClassAMember2023-11-09xbrli:shares0001641489us-gaap:CommonClassBMember2023-11-0900016414892023-09-30iso4217:USD00016414892022-12-310001641489us-gaap:CommonClassAMember2023-09-30iso4217:USDxbrli:shares0001641489us-gaap:CommonClassAMember2022-12-310001641489us-gaap:CommonClassBMember2022-12-310001641489us-gaap:CommonClassBMember2023-09-3000016414892023-07-012023-09-3000016414892022-07-012022-09-3000016414892022-01-012022-09-300001641489us-gaap:NonrelatedPartyMember2023-07-012023-09-300001641489us-gaap:NonrelatedPartyMember2022-07-012022-09-300001641489us-gaap:NonrelatedPartyMember2023-01-012023-09-300001641489us-gaap:NonrelatedPartyMember2022-01-012022-09-300001641489us-gaap:RelatedPartyMember2023-07-012023-09-300001641489us-gaap:RelatedPartyMember2022-07-012022-09-300001641489us-gaap:RelatedPartyMember2023-01-012023-09-300001641489us-gaap:RelatedPartyMember2022-01-012022-09-300001641489us-gaap:CommonClassAMember2023-07-012023-09-300001641489us-gaap:CommonClassAMember2022-07-012022-09-300001641489us-gaap:CommonClassAMember2023-01-012023-09-300001641489us-gaap:CommonClassAMember2022-01-012022-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2023-06-300001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-06-300001641489us-gaap:AdditionalPaidInCapitalMember2023-06-300001641489us-gaap:RetainedEarningsMember2023-06-3000016414892023-06-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2023-07-012023-09-300001641489us-gaap:RetainedEarningsMember2023-07-012023-09-300001641489us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2023-09-300001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2023-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2023-09-300001641489us-gaap:AdditionalPaidInCapitalMember2023-09-300001641489us-gaap:RetainedEarningsMember2023-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-06-300001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-06-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-06-300001641489us-gaap:ReceivablesFromStockholderMember2022-06-300001641489us-gaap:AdditionalPaidInCapitalMember2022-06-300001641489us-gaap:RetainedEarningsMember2022-06-3000016414892022-06-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-07-012022-09-300001641489us-gaap:RetainedEarningsMember2022-07-012022-09-300001641489us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-07-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:ReceivablesFromStockholderMember2022-07-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-09-300001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-09-300001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-09-300001641489us-gaap:ReceivablesFromStockholderMember2022-09-300001641489us-gaap:AdditionalPaidInCapitalMember2022-09-300001641489us-gaap:RetainedEarningsMember2022-09-3000016414892022-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-12-310001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2022-12-310001641489us-gaap:AdditionalPaidInCapitalMember2022-12-310001641489us-gaap:RetainedEarningsMember2022-12-310001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2023-01-012023-09-300001641489us-gaap:RetainedEarningsMember2023-01-012023-09-300001641489us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2021-12-310001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2021-12-310001641489us-gaap:CommonStockMemberus-gaap:CommonClassBMember2021-12-310001641489us-gaap:ReceivablesFromStockholderMember2021-12-310001641489us-gaap:AdditionalPaidInCapitalMember2021-12-310001641489us-gaap:RetainedEarningsMember2021-12-3100016414892021-12-310001641489us-gaap:NoncontrollingInterestMembervtvt:RedeemableNoncontrollingInterestsMember2022-01-012022-09-300001641489us-gaap:RetainedEarningsMember2022-01-012022-09-300001641489us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:CommonStockMember2022-01-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001641489us-gaap:CommonClassAMemberus-gaap:ReceivablesFromStockholderMember2022-01-012022-09-300001641489vtvt:CinRxMember2023-01-012023-09-300001641489vtvt:CinRxMember2022-01-012022-09-300001641489vtvt:VTvLLCMember2023-01-012023-09-30xbrli:pure0001641489vtvt:VTvLLCMemberus-gaap:CommonClassBMember2023-09-300001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMember2023-01-012023-09-300001641489us-gaap:CommonClassAMembervtvt:LPCPurchaseAgreementMember2023-09-300001641489us-gaap:SalesRevenueNetMembervtvt:OneCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001641489vtvt:G42InvestmentsMember2022-05-312022-05-310001641489vtvt:G42InvestmentsMember2022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-05-312022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-05-310001641489vtvt:G42InvestmentsMember2023-02-282023-02-280001641489vtvt:G42InvestmentsMember2023-02-280001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:CognaMember2022-05-312022-05-310001641489us-gaap:CommonClassAMembervtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2022-05-310001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2023-09-300001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2023-01-012023-09-300001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2023-07-012023-09-300001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2023-02-282023-02-280001641489vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMembervtvt:G42InvestmentsMember2023-02-280001641489us-gaap:CollaborativeArrangementMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2021-01-140001641489us-gaap:CollaborativeArrangementMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMembervtvt:PhaseTwoMultiRegionalClinicalTrialMembervtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember2023-01-012023-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMembervtvt:JDRFInternationalMembervtvt:PhaseTwoMultiRegionalClinicalTrialMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMembervtvt:JDRFInternationalMembervtvt:PhaseTwoMultiRegionalClinicalTrialMember2023-01-012023-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMember2020-12-112020-12-110001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMember2020-12-110001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMembervtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember2020-01-012020-12-310001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMember2022-01-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMember2023-07-012023-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMember2023-01-012023-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:AnterisBioIncMember2022-07-012022-09-300001641489us-gaap:CollaborativeArrangementMembervtvt:JDRFInternationalMember2017-08-012017-08-310001641489us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001641489us-gaap:EmployeeStockOptionMember2023-09-300001641489us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001641489us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2023-07-012023-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-09-300001641489us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2023-09-300001641489vtvt:ReneoPharmaceuticalsIncMemberus-gaap:CommonStockMember2023-09-300001641489vtvt:ReneoPharmaceuticalsIncMemberus-gaap:CommonStockMember2022-12-310001641489us-gaap:PreferredStockMembervtvt:AnterisBioIncMember2023-09-300001641489us-gaap:PreferredStockMembervtvt:AnterisBioIncMember2022-12-310001641489vtvt:ReneoPharmaceuticalsIncMember2023-07-012023-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2023-01-012023-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2022-07-012022-09-300001641489vtvt:ReneoPharmaceuticalsIncMember2022-01-012022-09-300001641489vtvt:ReneoPharmaceuticalsIncMemberus-gaap:SubsequentEventMember2023-10-302023-10-300001641489vtvt:NovoLicenseAgreementMembervtvt:TypeOneDiabetesMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMember2007-02-280001641489vtvt:TypeTwoDiabetesMembervtvt:NovoLicenseAgreementMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembersrt:MaximumMember2007-02-280001641489vtvt:OtherIndicationMembervtvt:NovoLicenseAgreementMembervtvt:DevelopmentalAndRegulatoryMilestonePaymentMembersrt:MaximumMember2007-02-280001641489vtvt:NovoLicenseAgreementMembervtvt:SalesBasedMilestonesPaymentMember2007-02-280001641489vtvt:NovoLicenseAgreementMembervtvt:SatisfactionOfMilestonePaymentMember2021-12-3100016414892022-11-300001641489us-gaap:CommonClassAMembervtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember2023-01-012023-09-300001641489us-gaap:CommonClassAMember2020-12-310001641489us-gaap:CommonClassAMember2021-05-040001641489us-gaap:CommonClassAMember2021-05-042021-05-040001641489us-gaap:CommonStockMember2020-12-310001641489us-gaap:CommonStockMember2021-05-0400016414892020-12-3100016414892021-05-040001641489vtvt:CinRxInvestmentMember2022-07-222022-07-220001641489vtvt:CinRxInvestmentMember2022-07-220001641489us-gaap:CommonClassAMembervtvt:CinRxInvestmentMember2022-07-222022-07-220001641489us-gaap:CommonClassAMembervtvt:CinRxInvestmentMember2022-07-220001641489vtvt:CinRxInvestmentMemberus-gaap:CommonStockMember2022-07-220001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2020-04-300001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2020-04-012020-04-300001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2021-01-142021-01-140001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2021-06-252021-06-250001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2023-07-012023-09-300001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2022-01-012022-09-300001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2022-07-012022-09-300001641489us-gaap:CommonClassAMembervtvt:CantorFitzgeraldMembervtvt:AtTheMarketOfferingMember2023-01-012023-09-300001641489us-gaap:CommonClassAMembervtvt:LPCPurchaseAgreementMembersrt:MaximumMember2020-11-242020-11-240001641489us-gaap:CommonClassAMembervtvt:LPCPurchaseAgreementMember2023-01-012023-09-300001641489us-gaap:CommonClassAMembervtvt:LPCPurchaseAgreementMember2022-07-012022-09-300001641489us-gaap:CommonClassAMembervtvt:LPCPurchaseAgreementMember2022-01-012022-09-300001641489us-gaap:CommonClassAMembervtvt:LPCPurchaseAgreementMember2023-07-012023-09-300001641489us-gaap:RelatedPartyMembervtvt:MacAndrewsAndForbesIncorporatedMemberus-gaap:CommonClassBMember2023-09-300001641489us-gaap:RelatedPartyMemberus-gaap:CommonClassAMembervtvt:MacAndrewsAndForbesIncorporatedMember2023-09-300001641489us-gaap:RelatedPartyMembervtvt:MacAndrewsAndForbesIncorporatedMember2023-01-012023-09-300001641489us-gaap:RelatedPartyMemberus-gaap:CommonClassAMembervtvt:G42InvestmentsMember2022-05-312022-05-310001641489us-gaap:RelatedPartyMemberus-gaap:CommonClassAMembervtvt:G42InvestmentsMember2022-05-310001641489us-gaap:RelatedPartyMembervtvt:G42InvestmentsMember2022-05-312022-05-310001641489us-gaap:RelatedPartyMembervtvt:G42InvestmentsMember2022-05-310001641489us-gaap:RelatedPartyMembervtvt:G42InvestmentsMember2023-02-282023-02-280001641489us-gaap:RelatedPartyMembervtvt:G42InvestmentsMember2023-02-280001641489us-gaap:RelatedPartyMembervtvt:MasterServiceAgreementMember2022-10-100001641489us-gaap:RelatedPartyMemberus-gaap:CommonClassAMembervtvt:MasterServiceAgreementMembervtvt:CinRxPharmaLLCMember2023-09-300001641489vtvt:MFTTPHoldingsLLCMember2023-01-012023-09-300001641489us-gaap:CommonClassBMember2023-01-012023-09-300001641489us-gaap:CommonClassBMember2022-01-012022-09-300001641489us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001641489us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001641489us-gaap:WarrantMember2023-01-012023-09-300001641489us-gaap:WarrantMember2022-01-012022-09-300001641489us-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueInputsLevel1Membervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueInputsLevel2Membervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001641489us-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel1Membervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel2Membervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel3Membervtvt:WarrantLiabilityRelatedPartyMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001641489us-gaap:FairValueInputsLevel3Member2022-12-310001641489us-gaap:FairValueInputsLevel3Member2023-01-012023-09-300001641489us-gaap:FairValueInputsLevel3Member2023-09-300001641489us-gaap:FairValueInputsLevel3Member2021-12-310001641489us-gaap:FairValueInputsLevel3Member2022-01-012022-09-300001641489us-gaap:FairValueInputsLevel3Member2022-09-300001641489srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMember2023-09-300001641489us-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMembersrt:MaximumMember2023-09-300001641489srt:WeightedAverageMemberus-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMember2023-09-300001641489srt:MinimumMemberus-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMember2022-12-310001641489us-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMembersrt:MaximumMember2022-12-310001641489srt:WeightedAverageMemberus-gaap:MeasurementInputPriceVolatilityMembervtvt:LetterAgreementWarrantsMember2022-12-310001641489srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMembervtvt:LetterAgreementWarrantsMember2023-09-300001641489us-gaap:MeasurementInputRiskFreeInterestRateMembervtvt:LetterAgreementWarrantsMembersrt:MaximumMember2023-09-300001641489srt:WeightedAverageMemberus-gaap:MeasurementInputRiskFreeInterestRateMembervtvt:LetterAgreementWarrantsMember2023-09-300001641489srt:MinimumMemberus-gaap:MeasurementInputRiskFreeInterestRateMembervtvt:LetterAgreementWarrantsMember2022-12-310001641489us-gaap:MeasurementInputRiskFreeInterestRateMembervtvt:LetterAgreementWarrantsMembersrt:MaximumMember2022-12-310001641489srt:WeightedAverageMemberus-gaap:MeasurementInputRiskFreeInterestRateMembervtvt:LetterAgreementWarrantsMember2022-12-310001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputPriceVolatilityMember2023-09-300001641489vtvt:CinRxWarrantsMember2023-09-300001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-09-300001641489vtvt:CinRxWarrantsMemberus-gaap:MeasurementInputExpectedDividendRateMember2023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________
FORM 10-Q
_____________________________
(Mark One)
xQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2023
Or
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from              to              
Commission file number: 001-37524
_____________________________
vTv Therapeutics Inc.
(Exact name of registrant as specified in its charter)
_____________________________
Delaware47-3916571
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
3980 Premier Dr, Suite 310
High Point, NC
27265
(Address of principal executive offices)(Zip Code)
(336) 841-0300
(Registrant’s telephone number, including area code)
(Former name, former address and former fiscal year, if changed since last report)
_____________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Class A common stock, par value $0.01 per shareVTVT
NASDAQ Capital Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated fileroAccelerated filero
Non-accelerated fileroSmaller reporting companyx
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x
Class of Stock
Shares Outstanding as of November 9, 2023
Class A common stock, par value $0.01 per share81,483,600 
Class B common stock, par value $0.01 per share23,093,860 

vTv THERAPEUTICS INC. AND SUBSIDIARIES
INDEX TO FORM 10-Q
FOR THE QUARTER ENDED SEPTEMBER 30, 2023
PAGE
NUMBER
 
2
PART I – FINANCIAL INFORMATION
The financial statements and other disclosures contained in this report include those of vTv Therapeutics Inc. (“we”, the “Company” or the “Registrant”), which is the registrant, and those of vTv Therapeutics LLC (“vTv LLC”), which is the principal operating subsidiary of the Registrant. Unless the context suggests otherwise, references in this Quarterly Report on Form 10-Q to the “Company”, “we”, “us” and “our” refer to vTv Therapeutics Inc. and its consolidated subsidiaries.
3
vTv Therapeutics Inc.
Condensed Consolidated Balance Sheets
(in thousands, except number of shares and per share data)
September 30,
2023		December 31,
2022
(Unaudited)
Assets
Current assets:
Cash and cash equivalents$8,238 $12,126 
Accounts receivable— 173 
G42 Promissory Note receivable— 12,243 
Prepaid expenses and other current assets1,872 2,537 
Current deposits15 15 
Total current assets10,125 27,094 
Property and equipment, net140 207 
Operating lease right-of-use assets272 349 
Long-term investments4,387 5,588 
Total assets$14,924 $33,238 
Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit
Current liabilities:
Accounts payable and accrued expenses$9,620 $7,313 
Current portion of operating lease liabilities165 154 
Current portion of contract liabilities17 17 
Current portion of notes payable473 224 
Total current liabilities10,275 7,708 
Contract liabilities, net of current portion18,669 18,669 
Operating lease liabilities, net of current portion213 338 
Warrant liability, related party278 684 
Total liabilities29,435 27,399 
Commitments and contingencies
Redeemable noncontrolling interest10,722 16,579 
Stockholders’ deficit:
Class A common stock, $0.01 par value; 200,000,000 shares authorized, 81,483,600 shares outstanding as of September 30, 2023 and December 31, 2022
815 815 
Class B common stock, $0.01 par value; 100,000,000 shares authorized, and 23,093,860 outstanding as of September 30, 2023 and December 31, 2022
232 232 
Additional paid-in capital254,912 253,737 
Accumulated deficit(281,192)(265,524)
Total stockholders’ deficit attributable to vTv Therapeutics Inc.(25,233)(10,740)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit$14,924 $33,238 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
4
vTv Therapeutics Inc.
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except number of shares and per share data)
Three Months Ended
September 30,		Nine Months Ended
September 30,
2023202220232022
Revenue$— $— $— $2,009 
Operating expenses:
Research and development2,824 3,055 11,457 8,393 
General and administrative2,544 2,634 9,338 9,813 
Total operating expenses5,368 5,689 20,795 18,206 
Operating loss(5,368)(5,689)(20,795)(16,197)
Other (expense) income, net(3,640)403 (1,514)(2,998)
Other income (expense) – related party341 (324)406 221 
Interest income131 150 384 200 
Interest expense(4)(8)(6)(9)
Loss before income taxes and noncontrolling interest(8,540)(5,468)(21,525)(18,783)
Income tax provision— — — 200 
Net loss before noncontrolling interest(8,540)(5,468)(21,525)(18,983)
Less: net loss attributable to noncontrolling interest(1,886)(1,207)(4,753)(4,564)
Net loss attributable to vTv Therapeutics Inc.$(6,654)$(4,261)$(16,772)$(14,419)
Net loss attributable to vTv Therapeutics Inc. common shareholders$(6,654)$(4,261)$(16,772)$(14,419)
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.08)$(0.05)$(0.21)$(0.20)
Weighted average number of vTv Therapeutics Inc. Class A common stock, basic and diluted81,483,600 80,490,121 81,483,600 72,649,531 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
5
vTv Therapeutics Inc.
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited
(in thousands, except number of shares)

For the three months ended September 30, 2023
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountSharesAmountAdditional
Paid-in
Capital		Accumulated DeficitTotal Stockholders' Deficit
Balances at June 30, 2023$18,879 81,483,600 $815 23,093,860 $232 $254,479 $(280,809)$(25,283)
Net loss(1,886)— — — — — (6,654)(6,654)
Share-based compensation— — — — — 433 — 433 
Change in redemption value of noncontrolling interest(6,271)— — — — — 6,271 6,271 
Balances at September 30, 2023$10,722 81,483,600 $815 23,093,860 $232 $254,912 $(281,192)$(25,233)


For the three months ended September 30, 2022
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountSharesAmountNote Receivable for Common StockAdditional
Paid-in
Capital		Accumulated DeficitTotal Stockholders' Deficit
Balances at June 30, 2022$15,916 77,329,051 $773 23,093,860 $232 $— $243,772 $(253,303)$(8,526)
Net loss(1,207)— — — — — — (4,261)(4,261)
Share-based compensation— — — — — — 338 — 338 
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs— 4,154,549 42 — — (4,000)9,336 — 5,378 
Change in redemption value of noncontrolling interest9,498 — — — — — — (9,498)(9,498)
Balances at September 30, 2022$24,207 81,483,600 $815 23,093,860 $232 $(4,000)$253,446 $(267,062)$(16,569)
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.

6
vTv Therapeutics Inc.
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit - Unaudited
(in thousands, except number of shares)
For the nine months ended September 30, 2023
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountShares AmountAdditional
Paid-in
Capital		Accumulated Deficit Total Stockholders' Deficit
Balances at December 31, 2022$16,579 81,483,600 $815 23,093,860 $232 $253,737 $(265,524)$(10,740)
Net loss(4,753)— — — — — (16,772)(16,772)
Share-based compensation— — — — — 1,175 — 1,175 
Change in redemption value of noncontrolling interest(1,104)— — — — — 1,104 1,104 
Balances at September 30, 2023$10,722 81,483,600 $815 23,093,860 $232 $254,912 $(281,192)$(25,233)

For the nine months ended September 30, 2022
Class A Common StockClass B Common Stock
Redeemable
Noncontrolling
Interest		SharesAmountShares AmountNote Receivable for Common StockAdditional
Paid-in
Capital		Accumulated Deficit Total Stockholders' Deficit
Balances at December 31, 2021$24,962 66,942,777 $669 23,093,860 $232 $— $238,193 $(248,834)$(9,740)
Net loss(4,564)— — — — — — (14,419)(14,419)
Share-based compensation— — — — — — 981 — 981 
Issuance of Class A common stock to collaboration partner, net of offering costs— 10,386,274 104 — — — 4,936 — 5,040 
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs— 4,154,549 42 — — (4,000)9,336 — 5,378 
Change in redemption value of noncontrolling interest3,809 — — — — — — (3,809)(3,809)
Balances at September 30, 2022$24,207 81,483,600 $815 23,093,860 $232 $(4,000)$253,446 $(267,062)$(16,569)
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
7
vTv Therapeutics Inc.
Condensed Consolidated Statements of Cash Flows - Unaudited
(in thousands)
Nine Months Ended September 30,
20232022
Cash flows from operating activities:
Net loss before noncontrolling interest$(21,525)$(18,983)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:
Depreciation expense67 69 
Loss from G42 Promissory Note early redemption313 — 
Non-cash interest income (100)(200)
Interest expense— 9 
Share-based compensation expense1,175 981 
Change in fair value of investments(3,044)2,998 
Impairment of investments in Anteris Bio, Inc.4,245 — 
Change in fair value of warrants, related party(406)(221)
Changes in assets and liabilities:
Accounts receivable173 — 
Prepaid expenses and other assets665 853 
Accounts payable and accrued expenses2,270 (1,417)
Contract liabilities— 6,769 
Net cash used in operating activities(16,167)(9,142)
Cash flows from investing activities:
Purchases of property and equipment— (21)
Net cash used in investing activities— (21)
Cash flows from financing activities:
Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner12,030 — 
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs— 5,040 
Proceeds from sale of Class A common stock and warrants, net of offering costs— 5,746 
Proceeds from debt issuance566 776 
Repayment of notes payable(317)(475)
Net cash provided by financing activities12,279 11,087 
Net (decrease) increase in cash and cash equivalents(3,888)1,924 
Total cash and cash equivalents, beginning of period12,126 13,415 
Total cash and cash equivalents, end of period$8,238 $15,339 
Non-cash activities:
Change in redemption value of noncontrolling interest$(1,104)$3,809 
Notes receivable recorded at fair value from collaboration partner— 11,891 
Notes receivable for common stock from CinRx purchase agreement$— $4,000 
The accompanying notes are an integral part of the unaudited condensed consolidated financial statements.
8
vTv Therapeutics Inc.
Notes to Condensed Consolidated Financial Statements – Unaudited
(dollar amounts are in thousands, unless otherwise noted)
Note 1: Description of Business, Basis of Presentation and Going Concern
Description of Business
vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.
Principles of Consolidation
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. Various holders own nonvoting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 77.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). In addition, vTv Therapeutics Inc. also entered into the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “ATM Offering”), the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.
Going Concern and Liquidity
To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September 30, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September 30, 2023, the Company had an accumulated deficit of $281.2 million and has generated net losses in each year of its existence.
As of September 30, 2023, the Company’s liquidity sources included cash and cash equivalents of $8.2 million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. To meet our future funding requirements into the third quarter of 2024, including
9
funding the ongoing and future clinical trials of cadisegliatin (TTP399), we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs.
The Company may also use its remaining availability of $37.3 million under its Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company’s Class A common stock and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock. See Note 9 for further details.
If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. As such, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.
Note 2: Summary of Significant Accounting Policies
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
10
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.
One hundred percent (100%) of the revenue earned during the nine months ended September 30, 2022 was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September 30, 2023.
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.
Research and Development
Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs
11
of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements
Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.

Note 3: Collaboration Agreements
G42 Purchase Agreement and Cogna Collaborative and License Agreement
The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”) on May 31, 2022, pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). As part of the G42 Purchase Agreement, G42 Investments nominated a director as appointee and the Company’s board of directors approved appointing the new director to the Company’s board. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024, (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for cadisegliatin (TTP399), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.
Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin
12
(TTP399) as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin (TTP399) in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin (TTP399) in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin (TTP399). Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin (TTP399) needed to conduct the trials.
Under the Cogna Agreement, Cogna has the right to develop and commercialize cadisegliatin (TTP399) in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin (TTP399) for commercial sale under terms to be agreed upon by the parties at a later date.
Separately, the Company will conduct its clinical trials for cadisegliatin (TTP399) outside of the Partner Territory at its own cost. The results of each party’s clinical trials will be combined by the Company to seek FDA approval in the United States for cadisegliatin (TTP399). On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.
The G42 Purchase Agreement also provides for, following the receipt of FDA approval of cadisegliatin (TTP399), at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the FDA approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA approval will be granted or as to the timing thereof.
Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin (TTP399) for a period of at least ten years after the first commercial sale of cadisegliatin (TTP399) in the Partner Territory.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this quarterly report on Form 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date.
A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.
The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin (TTP399), and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete R&D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.
By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of September 30, 2023, the clinical trials had not
13
commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September 30, 2023.
The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin (TTP399) is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September 30, 2023.
On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 Receivables (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September 30, 2023.
Huadong License Agreement
The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a nonexclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory.
On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the “First Huadong Amendment”) which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.
Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.
The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on a joint development committee (the “JDC”), and (iv) other obligations considered to be immaterial in nature.
The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the nine months ended
14
September 30, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the nine months ended September 30, 2023.
A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September 30, 2023, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September 30, 2023 was immaterial. An immaterial amount of revenue for this performance obligation was recognized during the nine months ended September 30, 2022. No revenue for this performance obligation has been recognized during the nine months ended September 30, 2023.
Anteris License Agreement
On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (“Anteris”) (the “Anteris License Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company’s Nrf2 activator, HPP971.
Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $2.0 million. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0 million. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.
Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the $2.0 million initial license payment as well as the fair value of the equity interest received in Anteris of $4.2 million. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. No revenue was recognized related to the Anteris License Agreement during the three and nine months ended September 30, 2023 and 2022.
On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement. Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023. The Company has begun the process of winding up the license, including obtaining all regulatory, manufacturing and other records generated by Anteris during the term of the Anteris License Agreement.
On October 16, 2023, the Company received a Section228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). (See Note 14).
Contract Liabilities
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
September 30, 2023December 31, 2022
Current portion of contract liabilities$17 $17 
Contract liabilities, net of current portion18,669 18,669 
Total contract liabilities$18,686 $18,686 
Note 4: Share-Based Compensation
The Company has issued nonqualified stock option awards to management, other key employees, consultants, and nonemployee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September 30, 2023, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.8 million, which is expected to be
15
recognized over a weighted average period of 2.2 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022 was $0.76 and $0.68 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September 30, 2023 was immaterial.
The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2023:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 20228,418,571 $2.17 
Granted1,176,868 0.87 
Forfeited(50,000)1.29 
Awards outstanding at September 30, 20239,545,439 $2.01 
Options exercisable at September 30, 20235,018,072 $3.04 
Weighted average remaining contractual term6.6 Years
Options vested and expected to vest at September 30, 20238,188,444 $2.21 
Weighted average remaining contractual term7.5 Years
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$113 $109 $316 $289 
General and administrative320 229 859 692 
Total share-based compensation expense$433 $338 $1,175 $981 
Note 5: Investments
In connection with the Reneo Pharmaceuticals, Inc. (“Reneo”) and Anteris License Agreements, the Company received equity ownership interests of less than 20% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company’s Condensed Consolidated Balance Sheets.
Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss.
The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.
The Company’s investments consist of the following:
September 30, 2023December 31, 2022
Equity investment with readily determinable fair value:
Reneo common stock$4,387 $1,343 
Equity investment without readily determinable fair values assessed under the measurement alternative:
Anteris preferred stock— 4,245 
Total$4,387 $5,588 
The Company recognized an unrealized gain on its investment in Reneo of $0.6 million and $3.0 million for the three and nine months ended September 30, 2023, respectively. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September 30, 2022,
16
respectively. These adjustments were recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
On October 16, 2023, the Company received a Section228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $4.2 million impairment charge during the three and nine months ended September 30, 2023.
On October 30, 2023, the Company entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $4.4 million.
Note 6: Commitments and Contingencies
Legal Matters
From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.
Novo Nordisk
In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin (TTP399). This agreement was amended in May 2019 to create milestone payments applicable to certain specific and nonspecific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments payable totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for cadisegliatin (TTP399) under this agreement.
Note 7: Leases
In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities of $0.1 million. Further, the second amendment to the lease does not include any material residual value guarantee or restrictive covenants.
At each of September 30, 2023 and December 31, 2022, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At September 30, 2023 and December 31, 2022, the weighted average remaining lease terms for the operating leases held by the Company were 2.2 years and 2.9 years, respectively.
17
Maturities of lease liabilities for the Company’s operating leases as of September 30, 2023 were as follows (in thousands):
2023 (remaining three months)$48 
2024194 
2025177 
2026— 
2027— 
Thereafter— 
Total lease payments419 
Less: imputed interest(41)
Present value of lease liabilities$378 
Operating lease cost and the related operating cash flows for the nine months ended September 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively.
Note 8: Redeemable Noncontrolling Interest
The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September 30, 2023 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.
The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2023 and December 31, 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $10.7 million and $16.6 million, respectively.
Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Net loss attributable to vTv Therapeutics Inc. common shareholders$(6,654)$(4,261)$(16,772)$(14,419)
Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances1,592 (1,174)4,212 (103)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest$(5,062)$(5,435)$(12,560)$(14,522)
Note 9: Stockholders’ Deficit
On May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.
18
G42 Investments Transaction
On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
CinPax and CinRx Transaction
On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement provides CinPax the right to nominate a director to be approved to sit on the Company’s Board of Directors and a board observer, which was subsequently approved by the Company’s board.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this quarterly report on Form 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date.
The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of common stock at an initial exercise of price of approximately $0.72 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)
The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (TTP399) (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.
Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)
The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.
ATM Offering
In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as
19
defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3.
On January 14, 2021 and June 25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of $5.5 million and $50.0 million, respectively.
During the three and nine months ended September 30, 2023 and 2022, the Company did not sell any shares under the ATM Offering.
Lincoln Park Capital Transaction
On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park pursuant to the LPC Purchase Agreement. During the three and nine months ended September 30, 2023 and 2022, the Company did not sell any shares under the LPC Purchase Agreement.
Note 10: Related-Party Transactions
MacAndrews & Forbes Incorporated
MacAndrews directly or indirectly controls 23,084,267 shares of Class B common stock. Further, as of September 30, 2023, MacAndrews directly or indirectly holds 36,519,212 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 57.0% of the combined voting power of the Company’s outstanding common stock.
The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:
Letter Agreements
The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock.
The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital.
Exchange Agreement
Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September 30, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.
Tax Receivable Agreement
The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that
20
the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2023.
Investor Rights Agreement
The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.
G42 Investments
On May 31, 2022, the Company entered into a common stock purchase agreement with G42 Investments pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid on May 31, 2023 (the “G42 Promissory Note”). As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors appointed the new director to the Company’s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $12.0 million from G42 Investments, which represented a 3.75% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
CinRx Pharma, LLC
Master Services Agreement
On July 22, 2022, the Company entered into the CinRx MSA with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company’s Class A common stock.
Note 11: Income Taxes
The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and nine months ended September 30, 2023. The Company’s income tax provision for the nine months ended September 30, 2022 was $0.2 million representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September 30, 2022.
Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September 30, 2023 is due to the valuation allowance against the Company’s expected net operating losses.
As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which
21
would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2023.
Note 12: Net Loss per Share
Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Numerator:
Net loss$(8,540)$(5,468)$(21,525)$(18,983)
Less: Net loss attributable to noncontrolling interests(1,886)(1,207)(4,753)(4,564)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted(6,654)(4,261)(16,772)(14,419)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted81,483,600 80,490,121 81,483,600 72,649,531 
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.08)$(0.05)$(0.21)$(0.20)
Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:
September 30, 2023September 30, 2022
Class B common stock (1)
23,093,860 23,093,860 
Common stock options granted under the Plan9,545,439 7,718,944 
Common stock warrants3,214,503 3,214,503 
Total35,853,802 34,027,307 
__________________________
(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.
Note 13: Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.
The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant
22
judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2023 and December 31, 2022 (in thousands):
Balance at September 30, 2023Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$4,387 $4,387 $— $— 
Total$4,387 $4,387 $— $— 
Liabilities:
Warrant liability, related party (1)
$278 $— $— $278 
Total$278 $— $— $278 
Balance at December 31, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,343 $1,343 $— $— 
Total$1,343 $1,343 $— $— 
Liabilities:
Warrant liability, related party (1)
$684 $— $— $684 
Total$684 $— $— $684 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
Changes in Level 3 instruments for the three months ended September 30,
Balance at January 1Net Change in
fair value included in
earnings		Purchases /
Issuance		Sales /
Repurchases		Balance at September 30,
2023
Warrant liability, related party$684 $(406)$— $— $278 
Total$684 $(406)$— $— $278 
2022
Warrant liability, related party$1,262 $(221)$368 $— $1,409 
Total$1,262 $(221)$368 $— $1,409 
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income – related party in the Company’s Condensed Consolidated Statements of Operations.
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility
23
of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2023 and December 31, 2022 were:
September 30, 2023December 31, 2022
RangeWeighted AverageRangeWeighted Average
Expected volatility
68.37% - 77.01%
76.06%
76.94% - 85.88%
82.17%
Risk-free interest rate
4.78% - 5.38%
4.88%
4.11% - 4.43%
4.19%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2023 were:
Expected volatility 82.38 %
Expected life of options in years3.75
Risk-free interest rate4.73 %
Expected dividend yield— %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.
Note 14: Subsequent Events
On October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”) (See Note 5).
On October 30, 2023, vTv LLC, entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with Reneo pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million, which was received by vTv LLC on October 30, 2023. vTv LLC had acquired the Reneo stock in connection with the December 21, 2017 License Agreement between vTv LLC and Reneo, which remains in effect.
24
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Cautionary Note Regarding Forward Looking Statements
In addition to historical financial information, this Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the federal securities laws regarding, among other things, our intentions, plans, estimates, assumptions, predictions and beliefs. Although we believe that these forward-looking statements are based upon reasonable assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances, our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to these differences include those discussed below and elsewhere in this report under “Part II, Other Information—Item 1A, Risk Factors” and under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K. Forward-looking statements include information concerning our possible or assumed future results of operations, business strategies and operations, financing plans, potential growth opportunities, potential market opportunities, potential results of our drug development efforts or trials, and the effects of competition. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “anticipates,” “believes,” “could,” “seeks,” “estimates,” “expects,” “intends,” “may,” “plans,” “potential,” “predicts,” “projects,” “should,” “will,” “would” or similar expressions and the negatives of those terms. Given the numerous uncertainties and factors to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, you should not place undue reliance on these forward-looking statements and understand that these statements are not guarantees of performance or results. Also, forward-looking statements represent our management’s plans, estimates, assumptions and beliefs only as of the date of this report. Except as required by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.

Company Overview
We are a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients. We have an innovative pipeline of first-in-class small molecule clinical and preclinical drug candidates. Our lead program is cadisegliatin (TTP399), an orally administered, small molecule, liver-selective glucokinase activator (“GKA”) as an adjunctive therapy to insulin for the treatment of type 1 diabetes (“T1D”).
Recent Developments

On September 6, 2023, the Board approved, and recommended that the stockholders of the Company entitled to vote thereon, approve, via written consent, the Amendment to the Certificate of Incorporation to effect a reverse stock split of the issued and outstanding Class A common stock and Class B common stock, by a ratio of any whole number in the range of 1-for-10 to 1-for-40 (the “Reverse Stock Split”), with such ratio to be determined at the discretion of the Board and with such action to be effected at such time and date, if at all, as determined by the Board on or prior to December 31, 2023. On September 13, 2023, the holders of a majority of the voting power of the Company’s issued and outstanding capital stock entitled to vote thereon (the “Consenting Stockholders”) approved the Reverse Stock Split by means of a written consent. The same ratio will be used to effect a reverse stock split of both the Class A common stock and the Class B common stock. The Reverse Stock Split will not change the number of authorized shares of Class A common stock or Class B common stock.

The Board has not yet determined the date on which the reverse stock split will occur or the ratio.
25
Our Product Pipeline
The following table summarizes our drug candidates, their partnership status and their respective stages of development:
Pipeline slide for 10-K 10-Q proxy_FINAL 11-02-2023.jpg
Our Type 1 Diabetes Program – Cadisegliatin (TTP399)
The Company has alignment with the FDA on trial designs that will support an efficient regulatory pathway to support registration of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes consistent with the breakthrough therapy designation granted by the FDA and expects to initiate studies as soon as possible. The FDA and the Company have agreed on the primary endpoint for the studies as the reduction in the number of hypoglycemic events between placebo and cadisegliatin (TTP399) treated groups.
In October 2021, we announced positive results of a mechanistic study of cadisegliatin (TTP399) in patients with T1D. The study demonstrated that patients with T1D taking cadisegliatin (TTP399) experienced no increase in ketone levels relative to placebo during a period of acute insulin withdrawal, indicating no increased risk of ketoacidosis. Consistent with previous clinical studies, improved fasting plasma glucose levels and fewer hypoglycemic events were observed in the cadisegliatin (TTP399) treated group during the week of treatment prior to the insulin withdrawal test. The results of the mechanistic study provided additional evidence to support the idea that treatment with cadisegliatin (TTP399) will not increase the risk of diabetic ketoacidosis (“DKA”) in patients with T1D. The data demonstrate that in contrast to agents such as SGLT2 inhibitors and GLP-1RAs, cadisegliatin (TTP399) does not increase the risk of ketoacidosis when used as an adjunctive therapy to insulin in individuals with T1D. Moreover, these findings support prior studies that demonstrate that cadisegliatin (TTP399) improves glucose control and reduces hypoglycemia and suggests a protective effect of cadisegliatin (TTP399) against acidosis in people with T1D. Full study results were published in the Diabetes Obesity and Metabolism journal in conjunction with the 82nd American Diabetes Association Scientific Sessions on June 6, 2022.
In April 2021, we announced that the FDA granted Breakthrough Therapy Designation (“BTD) for cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of T1D. This designation provides a sponsor with added support and the potential to expedite development and review timelines for a promising new investigational medicine.
Holding Company Structure
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the principal operating subsidiary. We have determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing
26
member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results under the VIE accounting model in its consolidated financial statements.
Financial Overview
Revenue
To date, we have not generated any revenue from drug sales. Our revenue has been primarily derived from milestone payments, up-front proceeds and research fees under collaboration and license agreements.
In the future, we may generate revenue from a combination of product sales, license fees, milestone payments and royalties from the sales of products developed under licenses of our intellectual property. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing and amount of license fees, milestone and other payments, and the amount and timing of payments that we receive upon the sale of our products, to the extent any are successfully commercialized. If we fail to complete the development of our drug candidates in a timely manner or obtain regulatory approval for them, our ability to generate future revenue and our results of operations and financial position will be materially adversely affected.
Research and Development Expenses
Since our inception, we have focused our resources on our research and development activities, including conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings for our drug candidates. We recognize research and development expenses as they are incurred. Our direct research and development expenses consist primarily of external costs such as fees paid to investigators, consultants, central laboratories and clinical research organizations in connection with our clinical trials, and costs related to acquiring and manufacturing clinical trial materials. Our indirect research and development costs consist primarily of cash and share-based compensation costs, the cost of employee benefits and related overhead expenses for personnel in research and development functions. Since we typically use our employee and infrastructure resources across multiple research and development programs such costs are not allocated to the individual projects.
From our inception, including our predecessor companies, through September 30, 2023, we have incurred approximately $623.9 million in research and development expenses.
Our research and development expenses by project for the three and nine months ended September 30, 2023 and 2022 were as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Direct research and development expense:
Cadisegliatin (TTP399)$1,854 $2,309 $8,943 $6,438 
Other projects*163 173 475 417 
Indirect research and development expense807 573 2,039 1,538 
Total research and development expense$2,824 $3,055 $11,457 $8,393 
*Includes HPP737 and Azeliragon
We plan to continue to incur significant research and development expenses for the foreseeable future as we continue the development of cadisegliatin (TTP399) and further advance the development of our other drug candidates, subject to the availability of additional funding.
The successful development of our clinical and preclinical drug candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing or costs of the efforts that will be necessary to complete the remainder of the development of any of our clinical or preclinical drug candidates or the period, if any, in which material net cash inflows from these drug candidates may commence. This is due to the numerous risks and uncertainties associated with the development of our drug candidates, including:
•the uncertainty of the scope, rate of progress and expense of our ongoing, as well as any additional, clinical trials and other research and development activities;
27
•the potential benefits of our candidates over other therapies;
•our ability to market, commercialize and achieve market acceptance for any of our drug candidates that we are developing or may develop in the future;
•future clinical trial results;
•our ability to enroll patients in our clinical trials;
•the timing and receipt of any regulatory approvals
•our ability to secure sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer-term cash requirements and other cash needs, at the times and in the amounts needed;
•legislation and regulatory actions and changes in laws or regulations; and
•the filing, prosecuting, defending and enforcing of patent claims and other intellectual property rights, and the expense of doing so.
A change in the outcome of any of these variables with respect to the development of a drug candidate could mean a significant change in the costs and timing associated with the development of that drug candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we currently anticipate will be required for the completion of clinical development of a drug candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time with respect to the development of that drug candidate.
General and Administrative Expenses
General and administrative expenses consist primarily of salaries, benefits and related costs for employees in executive, finance, corporate development, human resources and administrative support functions. Other significant general and administrative expenses include accounting and legal services, expenses associated with obtaining and maintaining patents, cost of various consultants, occupancy costs and information systems.
Interest Income
Interest income represents noncash interest income related to the imputed interest from the G42 Promissory Note receivable, using the effective interest method and cash interest income represents dividends and interest from our money market account, all of which are recognized in our Condensed Consolidated Statement of Operations.
Interest Expense
The Company’s interest expense is immaterial.
Other (Expense) Income, Net
Other income/expense primarily consists of unrealized gains or losses attributable to the changes in fair value of the equity investment held, the recognition of changes in fair value of the warrants to purchase shares of our Class A common stock held by related parties, the loss from the G42 Promissory Note early redemption on February 28, 2023 and the impairment charge from Anteris Bio, Inc. (“Anteris”) liquidation and dissolution.
28
Results of Operations
Comparison of the three months ended September 30, 2023 and 2022
The following table sets forth certain information concerning our results of operations for the periods shown:
(dollars in thousands)Three Months Ended September 30,
Statement of operations data:20232022Change
Revenue $—$—$—
Operating expenses:
Research and development 2,8243,055(231)
General and administrative 2,5442,634(90)
Total operating expenses 5,3685,689(321)
Operating loss(5,368)(5,689)321
Interest income131150(19)
Interest expense(4)(8)4
Other (expense) income, net(3,299)79(3,378)
Loss before income taxes and noncontrolling interest(8,540)(5,468)(3,072)
Income tax provision———
Net loss before noncontrolling interest(8,540)(5,468)(3,072)
Less: net loss attributable to noncontrolling interest(1,886)(1,207)(679)
Net loss attributable to vTv Therapeutics Inc.$(6,654)$(4,261)$(2,393)
Revenue
There was no revenue for the three months ended September 30, 2023 and September 30, 2022.
Research and Development Expenses
Research and development expenses were $2.8 million and $3.1 million for the three months ended September 30, 2023 and 2022, respectively. The decrease in research and development expenses during this period of $0.2 million, or 7.6%, was primarily driven by i) lower spending on cadisegliatin (TTP399) of $0.4 million, due to decreases in drug product related costs as well as lower spending on trial preparation costs, offset by ii) an increase in indirect costs and other projects of $0.2 million.
General and Administrative Expenses
General and administrative expenses were $2.5 million and $2.6 million for the three months ended September 30, 2023 and 2022, respectively. The decrease in general and administrative expenses during this period of $0.1 million, or 3.4%, was primarily driven by i) decreases of $0.4 million in legal expense, ii) decreases of $0.3 million in other general and administrative costs, partially offset by iii) increases of $0.5 million in payroll costs and iv) increases of $0.1 million in share-based expense.
Interest Income
Interest income for the three months ended September 30, 2023 of $0.1 million is related to dividend income from our money market account. Interest income for the three months ended September 30, 2022 of $0.2 million is related to imputed interest on the promissory notes.
Interest Expense
Interest expense for the three months ended September 30, 2023 and 2022 was insignificant.
Other (Expense) Income, Net
Other expense was $3.3 million for the three months ended September 30, 2023 and was driven by the recording of an impairment charge on a cost-method investment of $4.2 million and an unrealized gain related to our investment in Reneo, as well as gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties (“Related Party Warrants”). Other income was $0.1 million for the three months ended September 30, 2022
29
and was driven by an unrealized gain related to our investment in Reneo as well as the losses related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.
Comparison of the nine months ended September 30, 2023 and 2022
The following table sets forth certain information concerning our results of operations for the periods shown:
(dollars in thousands)Nine Months Ended September 30,
Statement of operations data:20232022Change
Revenue $—$2,009$(2,009)
Operating expenses:
Research and development 11,4578,3933,064
General and administrative 9,3389,813(475)
Total operating expenses 20,79518,2062,589
Operating loss(20,795)(16,197)(4,598)
Interest income384200184
Interest expense(6)(9)3
Other expense, net(1,108)(2,777)1,669
Loss before income taxes and noncontrolling interest(21,525)(18,783)(2,742)
Income tax provision—200(200)
Net loss before noncontrolling interest(21,525)(18,983)(2,542)
Less: net loss attributable to noncontrolling interest(4,753)(4,564)(189)
Net loss attributable to vTv Therapeutics Inc.$(16,772)$(14,419)$(2,353)
Revenue
There was no revenue for the nine months ended September 30, 2023. Revenue for the nine months ended September 30, 2022 relates to the increase in the transaction price for the license performance obligations under the amended license agreement with Huadong due to the satisfaction of a development milestone.
Research and Development Expenses
Research and development expenses were $11.5 million and $8.4 million for the nine months ended September 30, 2023 and 2022, respectively. The increase in research and development expenses during the period of $3.1 million, or 36.5%, was primarily driven by i) higher spending on cadisegliatin (TTP399) of $2.5 million due to increases in drug product related costs as well as higher spending on trial preparation costs, and ii) an increase of $0.6 million in indirect costs and other projects.
General and Administrative Expenses
General and administrative expenses were $9.3 million and $9.8 million for the nine months ended September 30, 2023 and 2022, respectively. The decrease of $0.5 million has been primarily driven by i) decreases of $2.8 million in legal expense, ii) decreases of $0.8 million in severance costs, partially offset by iii) increases of $1.7 million in payroll costs, iv) increases of $1.2 million in other general and administrative costs, and v) increases of $0.2 million share-based expense.
Interest income
Interest income for the nine months ended September 30, 2023 of $0.4 million is related to imputed interest on the G42 Promissory Note and dividend income from our money market account. Interest income for the nine months ended September 30, 2022 of $0.2 million is related to imputed interest on the promissory note.
Interest Expense
Interest expense for the nine months ended September 30, 2023 and 2022 was insignificant.
Other (Expense), Net
Other expense was $1.1 million for the nine months ended September 30, 2023, and is driven by the recording of a impairment charge on a cost-method investment of $4.2 million offset by an unrealized gain recognized related to the Company’s investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants to
30
purchase shares of our own stock held by related parties. Other expense was $2.8 million for the nine months ended September 30, 2022, and is driven by an unrealized loss recognized related to the Company’s investment in Reneo as well as gains related to the change in the fair value of the outstanding warrants to purchase shares of our own stock issued to related parties.
Liquidity and Capital Resources
Liquidity and Going Concern
As of September 30, 2023, we had an accumulated deficit of $281.2 million. Since our inception, we have experienced a history of negative cash flows from operating activities. We anticipate that we will continue to incur losses for the foreseeable future as we continue our clinical trials. Further, we expect that we will need additional capital to continue to fund our operations. As of September 30, 2023, we had cash and cash equivalents of $8.2 million. The Company received proceeds of $4.4 million from the sale of Reneo Pharmaceuticals, Inc stock on October 30, 2023 (see Note 14).
Based on our current operating plan, we may rely on the remaining availability of $37.3 million under our Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) pursuant to which we could offer and sell, from time to time, shares of our Class A common stock (the “ATM Offering”) and our ability to sell approximately 9.4 million shares of Class A common stock to Lincoln Park Capital Fund, LLC (“Lincoln Park”) pursuant and subject to the limitations of the purchase agreement (the “LPC Purchase Agreement”). However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in our Class A common stock.
In addition to available cash and cash equivalents and available funds discussed above, we are seeking possible additional partnering opportunities for our GKA, GLP-1r and other drug candidates, which we believe may provide additional cash for use in our operations and the continuation of the clinical trials for our drug candidates. We are evaluating several financing strategies to fund our planned and ongoing clinical trials, including direct equity investments and future public offerings of our common stock. The timing and availability of such financing are not yet known. We are currently in active discussions with respect to financing, partnering and licensing transactions for the future development of cadisegliatin (TTP399), but we may not be successful in completing such transactions. These factors raise substantial doubt about our ability to continue as a going concern.
ATM Offering
We have entered into the Sales Agreement with Cantor Fitzgerald pursuant to which we may offer and sell, from time to time, through or to Cantor Fitzgerald, as sales agent or principal, shares of our Class A common stock having an aggregate offering price of up to $68.5 million. We are not obligated to sell any shares under the Sales Agreement. Under the terms of the Sales Agreement, we will pay Cantor Fitzgerald a commission of up to 3% of the aggregate proceeds from the sale of shares and reimburse certain legal fees or other disbursements. As of September 30, 2023, we have sold $31.2 million worth of Class A common stock under the ATM Offering for net proceeds of $30.3 million, leaving $37.3 million available to be sold.
Lincoln Park Purchase Agreement
We have entered into the LPC Purchase Agreement, pursuant to which we have the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million. As of September 30, 2023, we have issued 5,331,306 of these shares for gross proceeds of approximately $11.1 million, leaving $35.9 million available to be sold.
Over the 36-month term of the LPC Purchase Agreement, we have the right, but not the obligation, from time to time, in our sole discretion, to direct Lincoln Park to purchase up to 250,000 shares per day (the “Regular Purchase Share Limit”) of the Class A common stock (each such purchase, a “Regular Purchase”). The Regular Purchase Share Limit will increase to 275,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $4.00 per share and will further increase to 300,000 shares per day if the closing price of the Class A common stock on the applicable purchase date is not below $5.00 per share. In any case, Lincoln Park’s maximum obligation under any single Regular Purchase will not exceed $2,000,000. The purchase price for shares of Class A common stock to be purchased by Lincoln Park under a Regular Purchase will be equal to the lower of (in each case, subject to the adjustments described in the LPC Purchase Agreement): (i) the lowest sale price for the Class A common stock on the applicable purchase date and (ii) the arithmetic average of the three lowest closing sales prices for the Class A common stock during the 10 consecutive trading days prior to the purchase date.
31
If we direct Lincoln Park to purchase the maximum number of shares of Class A common stock that we may sell in a Regular Purchase, then in addition to such Regular Purchase, and subject to certain conditions and limitations in the LPC Purchase Agreement, we may direct Lincoln Park to make an “accelerated purchase” and an “additional accelerated purchase”, each of an additional number of shares of Class A common stock which may not exceed the lesser of: (i) 300% of the number of shares purchased pursuant to the corresponding Regular Purchase and (ii) 30% of the total number of shares of the common stock traded during a specified period on the applicable purchase date as set forth in the LPC Purchase Agreement. The purchase price for such shares will be the lesser of (i) 97% of the volume weighted average price of the Class A common stock over a certain portion of the date of sale as set forth in the LPC Purchase Agreement and (ii) the closing sale price of the Class A common stock on the date of sale (an “Accelerated Purchase”). Under certain circumstances and in accordance with the LPC Purchase Agreement, we may direct Lincoln Park to purchase shares in multiple Accelerated Purchases on the same trading day.
The LPC Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of its Class A common stock if those shares, when aggregated with all other shares of Class A common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of Class A common stock as calculated pursuant to Section 13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 thereunder.
Cash Flows
Nine Months Ended September 30,
20232022
(dollars in thousands)
Net cash used in operating activities$(16,167)$(9,142)
Net cash used in investing activities— (21)
Net cash provided by financing activities12,279 11,087 
Net (decrease) increase in cash and cash equivalents$(3,888)$1,924 
Operating Activities
For the nine months ended September 30, 2023, our net cash used in operating activities increased by $7.0 million from the nine months ended September 30, 2022. The significant contributor to the change in cash used was driven by working capital changes, and offset by cash received of $6.8 million in excess of the fair value of the Class A common stock issued to G42 investments in 2022.
Investing Activities
There were no cash flows from investing activities for the nine months ended September 30, 2023. For the nine months ended September 30, 2022, net cash used in investing activities was insignificant.
Financing Activities
For the nine months ended September 30, 2023, net cash provided by financing activities driven by the receipt of proceeds of $12.0 million from the G42 Promissory Note early redemption during the nine months ended September 30, 2023. For the nine months ended September 30, 2022, net cash provided by financing activities was driven by sales of our Class A common stock to a collaboration partner and from the CinRx Purchase Agreement.
Future Funding Requirements
To date, we have not generated any revenue from drug product sales. We do not know when, or if, we will generate any revenue from drug product sales. We do not expect to generate revenue from drug sales unless and until we obtain regulatory approval of and commercialize any of our drug candidates. At the same time, we expect our expenses to continue or to increase in connection with our ongoing development activities, particularly as we continue the research, development and clinical trials of, and seek regulatory approval for, our drug candidates. In addition, subject to obtaining regulatory approval of any of our drug candidates, we expect to incur significant commercialization expenses for product sales, marketing, manufacturing and distribution. We anticipate that we will need substantial additional funding in connection with our continuing operations.
Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. We plan to finance our operations into the first quarter of 2024 through the use of our cash and cash equivalents and, based on current operating plans, we are evaluating several financing strategies
32
to fund the ongoing and future clinical trials of cadisegliatin (TTP399), including direct equity investments and the potential licensing and monetization of other Company programs. The timing of any such transactions is not certain, and we may not be able to complete such transactions on acceptable terms, or at all. Even if we are able to complete such transactions, they may contain restrictions on our operations or cause substantial dilution to our stockholders. We have based our estimates on assumptions that may prove to be wrong, and we may use our available capital resources sooner than we currently expect. Because of the numerous risks and uncertainties associated with the development and commercialization of our drug candidates, we are unable to estimate the amounts of increased capital outlays and operating expenditures necessary to complete the development of our drug candidates. Additionally, we may rely on our ability to sell shares of our Class A common stock pursuant to the ATM Offering and LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock.
Our future capital requirements will depend on many factors, including:
•the progress, costs, results and timing of our planned trials to evaluate cadisegliatin (TTP399) as a potential adjunctive therapy for the treatment of type 1 diabetes;
•the willingness of the FDA to rely upon our completed and planned clinical and preclinical studies and other work, as the basis for review and approval of our drug candidates;
•the outcome, costs and timing of seeking and obtaining FDA and any other regulatory approvals;
•the number and characteristics of drug candidates that we pursue, including our drug candidates in preclinical development;
•the ability of our drug candidates to progress through clinical development successfully;
•our need to expand our research and development activities;
•the costs associated with securing, establishing and maintaining commercialization capabilities;
•the costs of acquiring, licensing or investing in businesses, products, drug candidates and technologies;
•our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
•our need and ability to hire additional management, scientific, and medical personnel;
•the effect of competing technological and market developments;
•our need to implement additional internal systems and infrastructure, including financial and reporting systems;
•the economic and other terms, timing and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future; and
•the amount of any payments we are required to make to M&F TTP Holdings Two LLC in the future under the Tax Receivable Agreement.
Until such time, if ever, as we can generate substantial revenue from drug sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements. We currently have potential external source of funds available through the ATM Offering and LPC Purchase Agreement. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock.
To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interests of our common stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants that will further limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or drug candidates or grant licenses on terms that may not be favorable to us.
Our recurring losses, accumulated deficit and our current levels of cash and cash equivalents raise substantial doubt about our ability to continue as a going concern as of the date of this Quarterly Report on Form 10-Q. If we are unable to
33
continue as a going concern, we may have to liquidate our assets and it is likely that investors will lose all or a significant part of their investments. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms or at all, and such additional funding may cause substantial dilution to our existing investors. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate our research and development programs or commercialization efforts, or pursue one or more alternative strategies, such as restructuring, any of which could adversely affect our business prospects.
Discussion of Critical Accounting Policies
For a discussion of our critical accounting policies and estimates, please refer to Part II, Item 7. “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to our critical accounting policies and estimates in 2023.
Effect of Recent Accounting Pronouncements
See discussion of recent accounting pronouncements in Note 2, “Summary of Significant Accounting Policies”, to the Condensed Consolidated Financial Statements in this Form 10-Q.
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Interest Rate Risk
We do not currently have any material interest rate exposure.
Market Risk
Our exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of one year or less. The goals of our investment strategy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents in a financial institution that management believes to be of high credit quality. Because of the short-term maturities of our investments, we do not believe that an increase in market rates would have a material negative impact on the value of our investment portfolio.
Foreign Currency Risk
We do not have any material foreign currency exposure.
ITEM 4.    CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of our Chief Executive Officer (our principal executive officer) and Chief Financial Officer (our principal financial officer), management has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934) as of September 30, 2023. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of September 30, 2023, our disclosure controls and procedures were effective in causing material information relating to us (including our consolidated subsidiaries) to be recorded, processed, summarized, and reported by management on a timely basis and to ensure the quality and timeliness of our public disclosures pursuant to SEC disclosure obligations.
Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, with the Company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error and mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by management override of controls.
The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future
34
conditions. Over time, a control may become inadequate because of changes in conditions or because the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and may not be detected.
Changes to Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
Website Availability of Reports and other Corporate Governance Information
The Company maintains a comprehensive corporate governance program, including Corporate Governance Guidelines for its Board of Directors, Board Guidelines for Assessing Director Independence, and charters for its Audit Committee, Nominating and Corporate Governance Committee and Compensation Committee. The Company maintains a corporate investor relations website, www.vtvtherapeutics.com, where stockholders and other interested persons may review, without charge, among other things, corporate governance materials and certain SEC filings, which are generally available on the same business day as the filing date with the SEC on the SEC’s website http://www.sec.gov. The contents of our website are not made a part of this Quarterly Report on Form 10-Q.

PART II – OTHER INFORMATION

ITEM 1.    LEGAL PROCEEDINGS
We are not currently a party to any material legal proceedings.

ITEM 1A.    RISK FACTORS
Our risk factors are set forth under the heading “Risk Factors” under Item 1A of Part I in our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to our risk factors from those previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.

ITEM 2.    UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
There were no sales of unregistered equity securities during the three months ended September 30, 2023.
ITEM 3.    DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4.    MINE SAFETY DISCLOSURES
None.
ITEM 5.    OTHER INFORMATION
Rule 10b5-1 Trading Plans
During the fiscal quarter ended September 30, 2023, none of our directors or executive officers adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
35
ITEM 6.    EXHIBITS
Exhibit
Number		Description
31.1*
31.2*
32.1*
32.2*
101.INSInline XBRL Instance Document
101.SCHInline XBRL Taxonomy Extension Schema
101.CALInline XBRL Taxonomy Extension Calculation Linkbase
101.DEFInline XBRL Taxonomy Extension Definition Document
101.LABInline XBRL Taxonomy Extension Label Linkbase
101.PREInline XBRL Taxonomy Extension Presentation Linkbase
104Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
___________________________

*    Filed herewith
36
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Date: November 9, 2023
VTV THERAPEUTICS INC.
(Registrant)
By:/s/ Paul J. Sekhri
Paul J. Sekhri
President and Chief Executive Officer
By:/s/ Steven Tuch
Steven Tuch
Chief Financial Officer
37
 EX-31.1 2 vtvt-20230930xexx311.htm EX-31.1 Document

Exhibit 31.1
SECTION 302 CERTIFICATION
I, Paul J. Sekhri, certify that:
1.I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 9, 2023
By:/s/ Paul J. Sekhri
Paul J. Sekhri
President and Chief Executive Officer

 EX-31.2 3 vtvt-20230930xexx312.htm EX-31.2 Document

Exhibit 31.2
SECTION 302 CERTIFICATION
I, Steven Tuch, certify that:
1.I have reviewed this quarterly report on Form 10-Q of vTv Therapeutics Inc. (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Securities Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: November 9, 2023
By:/s/ Steven Tuch
 Steven Tuch
 Chief Financial Officer

 EX-32.1 4 vtvt-20230930xexx321.htm EX-32.1 Document

Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul J. Sekhri, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2023
By:/s/ Paul J. Sekhri
Paul J. Sekhri
President and Chief Executive Officer

 EX-32.2 5 vtvt-20230930xexx322.htm EX-32.2 Document

Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of vTv Therapeutics Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Tuch, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, in my capacity as an officer of the Company that, to my knowledge:
1.The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: November 9, 2023
By:/s/ Steven Tuch
Steven Tuch
Chief Financial Officer

 EX-101.SCH 6 vtvt-20230930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Collaboration Agreements link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Redeemable Noncontrolling Interest link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Stockholders' Deficit link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Net Loss per Share link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Fair Value of Financial Instruments link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Collaboration Agreements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Share-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Redeemable Noncontrolling Interest (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Net Loss per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Fair Value of Financial Instruments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Collaboration Agreements - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Share-Based Compensation - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Investments - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Stockholders' Deficit - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Related-Party Transactions - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Income Taxes - Additional Information (Detail) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 vtvt-20230930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 vtvt-20230930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 vtvt-20230930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Proceeds from sale of Class A common stock and warrants, net of offering costs Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Less: net loss attributable to noncontrolling interest Less: Net loss attributable to noncontrolling interests Net Income (Loss) Attributable to Noncontrolling Interest Pay vs Performance Disclosure [Line Items] Stock conversion ratio Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio Redeemable non controlling interest exchange agreement stock conversion ratio. vTv Therapeutics LLC V Tv L L C [Member] vTv LLC. Statistical Measurement Statistical Measurement [Domain] Liabilities: Nonfinancial Liabilities Fair Value Disclosure [Abstract] Research and development Research and Development Expense Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Related Party Transaction [Line Items] Related Party Transaction [Line Items] License Agreement Obligations License Agreement Obligations [Domain] License agreement obligations. Non-qualified stock option awards expiration term Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Award Type Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Investment, Name [Domain] Investment, Name [Domain] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Research and Development Research and Development Expense, Policy [Policy Text Block] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Equity investment with readily determinable fair value: Equity Investments With Readily Determinable Fair Value Equity investments with readily determinable fair value. Equity Securities Without Readily Determinable Fair Value [Line Items] Equity Securities without Readily Determinable Fair Value [Line Items] Options exercisable, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Collaborative arrangement, contingent consideration Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent. Restatement Determination Date: Restatement Determination Date [Axis] Investment, Name [Axis] Investment, Name [Axis] Commitments and contingencies Commitments and Contingencies Expected volatility Measurement Input, Price Volatility [Member] Discount rate Notes Receivable, Discount Rate Notes Receivable, Discount Rate Insider Trading Policies and Procedures [Line Items] Options exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] CinRx CinRx [Member] CinRx Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Stockholders' Deficit Equity [Text Block] Proceeds from sale of Class A common stock to collaboration partner, net of offering costs Proceeds from Issuance of Common Stock Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Axis] MacAndrews & Forbes Incorporated Mac Andrews And Forbes Incorporated [Member] MacAndrews and Forbes Incorporated. Income Taxes Income Tax Disclosure [Text Block] Description of Business, Basis of Presentation and Going Concern Business Description and Basis of Presentation [Text Block] Contract liabilities Increase (Decrease) in Contract with Customer, Liability Type 2 Diabetes Type Two Diabetes [Member] Type 2 diabetes. Noncontrolling Interest [Abstract] Noncontrolling Interest [Abstract] Customer [Axis] Customer [Axis] Current liabilities: Liabilities, Current [Abstract] Minority Interest [Table] Noncontrolling Interest [Table] Lessee, operating lease, termination period Lessee, Operating Lease, Termination Period Lessee, Operating Lease, Termination Period Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization Consolidation And Presentation Of Financial Statements [Line Items] Organization consolidation and presentation of financial statements. Subsequent Event Type [Domain] Subsequent Event Type [Domain] Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share) Earnings Per Share, Diluted Change in fair value of investments Unrealized gain (loss) on investment Unrealized Gain (Loss) on Investments PEO Total Compensation Amount PEO Total Compensation Amount Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Awards outstanding, Beginning balance (in shares) Awards outstanding, Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Redeemable noncontrolling interest Beginning balance Ending balance Redeemable Noncontrolling Interest, Equity, Carrying Amount Trading Symbol Trading Symbol Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Granted (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Weighted average grant date fair value of options granted (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Net loss attributable to vTv Therapeutics Inc. Net loss Net Income (Loss) Total current liabilities Liabilities, Current Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Leases Lessee, Operating Leases [Text Block] Liabilities, Redeemable Noncontrolling Interest and Stockholders’ Deficit Liabilities and Equity [Abstract] Net Change in fair value included in earnings Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings Stock repurchased during period Stock Repurchased During Period, Value Notes receivable recorded at fair value from collaboration partner Notes receivable for common stock from CinRx purchase agreement Notes Receivable from Collaborators Notes Receivable from Collaborators Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Stockholders’ deficit: Equity, Attributable to Parent [Abstract] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Contract liabilities, net of current portion Contract with Customer, Liability Cantor Fitzgerald Cantor Fitzgerald [Member] Cantor fitzgerald member. Impairment of investments in Anteris Bio, Inc. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Non-qualified stock option awards vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Executive Category: Executive Category [Axis] Class B Common Stock Common Class B [Member] Novo License Agreement Novo License Agreement [Member] Novo license agreement. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Quoted Prices in Active Markets for Identical Assets (Level 1) Fair Value, Inputs, Level 1 [Member] Name Measure Name Name Forgone Recovery, Individual Name Equity Components Equity Components [Axis] Financial Instruments Financial Instruments [Domain] Exercise price of warrants or rights (in usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Redeemable Noncontrolling Interest Redeemable Noncontrolling Interests [Member] Redeemable noncontrolling interests. Phase 2 MRCT Phase Two Multi Regional Clinical Trial [Member] Phase two multi-regional clinical trial. Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Transaction Transaction [Domain] Measurement Frequency Measurement Frequency [Axis] Common stock warrants Warrant [Member] Operating lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Depreciation expense Depreciation Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner Proceeds from Repayment of Loans to Purchase Common Stock Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Transaction Type Transaction Type [Axis] Income Statement Location Income Statement Location [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Redemption amount of noncontrolling interest Redeemable Noncontrolling Interest Temporary Equity Redemption Value Redeemable noncontrolling interest temporary equity redemption value. Schedule of Maturities of Lease Liabilities for Operating Leases Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Cash and Cash Equivalents Cash and Cash Equivalents, Policy [Policy Text Block] Shares sold (in shares) Sale of Stock, Number of Shares Issued in Transaction Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Product and Service Product and Service [Domain] Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Research and development Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Sale of stock, consideration received on transaction, gross Sale of Stock, Consideration Received on Transaction, Gross Sale of Stock, Consideration Received on Transaction, Gross Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type Award Type [Axis] Document Quarterly Report Document Quarterly Report Collaboration revenue recognized Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer Interest expense Interest Expense Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Loss from G42 Promissory Note early redemption Gain (Loss) on Extinguishment of Debt General and administrative General and Administrative Expense [Member] Trading Arrangement: Trading Arrangement [Axis] Related-Party Transactions Related Party Transactions Disclosure [Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Change in redemption value of noncontrolling interest Temporary Equity, Change In Redemption Value Temporary Equity, Change In Redemption Value Entity File Number Entity File Number Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Current portion of operating lease liabilities Operating Lease, Liability, Current Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three Long-term investments Long-Term Investments Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Commitments And Contingencies [Line Items] Commitments And Contingencies [Line Items] Commitments and Contingencies. CinRx Warrants CinRx Warrants [Member] CinRx Warrants Counterparty Name [Domain] Counterparty Name [Domain] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Total cash and cash equivalents, beginning of period Total cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Sale of stock, price per share (in usd per shares) Sale of Stock, Price Per Share Interest income Investment Income, Interest Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Operating lease cost Operating Lease, Cost Anteris Bio Inc Anteris Bio Inc [Member] Anteris Bio, Inc. Amount of cash savings percentage Percentage Of Amount Of Cash Savings Percentage of amount of cash savings. Collaborate arrangement, contingent consideration transferred, cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Collaborate Arrangement, Contingent Consideration Transferred, Cash Current portion of contract liabilities Contract with Customer, Liability, Current Security Exchange Name Security Exchange Name Type 1 Diabetes Type One Diabetes [Member] Type 1 diabetes. Total Assets, Fair Value Disclosure Sale of stock, consideration received on transaction Sale of Stock, Consideration Received on Transaction Collaboration Agreements Collaborative Arrangement Disclosure [Text Block] Stock Option Common stock options granted under the Plan Employee Stock Option [Member] Investments Investment, Policy [Policy Text Block] ATM Offering At The Market Offering [Member] At the market offering. G42 Investments G42 Investments [Member] G42 Investments Class A Common Stock Common Class A [Member] Weighted average period to recognize unrecognized share-based compensation cost Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Redeemable Noncontrolling Interest Noncontrolling Interest Disclosure [Text Block] Stock Conversion Description Stock Conversion Description [Axis] Income Taxes [Table] Income Taxes [Table] Income taxes. Maximum Maximum [Member] Document Type Document Type Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Schedule Of Earnings Per Share [Line Items] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Antidilutive Securities, Name Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Share-Based Compensation Share-Based Payment Arrangement [Text Block] Weighted Average Exercise Price Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Issuance of Class A common stock under CinRx purchase agreement, net of offering costs Stock Issued During Period, Value, Purchase Agreement Stock Issued During Period, Value, Purchase Agreement Subsequent Event Subsequent Event [Member] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Customer Customer Concentration Risk [Member] Shares held by related party (in shares) Investment Owned, Balance, Shares Accounts payable and accrued expenses Increase (Decrease) in Accounts Payable and Accrued Liabilities Income Statement [Abstract] Income Statement [Abstract] Current deposits Deposits Assets, Current Issuance of Class A Common Stock to Collaboration Partner (in shares) Stock Issued During Period, Shares, New Issues Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Title of 12(b) Security Title of 12(b) Security Assets: Short-Term Investments [Abstract] Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Non-cash interest income Interest Income, Operating Related Party Related Party, Type [Domain] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Numerator: Net Income (Loss) Attributable to Parent [Abstract] Class Of Stock [Line Items] Class of Stock [Line Items] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number CinRx Pharma, LLC CinRx Pharma, LLC [Member] CinRx Pharma, LLC Other Commitments Other Commitments [Domain] Statistical Measurement Statistical Measurement [Axis] Financial Instrument Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Receivables, fair value disclosure Receivables, Fair Value Disclosure Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Organization Consolidation And Presentation Of Financial Statements [Table] Total Shareholder Return Amount Total Shareholder Return Amount Number of days used to determine exchange value based on weighted average price of Class A common stock Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock Period used to determine exchange value based on weighted average price of Class A common stock. Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Non-cash activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Less: imputed interest Operating Leases Imputed Interest Operating leases imputed interest. Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Accumulated deficit Retained earnings (accumulated deficit) Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Revenue Recognition Revenue from Contract with Customer [Policy Text Block] JDRF J D R F International [Member] JDRF international. Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Summary of Net Income Attributable to Vtv Therapeutics Inc Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block] Leases [Abstract] Leases [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Counterparty Name [Axis] Counterparty Name [Axis] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Schedule Of Related Party Transactions By Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Common stock, shares outstanding (in shares) Beginning balance, shares (in shares) Ending balance, shares (in shares) Common Stock, Shares, Outstanding Change in redemption value of noncontrolling interest Change in redemption value of noncontrolling interest Noncontrolling Interest, Change in Redemption Value PEO PEO [Member] Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] M&F TTP Holdings LLC M F T T P Holdings L L C [Member] M&F TTP Holdings LLC. Conversion of Stock, Name Conversion of Stock, Name [Domain] Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Common stock par value (in usd per share) Common Stock, Par or Stated Value Per Share Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock Class of Stock [Domain] Equity securities with readily determinable fair value Equity Securities, FV-NI, Current Customer [Domain] Customer [Domain] Net loss attributable to vTv Therapeutics Inc. common shareholders Net loss attributable to common shareholders of vTv Therapeutics Inc., basic Net Income (Loss) Available to Common Stockholders, Basic Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Collaborative Arrangements Collaborative Arrangement [Member] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Present value of lease liabilities Operating Lease, Liability Potential milestone payment Potential Milestone Payment Potential milestone payment. Measurement Input Type Measurement Input Type [Domain] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Equity method investments, ownership percentage Investment Ownership Percentage Investment ownership percentage. Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block] Tabular disclosure of investment in equity security with and without readily determinable fair value. Options vested and expected to vest (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Measurement Frequency Measurement Frequency [Domain] Common stock, capital shares reserved for future issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance All Executive Categories All Executive Categories [Member] Contract liabilities, net of current portion Contract with Customer, Liability, Noncurrent Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table] Fair value of assets and liabilities measured on recurring basis table. Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Related Party Transaction [Domain] Related Party Transaction [Domain] Earnings Per Share [Abstract] Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock value Common Stock, Value, Issued General and administrative General and Administrative Expense Potential development and regulatory milestone payments Potential Development And Regulatory Milestone Payments Receivable Potential development and regulatory milestone payments receivable. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Preferred Stock Preferred Stock [Member] All Individuals All Individuals [Member] Satisfaction of Milestone Payment Satisfaction Of Milestone Payment [Member] Satisfaction of milestone payment. Discount on note receivable Collaborative Arrangement, Note Receivable, Discount Paid Collaborative Arrangement, Note Receivable, Discount Paid Income Taxes [Line Items] Income Taxes [Line Items] Income taxes. Other income (expense) Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Current Fiscal Year End Date Current Fiscal Year End Date Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares) Stock Issued During Period, Shares, Purchase Agreement Issuance of Class A Common Stock under LPC agreement shares.. Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items] Fair value of assets and liabilities measured on recurring basis. PEO Name PEO Name Expected dividend yield Measurement Input, Expected Dividend Rate [Member] Concentration risk percentage Concentration Risk, Percentage Beginning Balance Ending Balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Warrant liability, related party Warranty Liability Warranty Liability Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Class of Stock Class of Stock [Axis] Change in fair value of warrants, related party Change In Fair Value Of Warrants Related Party Change in fair value of warrants related party. Interest expense Interest Expense, Other Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] CinRx Investment CinRx Investment [Member] CinRx Investment Total stockholders’ deficit attributable to vTv Therapeutics Inc. Beginning balance Ending balance Equity, Attributable to Parent Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Contract with customer, liability, revenue recognized Contract with Customer, Liability, Revenue Recognized Schedule Of Stock By Class [Table] Schedule of Stock by Class [Table] Concentration Risk Type Concentration Risk Type [Axis] Developmental and Regulatory Milestone Payment Developmental And Regulatory Milestone Payment [Member] Developmental and regulatory milestone payment. Subsequent Events [Abstract] Subsequent Events [Abstract] Loss before income taxes and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Inputs utilized in the valuation of warrants Warrants and Rights Outstanding, Measurement Input Equity investment without readily determinable fair values assessed under the measurement alternative: Equity Securities without Readily Determinable Fair Value, Amount Significant Other Observable Inputs (Level 2) Fair Value, Inputs, Level 2 [Member] Royalties receivable, period Collaborative Arrangement, Royalties Receivable, Period Collaborative Arrangement, Royalties Receivable, Period Equity interest received Proceeds from Interest and Dividends Received Entity Emerging Growth Company Entity Emerging Growth Company Thereafter Lessee, Operating Lease, Liability, to be Paid, After Year Four Lessee, Operating Lease, Liability, to be Paid, After Year Four Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Other Indication Other Indication [Member] Other indication. Title Trading Arrangement, Individual Title Awards outstanding, Beginning balance (in usd per share) Awards outstanding, Ending balance (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Share-based compensation expense Share-Based Payment Arrangement, Noncash Expense Weighted Average Weighted Average [Member] Capital stock, shares authorized (in shares) Common Stock And Preferred Stock Shares Authorized Common stock and preferred stock shares authorized. Common Stock Common Stock [Member] Individual: Individual [Axis] Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC Percentage Of Non Voting Economic Interest By Parent Percentage of non voting economic interest by parent. City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service Product and Service [Axis] Net Loss per Share Earnings Per Share [Text Block] Income Statement Location Income Statement Location [Domain] Maximum funding percentage of research and development milestones Maximum Funding Percentage Of Research And Development Milestones Maximum funding percentage of research and development milestones. G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member] G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement Document Fiscal Year Focus Document Fiscal Year Focus Minimum Minimum [Member] Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Property and equipment, net Property, Plant and Equipment, Net Summary of Stock Award Activity for the Period Share-Based Payment Arrangement, Option, Activity [Table Text Block] Exercise Price Award Exercise Price Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Warranty liability, related party Liabilities, Fair Value Disclosure Nonrelated Party Nonrelated Party [Member] Net loss before noncontrolling interest Net loss before noncontrolling interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Purchases / Issuance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Accumulated Deficit Retained Earnings [Member] Exchange of Redeemable Non controlling Interest To Class A Common Stock Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member] Exchange of redeemable non controlling interest to class A common stock. Summary of Compensation Expense Related to Grants of Stock Options Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities, redeemable noncontrolling interest and stockholders’ deficit Liabilities and Equity Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Domain] Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share) Earnings Per Share, Basic Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Unrecognized compensation cost related to non-vested share-based compensation arrangements Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Schedule Of Earnings Per Share [Table] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Warrants, term Expected life of options in years Warrants and Rights Outstanding, Term Sales-based Milestones Payment Sales Based Milestones Payment [Member] Sales-based milestones payment. Note Receivable for Common Stock Receivables from Stockholder [Member] 2023 (remaining three months) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Number of securities called by warrants or rights (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted Net Income (Loss) Available to Common Stockholders, Diluted Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Related Party Related Party [Member] Master Service Agreement Master Service Agreement [Member] Master Service Agreement License Fee Received License Fee Received License Fee Received Aggregate offering price Aggregate Offering Price Of Shares Aggregate offering price of shares. Sale of stock, consideration, receivables, payment term Sale Of Stock, Consideration, Receivable, Term Sale Of Stock, Consideration, Receivable, Term Options vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number Proceeds from debt issuance Proceeds from Issuance of Debt Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Summary of significant accounting policies. Termination Date Trading Arrangement Termination Date Common stock, shares authorized (in shares) Common Stock, Shares Authorized Proceeds from collection of notes receivable Proceeds from Collection of Notes Receivable Document Information [Table] Document Information [Table] Adjustments to transaction price for performance obligations Adjustments To Transaction Price For Performance Obligations Adjustments to transaction price for performance obligations. Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC Noncontrolling interest ownership percentage Percentage Of Non Voting Economic Interest Percentage of non voting economic interest. Noncontrolling Interest [Line Items] Noncontrolling Interest [Line Items] Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Related Party Transactions [Abstract] All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type Measurement Input Type [Axis] Unaudited Interim Financial Information Unaudited Interim Financial Information Policy [Policy Text Block] Unaudited interim financial information policy. Current portion of notes payable Notes Payable, Current All Adjustments to Compensation All Adjustments to Compensation [Member] Common stock, value Common Stock, Value, Outstanding Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount LPC Purchase Agreement L P C Purchase Agreement [Member] LPC purchase agreement. Other Commitments Other Commitments [Axis] Research and Development Arrangement, Contract to Perform for Others, Type Research and Development Arrangement, Contract to Perform for Others, Type [Axis] Net loss Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Document Information [Line Items] Document Information [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Forfeited (in usd per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Warrant liability, related party Warrant Liability Related Party [Member] Warrant liability, related party. Insider Trading Arrangements [Line Items] Letter Agreement Warrants Letter Agreement Warrants [Member] Letter agreement warrants. Increase in shares authorized (in shares) Increase In Common Stock Shares Authorized Increase in common stock shares authorized. Share price (in usd per share) Share Price Related Party Related Party, Type [Axis] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Maximum contribution amount to clinical trial Maximum Sponsoring Contribution Amount Maximum sponsoring contribution amount. Warrants, fair value Warrants and Rights Outstanding Adjustment to Compensation, Amount Adjustment to Compensation Amount Equity Securities Without Readily Determinable Fair Value [Table] Equity Securities without Readily Determinable Fair Value [Table] Cogna Cogna [Member] Cogna Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Adoption Date Trading Arrangement Adoption Date Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Summarizes the Conclusions Reached Regarding Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Options exercisable (in usd per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Entity Central Index Key Entity Central Index Key Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Total share-based compensation expense Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Income tax provision Income Tax Expense (Benefit) One Customer One Customer [Member] One Customer Fair Value of Financial Instruments Fair Value Disclosures [Text Block] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Commitments And Contingencies [Table] Revenue Revenue Benchmark [Member] Name Trading Arrangement, Individual Name Issuance of Class A common stock to collaboration partner, net of offering cost Stock issued during period Stock Issued During Period, Value, New Issues Equity [Abstract] Equity [Abstract] Remaining operating lease term Operating Lease, Weighted Average Remaining Lease Term Revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Legal Entity Legal Entity [Axis] Cash and cash equivalents Cash and cash equivalent Cash and Cash Equivalents, at Carrying Value Repayment of notes payable Repayments of Notes Payable Weighted average incremental borrowing rate Operating Lease, Weighted Average Discount Rate, Percent Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Sales / Repurchases Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Summary of Contract Liabilities Related to Company's Collaboration Agreements Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] License and Technology Transfer Services of Chemistry and Manufacturing Know-How License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member] License and technology transfer services of chemistry and manufacturing know-how. Operating expenses: Operating Expenses [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Additional Paid-in Capital Additional Paid-in Capital [Member] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Due to related parties, monthly amount Due To Related Parties, Monthly Amount Due To Related Parties, Monthly Amount G42 Promissory Note receivable Notes Receivable, Current Notes Receivable, Current Cover [Abstract] Cover [Abstract] Options vested and expected to vest, weighted average remaining contractual term Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Subsequent Events Subsequent Events [Text Block] Share-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Remaining available stock value Remaining Availability Stock Issued During Period Value New Issues Remaining availability under our controlled equity offering sales agreement Non-NEOs Non-NEOs [Member] Total lease payments Lessee, Operating Lease, Liability, to be Paid License Agreement Obligations License Agreement Obligations [Axis] License agreement obligations. Total operating expenses Operating Expenses Net (decrease) increase in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Lessee, operating lease, renewal term Lessee, Operating Lease, Renewal Term Equity Component Equity Component [Domain] Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member] Hangzhou Zhongmei Huadong Pharmaceutical Company Limited. Adjustment to Compensation: Adjustment to Compensation [Axis] Accounts and financing receivable, after allowance for credit loss Accounts and Financing Receivable, after Allowance for Credit Loss, Current Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Concentration Risk Type Concentration Risk Type [Domain] Operating loss Operating Income (Loss) Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Related Party Transaction [Axis] Related Party Transaction [Axis] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement [Line Items] Statement [Line Items] Ownership percentage of majority owner Ownership Percentage Of Majority Owner Ownership percentage of majority owner. Reneo Reneo Pharmaceuticals Inc [Member] Reneo Pharmaceuticals Inc. Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Redeemable Noncontrolling Interest Noncontrolling Interest [Member] EX-101.PRE 10 vtvt-20230930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 11 vtvt-20230930_g1.jpg GRAHPIC begin 644 vtvt-20230930_g1.jpg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htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
 9 Months Ended
Sep. 30, 2023
Nov. 09, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-37524  
Entity Registrant Name vTv Therapeutics Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 47-3916571  
Entity Address, Address Line One 3980 Premier Dr  
Entity Address, Address Line Two Suite 310  
Entity Address, City or Town High Point  
Entity Address, State or Province NC  
Entity Address, Postal Zip Code 27265  
City Area Code 336  
Local Phone Number 841-0300  
Title of 12(b) Security Class A common stock, par value $0.01 per share  
Trading Symbol VTVT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Central Index Key 0001641489  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Class A Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding (in shares)   81,483,600
Class B Common Stock    
Document Information [Line Items]    
Entity Common Stock, Shares Outstanding (in shares)   23,093,860

XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 8,238 $ 12,126
Accounts receivable 0 173
G42 Promissory Note receivable 0 12,243
Prepaid expenses and other current assets 1,872 2,537
Current deposits 15 15
Total current assets 10,125 27,094
Property and equipment, net 140 207
Operating lease right-of-use assets 272 349
Long-term investments 4,387 5,588
Total assets 14,924 33,238
Current liabilities:    
Accounts payable and accrued expenses 9,620 7,313
Current portion of operating lease liabilities 165 154
Current portion of contract liabilities 17 17
Current portion of notes payable 473 224
Total current liabilities 10,275 7,708
Contract liabilities, net of current portion 18,669 18,669
Operating lease liabilities, net of current portion 213 338
Warrant liability, related party 278 684
Total liabilities 29,435 27,399
Commitments and contingencies
Redeemable noncontrolling interest 10,722 16,579
Stockholders’ deficit:    
Additional paid-in capital 254,912 253,737
Accumulated deficit (281,192) (265,524)
Total stockholders’ deficit attributable to vTv Therapeutics Inc. (25,233) (10,740)
Total liabilities, redeemable noncontrolling interest and stockholders’ deficit 14,924 33,238
Class A Common Stock    
Stockholders’ deficit:    
Common stock value 815 815
Class B Common Stock    
Stockholders’ deficit:    
Common stock value $ 232 $ 232
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
May 04, 2021
Dec. 31, 2020
Class A Common Stock        
Common stock par value (in usd per share) $ 0.01 $ 0.01    
Common stock, shares authorized (in shares) 200,000,000 200,000,000 200,000,000 100,000,000
Common stock, shares outstanding (in shares) 81,483,600 81,483,600    
Class B Common Stock        
Common stock par value (in usd per share) $ 0.01 $ 0.01    
Common stock, shares authorized (in shares) 100,000,000 100,000,000    
Common stock, shares outstanding (in shares) 23,093,860 23,093,860    
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations - Unaudited - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenue $ 0 $ 0 $ 0 $ 2,009
Operating expenses:        
Research and development 2,824 3,055 11,457 8,393
General and administrative 2,544 2,634 9,338 9,813
Total operating expenses 5,368 5,689 20,795 18,206
Operating loss (5,368) (5,689) (20,795) (16,197)
Interest income 131 150 384 200
Interest expense (4) (8) (6) (9)
Loss before income taxes and noncontrolling interest (8,540) (5,468) (21,525) (18,783)
Income tax provision 0 0 0 200
Net loss before noncontrolling interest (8,540) (5,468) (21,525) (18,983)
Less: net loss attributable to noncontrolling interest (1,886) (1,207) (4,753) (4,564)
Net loss attributable to vTv Therapeutics Inc. (6,654) (4,261) (16,772) (14,419)
Net loss attributable to vTv Therapeutics Inc. common shareholders (6,654) (4,261) (16,772) (14,419)
Nonrelated Party        
Operating expenses:        
Other income (expense) (3,640) 403 (1,514) (2,998)
Related Party        
Operating expenses:        
Other income (expense) $ 341 $ (324) $ 406 $ 221
Class A Common Stock        
Operating expenses:        
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited - USD ($)
$ in Thousands
Total
Class A Common Stock
Class B Common Stock
Redeemable Noncontrolling Interest
Redeemable Noncontrolling Interest
Common Stock
Class A Common Stock
Common Stock
Class B Common Stock
Note Receivable for Common Stock
Note Receivable for Common Stock
Class A Common Stock
Additional Paid-in Capital
Additional Paid-in Capital
Class A Common Stock
Accumulated Deficit
Beginning balance at Dec. 31, 2021       $ 24,962              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (4,564)              
Change in redemption value of noncontrolling interest       3,809              
Ending balance at Sep. 30, 2022       24,207              
Beginning balance, shares (in shares) at Dec. 31, 2021         66,942,777 23,093,860          
Beginning balance at Dec. 31, 2021 $ (9,740)       $ 669 $ 232 $ 0   $ 238,193   $ (248,834)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (14,419)                   (14,419)
Share-based compensation 981               981    
Issuance of Class A Common Stock to Collaboration Partner (in shares)         10,386,274            
Issuance of Class A common stock to collaboration partner, net of offering cost 5,040       $ 104         $ 4,936  
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)         4,154,549            
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs 5,378       $ 42     $ (4,000)   9,336  
Change in redemption value of noncontrolling interest (3,809)                   (3,809)
Ending balance, shares (in shares) at Sep. 30, 2022         81,483,600 23,093,860          
Ending balance at Sep. 30, 2022 (16,569)       $ 815 $ 232 (4,000)   253,446   (267,062)
Beginning balance at Jun. 30, 2022       15,916              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (1,207)              
Change in redemption value of noncontrolling interest       9,498              
Ending balance at Sep. 30, 2022       24,207              
Beginning balance, shares (in shares) at Jun. 30, 2022         77,329,051 23,093,860          
Beginning balance at Jun. 30, 2022 (8,526)       $ 773 $ 232 0   243,772   (253,303)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (4,261)                   (4,261)
Share-based compensation 338               338    
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)         4,154,549            
Issuance of Class A common stock under CinRx purchase agreement, net of offering costs 5,378       $ 42     $ (4,000)   $ 9,336  
Change in redemption value of noncontrolling interest (9,498)                   (9,498)
Ending balance, shares (in shares) at Sep. 30, 2022         81,483,600 23,093,860          
Ending balance at Sep. 30, 2022 (16,569)       $ 815 $ 232 $ (4,000)   253,446   (267,062)
Beginning balance at Dec. 31, 2022 16,579     16,579              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (4,753)              
Change in redemption value of noncontrolling interest       (1,104)              
Ending balance at Sep. 30, 2023 10,722     10,722              
Beginning balance, shares (in shares) at Dec. 31, 2022   81,483,600 23,093,860   81,483,600 23,093,860          
Beginning balance at Dec. 31, 2022 (10,740)       $ 815 $ 232     253,737   (265,524)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (16,772)                   (16,772)
Share-based compensation 1,175               1,175    
Change in redemption value of noncontrolling interest 1,104                   1,104
Ending balance, shares (in shares) at Sep. 30, 2023   81,483,600 23,093,860   81,483,600 23,093,860          
Ending balance at Sep. 30, 2023 (25,233)       $ 815 $ 232     254,912   (281,192)
Beginning balance at Jun. 30, 2023       18,879              
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]                      
Net loss       (1,886)              
Change in redemption value of noncontrolling interest       (6,271)              
Ending balance at Sep. 30, 2023 10,722     $ 10,722              
Beginning balance, shares (in shares) at Jun. 30, 2023         81,483,600 23,093,860          
Beginning balance at Jun. 30, 2023 (25,283)       $ 815 $ 232     254,479   (280,809)
Increase (Decrease) in Stockholders' Equity [Roll Forward]                      
Net loss (6,654)                   (6,654)
Share-based compensation 433               433    
Change in redemption value of noncontrolling interest 6,271                   6,271
Ending balance, shares (in shares) at Sep. 30, 2023   81,483,600 23,093,860   81,483,600 23,093,860          
Ending balance at Sep. 30, 2023 $ (25,233)       $ 815 $ 232     $ 254,912   $ (281,192)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:    
Net loss before noncontrolling interest $ (21,525) $ (18,983)
Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:    
Depreciation expense 67 69
Loss from G42 Promissory Note early redemption 313 0
Non-cash interest income (100) (200)
Interest expense 0 9
Share-based compensation expense 1,175 981
Change in fair value of investments (3,044) 2,998
Impairment of investments in Anteris Bio, Inc. 4,245 0
Change in fair value of warrants, related party (406) (221)
Changes in assets and liabilities:    
Accounts receivable 173 0
Prepaid expenses and other assets 665 853
Accounts payable and accrued expenses 2,270 (1,417)
Contract liabilities 0 6,769
Net cash used in operating activities (16,167) (9,142)
Cash flows from investing activities:    
Purchases of property and equipment 0 (21)
Net cash used in investing activities 0 (21)
Cash flows from financing activities:    
Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner 12,030 0
Proceeds from sale of Class A common stock to collaboration partner, net of offering costs 0 5,040
Proceeds from sale of Class A common stock and warrants, net of offering costs 0 5,746
Proceeds from debt issuance 566 776
Repayment of notes payable (317) (475)
Net cash provided by financing activities 12,279 11,087
Net (decrease) increase in cash and cash equivalents (3,888) 1,924
Total cash and cash equivalents, beginning of period 12,126 13,415
Total cash and cash equivalents, end of period 8,238 15,339
Non-cash activities:    
Change in redemption value of noncontrolling interest (1,104) 3,809
Notes receivable recorded at fair value from collaboration partner 0 11,891
Notes receivable for common stock from CinRx purchase agreement 0 11,891
CinRx    
Non-cash activities:    
Notes receivable recorded at fair value from collaboration partner 0 4,000
Notes receivable for common stock from CinRx purchase agreement $ 0 $ 4,000
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Description of Business, Basis of Presentation and Going Concern
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Description of Business, Basis of Presentation and Going Concern Description of Business, Basis of Presentation and Going Concern
Description of Business
vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.
Principles of Consolidation
vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.
The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. Various holders own nonvoting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 77.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&F Group”), a related party and an affiliate of MacAndrews & Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). In addition, vTv Therapeutics Inc. also entered into the Controlled Equity OfferingSM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. (“Cantor Fitzgerald”) (the “ATM Offering”), the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). vTv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.
Going Concern and Liquidity
To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September 30, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September 30, 2023, the Company had an accumulated deficit of $281.2 million and has generated net losses in each year of its existence.
As of September 30, 2023, the Company’s liquidity sources included cash and cash equivalents of $8.2 million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. To meet our future funding requirements into the third quarter of 2024, including
funding the ongoing and future clinical trials of cadisegliatin (TTP399), we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs.
The Company may also use its remaining availability of $37.3 million under its Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company’s Class A common stock and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock. See Note 9 for further details.
If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative impact on our financial condition. As such, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.
The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies Summary of Significant Accounting Policies
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.
One hundred percent (100%) of the revenue earned during the nine months ended September 30, 2022 was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September 30, 2023.
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.
Research and Development
Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs
of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements
Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration Agreements Collaboration Agreements
G42 Purchase Agreement and Cogna Collaborative and License Agreement
The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”) on May 31, 2022, pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). As part of the G42 Purchase Agreement, G42 Investments nominated a director as appointee and the Company’s board of directors approved appointing the new director to the Company’s board. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024, (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for cadisegliatin (TTP399), the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.
Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for cadisegliatin
(TTP399) as well as jointly creating a global development plan to develop, market, and commercialize cadisegliatin (TTP399) in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercialize cadisegliatin (TTP399) in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and cadisegliatin (TTP399). Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of cadisegliatin (TTP399) needed to conduct the trials.
Under the Cogna Agreement, Cogna has the right to develop and commercialize cadisegliatin (TTP399) in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, cadisegliatin (TTP399) for commercial sale under terms to be agreed upon by the parties at a later date.
Separately, the Company will conduct its clinical trials for cadisegliatin (TTP399) outside of the Partner Territory at its own cost. The results of each party’s clinical trials will be combined by the Company to seek FDA approval in the United States for cadisegliatin (TTP399). On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.
The G42 Purchase Agreement also provides for, following the receipt of FDA approval of cadisegliatin (TTP399), at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the FDA approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA approval will be granted or as to the timing thereof.
Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of cadisegliatin (TTP399) for a period of at least ten years after the first commercial sale of cadisegliatin (TTP399) in the Partner Territory.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this quarterly report on Form 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date.
A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account.
The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of cadisegliatin (TTP399), and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete R&D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.
By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of September 30, 2023, the clinical trials had not
commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September 30, 2023.
The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after cadisegliatin (TTP399) is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September 30, 2023.
On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations. The G42 Promissory Note receivable was classified and accounted for under ASC 310 Receivables (“ASC 310”) and was initially measured at its fair value of $11.9 million. The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September 30, 2023.
Huadong License Agreement
The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound TTP273, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a nonexclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory.
On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the “First Huadong Amendment”) which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.
Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.
The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on a joint development committee (the “JDC”), and (iv) other obligations considered to be immaterial in nature.
The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the nine months ended
September 30, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the nine months ended September 30, 2023.
A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September 30, 2023, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September 30, 2023 was immaterial. An immaterial amount of revenue for this performance obligation was recognized during the nine months ended September 30, 2022. No revenue for this performance obligation has been recognized during the nine months ended September 30, 2023.
Anteris License Agreement
On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (“Anteris”) (the “Anteris License Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company’s Nrf2 activator, HPP971.
Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of $2.0 million. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to $151.0 million. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.
Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the $2.0 million initial license payment as well as the fair value of the equity interest received in Anteris of $4.2 million. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. No revenue was recognized related to the Anteris License Agreement during the three and nine months ended September 30, 2023 and 2022.
On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement. Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023. The Company has begun the process of winding up the license, including obtaining all regulatory, manufacturing and other records generated by Anteris during the term of the Anteris License Agreement.
On October 16, 2023, the Company received a Section228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). (See Note 14).
Contract Liabilities
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
September 30, 2023December 31, 2022
Current portion of contract liabilities$17 $17 
Contract liabilities, net of current portion18,669 18,669 
Total contract liabilities$18,686 $18,686 
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Share-Based Compensation Share-Based CompensationThe Company has issued nonqualified stock option awards to management, other key employees, consultants, and nonemployee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September 30, 2023, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.8 million, which is expected to be
recognized over a weighted average period of 2.2 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022 was $0.76 and $0.68 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September 30, 2023 was immaterial.
The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2023:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 20228,418,571 $2.17 
Granted1,176,868 0.87 
Forfeited(50,000)1.29 
Awards outstanding at September 30, 20239,545,439 $2.01 
Options exercisable at September 30, 20235,018,072 $3.04 
Weighted average remaining contractual term6.6 Years
Options vested and expected to vest at September 30, 20238,188,444 $2.21 
Weighted average remaining contractual term7.5 Years
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$113 $109 $316 $289 
General and administrative320 229 859 692 
Total share-based compensation expense$433 $338 $1,175 $981 
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Investments
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
In connection with the Reneo Pharmaceuticals, Inc. (“Reneo”) and Anteris License Agreements, the Company received equity ownership interests of less than 20% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company’s Condensed Consolidated Balance Sheets.
Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss.
The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.
The Company’s investments consist of the following:
September 30, 2023December 31, 2022
Equity investment with readily determinable fair value:
Reneo common stock$4,387 $1,343 
Equity investment without readily determinable fair values assessed under the measurement alternative:
Anteris preferred stock— 4,245 
Total$4,387 $5,588 
The Company recognized an unrealized gain on its investment in Reneo of $0.6 million and $3.0 million for the three and nine months ended September 30, 2023, respectively. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September 30, 2022,
respectively. These adjustments were recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
On October 16, 2023, the Company received a Section228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $4.2 million impairment charge during the three and nine months ended September 30, 2023.
On October 30, 2023, the Company entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $4.4 million.
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies
 9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Legal Matters
From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.
Novo Nordisk
In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as cadisegliatin (TTP399). This agreement was amended in May 2019 to create milestone payments applicable to certain specific and nonspecific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments payable totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for cadisegliatin (TTP399) under this agreement.
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Leases Leases
In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities of $0.1 million. Further, the second amendment to the lease does not include any material residual value guarantee or restrictive covenants.
At each of September 30, 2023 and December 31, 2022, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At September 30, 2023 and December 31, 2022, the weighted average remaining lease terms for the operating leases held by the Company were 2.2 years and 2.9 years, respectively.
Maturities of lease liabilities for the Company’s operating leases as of September 30, 2023 were as follows (in thousands):
2023 (remaining three months)$48 
2024194 
2025177 
2026— 
2027— 
Thereafter— 
Total lease payments419 
Less: imputed interest(41)
Present value of lease liabilities$378 
Operating lease cost and the related operating cash flows for the nine months ended September 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively.
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Redeemable Noncontrolling Interest Redeemable Noncontrolling Interest
The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September 30, 2023 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.
The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2023 and December 31, 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $10.7 million and $16.6 million, respectively.
Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Net loss attributable to vTv Therapeutics Inc. common shareholders$(6,654)$(4,261)$(16,772)$(14,419)
Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances1,592 (1,174)4,212 (103)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest$(5,062)$(5,435)$(12,560)$(14,522)
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Deficit
 9 Months Ended
Sep. 30, 2023
Equity [Abstract]  
Stockholders' Deficit Stockholders’ DeficitOn May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.
G42 Investments Transaction
On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
CinPax and CinRx Transaction
On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement provides CinPax the right to nominate a director to be approved to sit on the Company’s Board of Directors and a board observer, which was subsequently approved by the Company’s board.
Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this quarterly report on Form 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date.
The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of common stock at an initial exercise of price of approximately $0.72 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)
The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, cadisegliatin (TTP399) (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.
Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)
The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.
ATM Offering
In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as
defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3.
On January 14, 2021 and June 25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of $5.5 million and $50.0 million, respectively.
During the three and nine months ended September 30, 2023 and 2022, the Company did not sell any shares under the ATM Offering.
Lincoln Park Capital Transaction
On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park pursuant to the LPC Purchase Agreement. During the three and nine months ended September 30, 2023 and 2022, the Company did not sell any shares under the LPC Purchase Agreement.
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Related-Party Transactions
 9 Months Ended
Sep. 30, 2023
Related Party Transactions [Abstract]  
Related-Party Transactions Related-Party Transactions
MacAndrews & Forbes Incorporated
MacAndrews directly or indirectly controls 23,084,267 shares of Class B common stock. Further, as of September 30, 2023, MacAndrews directly or indirectly holds 36,519,212 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 57.0% of the combined voting power of the Company’s outstanding common stock.
The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:
Letter Agreements
The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock.
The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital.
Exchange Agreement
Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September 30, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.
Tax Receivable Agreement
The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&F TTP Holdings Two LLC (“M&F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that
the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement.
As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2023.
Investor Rights Agreement
The Company is party to an investor rights agreement with M&F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.
G42 Investments
On May 31, 2022, the Company entered into a common stock purchase agreement with G42 Investments pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid on May 31, 2023 (the “G42 Promissory Note”). As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors appointed the new director to the Company’s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $12.0 million from G42 Investments, which represented a 3.75% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.
CinRx Pharma, LLC
Master Services Agreement
On July 22, 2022, the Company entered into the CinRx MSA with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company’s Class A common stock.
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes
 9 Months Ended
Sep. 30, 2023
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and nine months ended September 30, 2023. The Company’s income tax provision for the nine months ended September 30, 2022 was $0.2 million representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September 30, 2022.
Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September 30, 2023 is due to the valuation allowance against the Company’s expected net operating losses.
As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which
would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2023.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net Loss per Share Net Loss per Share
Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive.
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Numerator:
Net loss$(8,540)$(5,468)$(21,525)$(18,983)
Less: Net loss attributable to noncontrolling interests(1,886)(1,207)(4,753)(4,564)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted(6,654)(4,261)(16,772)(14,419)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted81,483,600 80,490,121 81,483,600 72,649,531 
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.08)$(0.05)$(0.21)$(0.20)
Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:
September 30, 2023September 30, 2022
Class B common stock (1)
23,093,860 23,093,860 
Common stock options granted under the Plan9,545,439 7,718,944 
Common stock warrants3,214,503 3,214,503 
Total35,853,802 34,027,307 
__________________________
(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value of Financial Instruments Fair Value of Financial Instruments
The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.
The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant
judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2023 and December 31, 2022 (in thousands):
Balance at September 30, 2023Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$4,387 $4,387 $— $— 
Total$4,387 $4,387 $— $— 
Liabilities:
Warrant liability, related party (1)
$278 $— $— $278 
Total$278 $— $— $278 
Balance at December 31, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,343 $1,343 $— $— 
Total$1,343 $1,343 $— $— 
Liabilities:
Warrant liability, related party (1)
$684 $— $— $684 
Total$684 $— $— $684 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
Changes in Level 3 instruments for the three months ended September 30,
Balance at January 1Net Change in
fair value included in
earnings		Purchases /
Issuance		Sales /
Repurchases		Balance at September 30,
2023
Warrant liability, related party$684 $(406)$— $— $278 
Total$684 $(406)$— $— $278 
2022
Warrant liability, related party$1,262 $(221)$368 $— $1,409 
Total$1,262 $(221)$368 $— $1,409 
There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income – related party in the Company’s Condensed Consolidated Statements of Operations.
The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility
of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2023 and December 31, 2022 were:
September 30, 2023December 31, 2022
RangeWeighted AverageRangeWeighted Average
Expected volatility
68.37% - 77.01%
76.06%
76.94% - 85.88%
82.17%
Risk-free interest rate
4.78% - 5.38%
4.88%
4.11% - 4.43%
4.19%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2023 were:
Expected volatility 82.38 %
Expected life of options in years3.75
Risk-free interest rate4.73 %
Expected dividend yield— %
The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.
Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events
 9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent Events Subsequent EventsOn October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”) (See Note 5).On October 30, 2023, vTv LLC, entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with Reneo pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million, which was received by vTv LLC on October 30, 2023. vTv LLC had acquired the Reneo stock in connection with the December 21, 2017 License Agreement between vTv LLC and Reneo, which remains in effect.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure        
Net loss $ (6,654) $ (4,261) $ (16,772) $ (14,419)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies (Policies)
 9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Unaudited Interim Financial Information
Unaudited Interim Financial Information
The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.
The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.
The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.
Concentration of Credit Risk
Concentration of Credit Risk
Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.
One hundred percent (100%) of the revenue earned during the nine months ended September 30, 2022 was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September 30, 2023.
Cash and Cash Equivalents
Cash and Cash Equivalents
The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.
Investments
Investments
Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.
Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment.
Revenue Recognition
Revenue Recognition
The Company uses the revenue recognition guidance established by ASC 606, Revenue From Contracts With Customers (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, Collaborative Arrangements (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.
The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.
The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided.
Research and Development
Research and Development
Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs
of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.
The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.
The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.
Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements
Fair Value Measurements: In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements (Tables)
 9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Summary of Contract Liabilities Related to Company's Collaboration Agreements
Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):
September 30, 2023December 31, 2022
Current portion of contract liabilities$17 $17 
Contract liabilities, net of current portion18,669 18,669 
Total contract liabilities$18,686 $18,686 
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation (Tables)
 9 Months Ended
Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]  
Summary of Stock Award Activity for the Period
The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2023:
Number of Shares Weighted
Average Exercise Price
Awards outstanding at December 31, 20228,418,571 $2.17 
Granted1,176,868 0.87 
Forfeited(50,000)1.29 
Awards outstanding at September 30, 20239,545,439 $2.01 
Options exercisable at September 30, 20235,018,072 $3.04 
Weighted average remaining contractual term6.6 Years
Options vested and expected to vest at September 30, 20238,188,444 $2.21 
Weighted average remaining contractual term7.5 Years
Summary of Compensation Expense Related to Grants of Stock Options
Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):
Three Months Ended September 30,Nine Months Ended September 30,
2023202220232022
Research and development$113 $109 $316 $289 
General and administrative320 229 859 692 
Total share-based compensation expense$433 $338 $1,175 $981 
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Investments (Tables)
 9 Months Ended
Sep. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed
The Company’s investments consist of the following:
September 30, 2023December 31, 2022
Equity investment with readily determinable fair value:
Reneo common stock$4,387 $1,343 
Equity investment without readily determinable fair values assessed under the measurement alternative:
Anteris preferred stock— 4,245 
Total$4,387 $5,588 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Leases (Tables)
 9 Months Ended
Sep. 30, 2023
Leases [Abstract]  
Schedule of Maturities of Lease Liabilities for Operating Leases
Maturities of lease liabilities for the Company’s operating leases as of September 30, 2023 were as follows (in thousands):
2023 (remaining three months)$48 
2024194 
2025177 
2026— 
2027— 
Thereafter— 
Total lease payments419 
Less: imputed interest(41)
Present value of lease liabilities$378 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest (Tables)
 9 Months Ended
Sep. 30, 2023
Noncontrolling Interest [Abstract]  
Summary of Net Income Attributable to Vtv Therapeutics Inc The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Net loss attributable to vTv Therapeutics Inc. common shareholders$(6,654)$(4,261)$(16,772)$(14,419)
Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances1,592 (1,174)4,212 (103)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest$(5,062)$(5,435)$(12,560)$(14,522)
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share (Tables)
 9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock
A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):
For the Three Months Ended September 30,For the Nine Months Ended September 30,
2023202220232022
Numerator:
Net loss$(8,540)$(5,468)$(21,525)$(18,983)
Less: Net loss attributable to noncontrolling interests(1,886)(1,207)(4,753)(4,564)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted(6,654)(4,261)(16,772)(14,419)
Denominator:
Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted81,483,600 80,490,121 81,483,600 72,649,531 
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted$(0.08)$(0.05)$(0.21)$(0.20)
Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share
Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:
September 30, 2023September 30, 2022
Class B common stock (1)
23,093,860 23,093,860 
Common stock options granted under the Plan9,545,439 7,718,944 
Common stock warrants3,214,503 3,214,503 
Total35,853,802 34,027,307 
__________________________
(1)Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments (Tables)
 9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Summarizes the Conclusions Reached Regarding Fair Value Measurements The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2023 and December 31, 2022 (in thousands):
Balance at September 30, 2023Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$4,387 $4,387 $— $— 
Total$4,387 $4,387 $— $— 
Liabilities:
Warrant liability, related party (1)
$278 $— $— $278 
Total$278 $— $— $278 
Balance at December 31, 2022Quoted Prices in Active
Markets for Identical Assets
(Level 1)		Significant Other Observable
Inputs
(Level 2)		Significant Unobservable Inputs
(Level 3)
Assets:
Equity securities with readily determinable fair value$1,343 $1,343 $— $— 
Total$1,343 $1,343 $— $— 
Liabilities:
Warrant liability, related party (1)
$684 $— $— $684 
Total$684 $— $— $684 
_____________________________
(1)Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.
Changes in Level 3 instruments for the three months ended September 30,
Balance at January 1Net Change in
fair value included in
earnings		Purchases /
Issuance		Sales /
Repurchases		Balance at September 30,
2023
Warrant liability, related party$684 $(406)$— $— $278 
Total$684 $(406)$— $— $278 
2022
Warrant liability, related party$1,262 $(221)$368 $— $1,409 
Total$1,262 $(221)$368 $— $1,409 
Fair Value Measurement Inputs and Valuation Techniques Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2023 and December 31, 2022 were:
September 30, 2023December 31, 2022
RangeWeighted AverageRangeWeighted Average
Expected volatility
68.37% - 77.01%
76.06%
76.94% - 85.88%
82.17%
Risk-free interest rate
4.78% - 5.38%
4.88%
4.11% - 4.43%
4.19%
The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2023 were:
Expected volatility 82.38 %
Expected life of options in years3.75
Risk-free interest rate4.73 %
Expected dividend yield— %
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Description of Business, Basis of Presentation and Going Concern (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Retained earnings (accumulated deficit) $ (281,192) $ (265,524)
Cash and cash equivalent $ 8,238 $ 12,126
Class A Common Stock    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Common stock par value (in usd per share) $ 0.01 $ 0.01
Class A Common Stock | Cantor Fitzgerald    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Remaining available stock value $ 37,300  
Class A Common Stock | LPC Purchase Agreement    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Common stock, capital shares reserved for future issuance (in shares) 9,437,376  
Class B Common Stock    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Common stock par value (in usd per share) $ 0.01 $ 0.01
vTv Therapeutics LLC    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC 22.10%  
Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC 77.90%  
vTv Therapeutics LLC | Class B Common Stock    
Organization Consolidation And Presentation Of Financial Statements [Line Items]    
Common stock par value (in usd per share) $ 0.01  
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Summary Of Significant Accounting Policies [Line Items]        
Revenue $ 0 $ 0 $ 0 $ 2,009
Revenue | Customer | One Customer        
Summary Of Significant Accounting Policies [Line Items]        
Concentration risk percentage       100.00%
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Feb. 28, 2023
May 31, 2022
Dec. 11, 2020
Aug. 31, 2017
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2020
Dec. 31, 2022
Jan. 14, 2021
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Loss from G42 Promissory Note early redemption             $ 313,000 $ 0      
Contract liabilities, net of current portion         $ 18,669,000   18,669,000     $ 18,669,000  
Revenue         0 $ 0 0 2,009,000      
G42 Investments                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Shares sold (in shares)   10,386,274                  
Sale of stock, price per share (in usd per shares)   $ 2.41                  
Sale of stock, consideration received on transaction, gross   $ 25,000,000                  
Sale of stock, consideration received on transaction   12,500,000                  
Accounts and financing receivable, after allowance for credit loss   12,500,000                  
Proceeds from collection of notes receivable $ 12,000,000                    
Discount rate 3.75%                    
Loss from G42 Promissory Note early redemption $ 300,000                    
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Sale of stock, consideration received on transaction, gross   25,000,000                  
Accounts and financing receivable, after allowance for credit loss   12,500,000                  
Proceeds from collection of notes receivable $ 12,000,000                    
Discount rate 3.75%                    
Loss from G42 Promissory Note early redemption $ 300,000                    
Collaborative arrangement, contingent consideration   30,000,000                  
Collaborate arrangement, contingent consideration transferred, cash   30,000,000                  
Contract liabilities, net of current portion         18,700,000   18,700,000        
Discount on note receivable             600,000        
Collaboration revenue recognized         0   0        
Revenue         0   0        
Receivables, fair value disclosure         11,900,000   11,900,000        
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | G42 Investments | Class A Common Stock                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Common stock, value   $ 5,700,000                  
Share price (in usd per share)   $ 0.55                  
G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement | Cogna                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Royalties receivable, period   10 years                  
Collaborative Arrangements | JDRF                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Maximum funding percentage of research and development milestones       50.00%              
Collaborative Arrangements | JDRF | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Adjustments to transaction price for performance obligations             0 0      
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Maximum contribution amount to clinical trial                     $ 3,000,000
Potential development and regulatory milestone payments                     $ 3,000,000
Collaborative Arrangements | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Phase 2 MRCT | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Adjustments to transaction price for performance obligations             0 2,000,000      
Collaborative Arrangements | Anteris Bio Inc                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Potential development and regulatory milestone payments     $ 151,000,000                
License Fee Received     $ 2,000,000                
Contract with customer, liability, revenue recognized         $ 0 $ 0 $ 0 $ 0      
Collaborative Arrangements | Anteris Bio Inc | License and Technology Transfer Services of Chemistry and Manufacturing Know-How                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
License Fee Received                 $ 2,000,000    
Equity interest received                 $ 4,200,000    
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Current portion of contract liabilities $ 17 $ 17
Contract liabilities, net of current portion 18,669 18,669
Contract liabilities, net of current portion $ 18,686 $ 18,686
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Additional Information (Detail) - Stock Option - USD ($)
$ / shares in Units, $ in Millions
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Non-qualified stock option awards vesting period 3 years  
Non-qualified stock option awards expiration term 10 years  
Unrecognized compensation cost related to non-vested share-based compensation arrangements $ 1.8  
Weighted average period to recognize unrecognized share-based compensation cost 2 years 2 months 12 days  
Weighted average grant date fair value of options granted (in usd per share) $ 0.76 $ 0.68
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)
 9 Months Ended
Sep. 30, 2023
$ / shares
shares
Number of Shares  
Awards outstanding, Beginning balance (in shares) | shares 8,418,571
Granted (in shares) | shares 1,176,868
Forfeited (in shares) | shares (50,000)
Awards outstanding, Ending balance (in shares) | shares 9,545,439
Options exercisable (in shares) | shares 5,018,072
Options exercisable, weighted average remaining contractual term 6 years 7 months 6 days
Options vested and expected to vest (in shares) | shares 8,188,444
Options vested and expected to vest, weighted average remaining contractual term 7 years 6 months
Weighted Average Exercise Price  
Awards outstanding, Beginning balance (in usd per share) | $ / shares $ 2.17
Granted (in usd per share) | $ / shares 0.87
Forfeited (in usd per share) | $ / shares 1.29
Awards outstanding, Ending balance (in usd per share) | $ / shares 2.01
Options exercisable (in usd per share) | $ / shares 3.04
Options vested and expected to vest (in usd per share) | $ / shares $ 2.21
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Total share-based compensation expense $ 433 $ 338 $ 1,175 $ 981
Research and development        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Total share-based compensation expense 113 109 316 289
General and administrative        
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]        
Total share-based compensation expense $ 320 $ 229 $ 859 $ 692
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Investments - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Oct. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Equity Securities Without Readily Determinable Fair Value [Line Items]          
Unrealized gain (loss) on investment       $ 3,044 $ (2,998)
Impairment of investments in Anteris Bio, Inc.   $ 4,200   $ 4,245 0
Reneo          
Equity Securities Without Readily Determinable Fair Value [Line Items]          
Equity method investments, ownership percentage   20.00%   20.00%  
Unrealized gain (loss) on investment   $ 600 $ 400 $ 3,000 $ (3,000)
Reneo | Subsequent Event          
Equity Securities Without Readily Determinable Fair Value [Line Items]          
Stock repurchased during period $ 4,400        
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Equity Securities Without Readily Determinable Fair Value [Line Items]    
Equity investment without readily determinable fair values assessed under the measurement alternative: $ 4,387 $ 5,588
Reneo | Common Stock    
Equity Securities Without Readily Determinable Fair Value [Line Items]    
Equity investment with readily determinable fair value: 4,387 1,343
Anteris Bio Inc | Preferred Stock    
Equity Securities Without Readily Determinable Fair Value [Line Items]    
Equity investment without readily determinable fair values assessed under the measurement alternative: $ 0 $ 4,245
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and Contingencies - Additional Information (Detail) - Novo License Agreement - USD ($)
$ in Millions
Dec. 31, 2021
Feb. 28, 2007
Developmental and Regulatory Milestone Payment | Type 1 Diabetes    
Commitments And Contingencies [Line Items]    
Potential milestone payment   $ 9.0
Developmental and Regulatory Milestone Payment | Type 2 Diabetes | Maximum    
Commitments And Contingencies [Line Items]    
Potential milestone payment   50.5
Developmental and Regulatory Milestone Payment | Other Indication | Maximum    
Commitments And Contingencies [Line Items]    
Potential milestone payment   115.0
Sales-based Milestones Payment    
Commitments And Contingencies [Line Items]    
Potential milestone payment   $ 75.0
Satisfaction of Milestone Payment    
Commitments And Contingencies [Line Items]    
Potential milestone payment $ 2.0  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Additional Information (Details) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Nov. 30, 2022
Leases [Abstract]        
Lessee, operating lease, renewal term 5 years      
Lessee, operating lease, termination period 3 years      
Present value of lease liabilities $ 378     $ 100
Operating lease right-of-use assets $ 272   $ 349 $ 100
Weighted average incremental borrowing rate 9.50%   9.50%  
Remaining operating lease term 2 years 2 months 12 days   2 years 10 months 24 days  
Operating lease cost $ 200 $ 100    
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) - USD ($)
$ in Thousands
Sep. 30, 2023
Nov. 30, 2022
Leases [Abstract]    
2023 (remaining three months) $ 48  
2024 194  
2025 177  
2026 0  
2027 0  
Thereafter 0  
Total lease payments 419  
Less: imputed interest (41)  
Present value of lease liabilities $ 378 $ 100
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest - Additional Information (Detail) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Noncontrolling Interest [Line Items]    
Redemption amount of noncontrolling interest $ 10.7 $ 16.6
Class A Common Stock    
Noncontrolling Interest [Line Items]    
Number of days used to determine exchange value based on weighted average price of Class A common stock 20 days  
Class A Common Stock | Exchange of Redeemable Non controlling Interest To Class A Common Stock    
Noncontrolling Interest [Line Items]    
Stock conversion ratio 1  
vTv Therapeutics LLC    
Noncontrolling Interest [Line Items]    
Noncontrolling interest ownership percentage 22.10%  
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Noncontrolling Interest [Abstract]        
Net loss attributable to vTv Therapeutics Inc. common shareholders $ (6,654) $ (4,261) $ (16,772) $ (14,419)
Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances 1,592 (1,174) 4,212 (103)
Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest $ (5,062) $ (5,435) $ (12,560) $ (14,522)
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Stockholders' Deficit - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended
Feb. 28, 2023
Jul. 22, 2022
May 31, 2022
Jun. 25, 2021
May 04, 2021
Jan. 14, 2021
Nov. 24, 2020
Apr. 30, 2020
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Dec. 31, 2020
Class Of Stock [Line Items]                            
Capital stock, shares authorized (in shares)         350,000,000                 250,000,000
Loss from G42 Promissory Note early redemption                     $ 313 $ 0    
Stock issued during period                       $ 5,040    
G42 Investments                            
Class Of Stock [Line Items]                            
Shares sold (in shares)     10,386,274                      
Sale of stock, price per share (in usd per shares)     $ 2.41                      
Sale of stock, consideration received on transaction, gross     $ 25,000                      
Sale of stock, consideration received on transaction     12,500                      
Accounts and financing receivable, after allowance for credit loss     $ 12,500                      
Sale of stock, consideration, receivables, payment term     1 year                      
Proceeds from collection of notes receivable $ 12,000                          
Discount rate 3.75%                          
Loss from G42 Promissory Note early redemption $ 300                          
CinRx Investment                            
Class Of Stock [Line Items]                            
Shares sold (in shares)   4,154,549                        
Sale of stock, price per share (in usd per shares)   $ 2.41                        
Sale of stock, consideration received on transaction, gross   $ 10,000                        
Sale of stock, consideration received on transaction   6,000                        
Accounts and financing receivable, after allowance for credit loss   $ 4,000                        
Warrants, term   5 years                        
Class A Common Stock                            
Class Of Stock [Line Items]                            
Common stock, shares authorized (in shares)         200,000,000       200,000,000   200,000,000   200,000,000 100,000,000
Increase in shares authorized (in shares)         100,000,000                  
Common stock par value (in usd per share)                 $ 0.01   $ 0.01   $ 0.01  
Class A Common Stock | CinRx Investment                            
Class Of Stock [Line Items]                            
Sale of stock, price per share (in usd per shares)   $ 0.72                        
Sale of stock, consideration received on transaction   $ 3,000                        
Class A Common Stock | Cantor Fitzgerald | ATM Offering                            
Class Of Stock [Line Items]                            
Shares sold (in shares)                 0 0 0 0    
Common stock par value (in usd per share)               $ 0.01            
Stock issued during period               $ 13,000            
Aggregate offering price       $ 50,000   $ 5,500                
Class A Common Stock | LPC Purchase Agreement                            
Class Of Stock [Line Items]                            
Shares sold (in shares)                 0 0 0 0    
Class A Common Stock | LPC Purchase Agreement | Maximum                            
Class Of Stock [Line Items]                            
Stock issued during period             $ 47,000              
Common Stock                            
Class Of Stock [Line Items]                            
Common stock, shares authorized (in shares)         300,000,000                 200,000,000
Common Stock | CinRx Investment                            
Class Of Stock [Line Items]                            
Number of securities called by warrants or rights (in shares)   1,200,000                        
Exercise price of warrants or rights (in usd per share)   $ 0.72                        
Warrants, fair value   $ 400                        
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Related-Party Transactions - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 9 Months Ended
Feb. 28, 2023
May 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Oct. 10, 2022
Related Party Transaction [Line Items]          
Loss from G42 Promissory Note early redemption     $ 313 $ 0  
Related Party | MacAndrews & Forbes Incorporated          
Related Party Transaction [Line Items]          
Ownership percentage of majority owner     57.00%    
Amount of cash savings percentage     85.00%    
Related Party | G42 Investments          
Related Party Transaction [Line Items]          
Sale of stock, consideration received on transaction, gross   $ 25,000      
Sale of stock, consideration received on transaction   12,500      
Accounts and financing receivable, after allowance for credit loss   $ 12,500      
Proceeds from collection of notes receivable $ 12,000        
Discount rate 3.75%        
Loss from G42 Promissory Note early redemption $ 300        
Related Party | Master Service Agreement          
Related Party Transaction [Line Items]          
Due to related parties, monthly amount         $ 200
Related Party | Class B Common Stock | MacAndrews & Forbes Incorporated          
Related Party Transaction [Line Items]          
Shares held by related party (in shares)     23,084,267    
Related Party | Class A Common Stock | MacAndrews & Forbes Incorporated          
Related Party Transaction [Line Items]          
Shares held by related party (in shares)     36,519,212    
Related Party | Class A Common Stock | G42 Investments          
Related Party Transaction [Line Items]          
Shares sold (in shares)   10,386,274      
Sale of stock, price per share (in usd per shares)   $ 2.41      
Related Party | Class A Common Stock | CinRx Pharma, LLC | Master Service Agreement          
Related Party Transaction [Line Items]          
Shares held by related party (in shares)     4,154,549    
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Income Taxes - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Taxes [Line Items]        
Income tax provision $ 0 $ 0 $ 0 $ 200
M&F TTP Holdings LLC        
Income Taxes [Line Items]        
Amount of cash savings percentage     85.00%  
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator:        
Net loss $ (8,540) $ (5,468) $ (21,525) $ (18,983)
Less: Net loss attributable to noncontrolling interests (1,886) (1,207) (4,753) (4,564)
Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted (6,654) (4,261) (16,772) (14,419)
Net loss attributable to common shareholders of vTv Therapeutics Inc., basic $ (6,654) $ (4,261) $ (16,772) $ (14,419)
Class A Common Stock        
Denominator:        
Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares) 81,483,600 80,490,121 81,483,600 72,649,531
Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share) $ (0.08) $ (0.05) $ (0.21) $ (0.20)
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) - shares
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 35,853,802 34,027,307
Class B Common Stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 23,093,860 23,093,860
Common stock options granted under the Plan    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 9,545,439 7,718,944
Common stock warrants    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares) 3,214,503 3,214,503
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) - USD ($)
$ in Thousands
 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Significant Unobservable Inputs (Level 3)      
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]      
Beginning Balance $ 684 $ 1,262  
Net Change in fair value included in earnings (406) (221)  
Purchases / Issuance 0 368  
Sales / Repurchases 0 0  
Ending Balance 278 $ 1,409  
Fair Value, Measurements, Recurring      
Assets:      
Equity securities with readily determinable fair value 4,387   $ 1,343
Total 4,387   1,343
Liabilities:      
Warranty liability, related party 278   684
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)      
Assets:      
Equity securities with readily determinable fair value 4,387   1,343
Total 4,387   1,343
Liabilities:      
Warranty liability, related party 0   0
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1) | Warrant liability, related party      
Liabilities:      
Warranty liability, related party 0   0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)      
Assets:      
Equity securities with readily determinable fair value 0   0
Total 0   0
Liabilities:      
Warranty liability, related party 0   0
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2) | Warrant liability, related party      
Liabilities:      
Warranty liability, related party 0   0
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)      
Assets:      
Equity securities with readily determinable fair value 0   0
Total 0   0
Liabilities:      
Warranty liability, related party 278   684
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3) | Warrant liability, related party      
Liabilities:      
Warranty liability, related party $ 278   $ 684
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)
Sep. 30, 2023
Dec. 31, 2022
CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Expected life of options in years 3 years 9 months  
Expected volatility | CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.8238  
Risk-free interest rate | CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0473  
Expected dividend yield | CinRx Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0  
Minimum | Expected volatility | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.6837 0.7694
Minimum | Risk-free interest rate | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0478 0.0411
Maximum | Expected volatility | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.7701 0.8588
Maximum | Risk-free interest rate | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0538 0.0443
Weighted Average | Expected volatility | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.7606 0.8217
Weighted Average | Risk-free interest rate | Letter Agreement Warrants    
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]    
Inputs utilized in the valuation of warrants 0.0488 0.0419
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent Events (Details)
$ in Millions
Oct. 30, 2023
USD ($)
Subsequent Event | Reneo  
Subsequent Event [Line Items]  
Stock repurchased during period $ 4.4
XML 64 vtvt-20230930_htm.xml IDEA: XBRL DOCUMENT 0001641489 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassAMember 2023-11-09 0001641489 us-gaap:CommonClassBMember 2023-11-09 0001641489 2023-09-30 0001641489 2022-12-31 0001641489 us-gaap:CommonClassAMember 2023-09-30 0001641489 us-gaap:CommonClassAMember 2022-12-31 0001641489 us-gaap:CommonClassBMember 2022-12-31 0001641489 us-gaap:CommonClassBMember 2023-09-30 0001641489 2023-07-01 2023-09-30 0001641489 2022-07-01 2022-09-30 0001641489 2022-01-01 2022-09-30 0001641489 us-gaap:NonrelatedPartyMember 2023-07-01 2023-09-30 0001641489 us-gaap:NonrelatedPartyMember 2022-07-01 2022-09-30 0001641489 us-gaap:NonrelatedPartyMember 2023-01-01 2023-09-30 0001641489 us-gaap:NonrelatedPartyMember 2022-01-01 2022-09-30 0001641489 us-gaap:RelatedPartyMember 2023-07-01 2023-09-30 0001641489 us-gaap:RelatedPartyMember 2022-07-01 2022-09-30 0001641489 us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001641489 us-gaap:RelatedPartyMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001641489 us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2023-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001641489 us-gaap:RetainedEarningsMember 2023-06-30 0001641489 2023-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001641489 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2023-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-09-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001641489 us-gaap:RetainedEarningsMember 2023-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-06-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-06-30 0001641489 us-gaap:ReceivablesFromStockholderMember 2022-06-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001641489 us-gaap:RetainedEarningsMember 2022-06-30 0001641489 2022-06-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001641489 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:ReceivablesFromStockholderMember 2022-07-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-09-30 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-09-30 0001641489 us-gaap:ReceivablesFromStockholderMember 2022-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001641489 us-gaap:RetainedEarningsMember 2022-09-30 0001641489 2022-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-12-31 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2022-12-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001641489 us-gaap:RetainedEarningsMember 2022-12-31 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2023-01-01 2023-09-30 0001641489 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2021-12-31 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001641489 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2021-12-31 0001641489 us-gaap:ReceivablesFromStockholderMember 2021-12-31 0001641489 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001641489 us-gaap:RetainedEarningsMember 2021-12-31 0001641489 2021-12-31 0001641489 vtvt:RedeemableNoncontrollingInterestsMember us-gaap:NoncontrollingInterestMember 2022-01-01 2022-09-30 0001641489 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001641489 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001641489 us-gaap:CommonClassAMember us-gaap:ReceivablesFromStockholderMember 2022-01-01 2022-09-30 0001641489 vtvt:CinRxMember 2023-01-01 2023-09-30 0001641489 vtvt:CinRxMember 2022-01-01 2022-09-30 0001641489 vtvt:VTvLLCMember 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassBMember vtvt:VTvLLCMember 2023-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassAMember vtvt:LPCPurchaseAgreementMember 2023-09-30 0001641489 vtvt:OneCustomerMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001641489 vtvt:G42InvestmentsMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember 2023-02-28 2023-02-28 0001641489 vtvt:G42InvestmentsMember 2023-02-28 0001641489 vtvt:CognaMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember us-gaap:CommonClassAMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-09-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-01-01 2023-09-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-07-01 2023-09-30 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-02-28 2023-02-28 0001641489 vtvt:G42InvestmentsMember vtvt:G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember 2023-02-28 0001641489 vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2021-01-14 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2022-01-01 2022-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember 2023-01-01 2023-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2022-01-01 2022-09-30 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember vtvt:PhaseTwoMultiRegionalClinicalTrialMember us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2023-01-01 2023-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2020-12-11 2020-12-11 0001641489 us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2020-12-11 0001641489 vtvt:LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2020-01-01 2020-12-31 0001641489 us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2022-01-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2023-07-01 2023-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2023-01-01 2023-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:AnterisBioIncMember 2022-07-01 2022-09-30 0001641489 us-gaap:CollaborativeArrangementMember vtvt:JDRFInternationalMember 2017-08-01 2017-08-31 0001641489 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2023-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001641489 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2023-07-01 2023-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2022-07-01 2022-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-09-30 0001641489 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2023-09-30 0001641489 us-gaap:CommonStockMember vtvt:ReneoPharmaceuticalsIncMember 2023-09-30 0001641489 us-gaap:CommonStockMember vtvt:ReneoPharmaceuticalsIncMember 2022-12-31 0001641489 us-gaap:PreferredStockMember vtvt:AnterisBioIncMember 2023-09-30 0001641489 us-gaap:PreferredStockMember vtvt:AnterisBioIncMember 2022-12-31 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2023-07-01 2023-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2023-01-01 2023-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2022-07-01 2022-09-30 0001641489 vtvt:ReneoPharmaceuticalsIncMember 2022-01-01 2022-09-30 0001641489 us-gaap:SubsequentEventMember vtvt:ReneoPharmaceuticalsIncMember 2023-10-30 2023-10-30 0001641489 vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:TypeOneDiabetesMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 srt:MaximumMember vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:TypeTwoDiabetesMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 srt:MaximumMember vtvt:DevelopmentalAndRegulatoryMilestonePaymentMember vtvt:OtherIndicationMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 vtvt:SalesBasedMilestonesPaymentMember vtvt:NovoLicenseAgreementMember 2007-02-28 0001641489 vtvt:SatisfactionOfMilestonePaymentMember vtvt:NovoLicenseAgreementMember 2021-12-31 0001641489 2022-11-30 0001641489 vtvt:ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassAMember 2020-12-31 0001641489 us-gaap:CommonClassAMember 2021-05-04 0001641489 us-gaap:CommonClassAMember 2021-05-04 2021-05-04 0001641489 us-gaap:CommonStockMember 2020-12-31 0001641489 us-gaap:CommonStockMember 2021-05-04 0001641489 2020-12-31 0001641489 2021-05-04 0001641489 vtvt:CinRxInvestmentMember 2022-07-22 2022-07-22 0001641489 vtvt:CinRxInvestmentMember 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonClassAMember 2022-07-22 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonClassAMember 2022-07-22 0001641489 vtvt:CinRxInvestmentMember us-gaap:CommonStockMember 2022-07-22 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2020-04-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2020-04-01 2020-04-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2021-01-14 2021-01-14 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2021-06-25 2021-06-25 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2023-07-01 2023-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2022-01-01 2022-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2022-07-01 2022-09-30 0001641489 vtvt:CantorFitzgeraldMember us-gaap:CommonClassAMember vtvt:AtTheMarketOfferingMember 2023-01-01 2023-09-30 0001641489 srt:MaximumMember vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2020-11-24 2020-11-24 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2023-01-01 2023-09-30 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2022-07-01 2022-09-30 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2022-01-01 2022-09-30 0001641489 vtvt:LPCPurchaseAgreementMember us-gaap:CommonClassAMember 2023-07-01 2023-09-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:RelatedPartyMember us-gaap:CommonClassBMember 2023-09-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2023-09-30 0001641489 vtvt:MacAndrewsAndForbesIncorporatedMember us-gaap:RelatedPartyMember 2023-01-01 2023-09-30 0001641489 vtvt:G42InvestmentsMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember us-gaap:RelatedPartyMember 2022-05-31 2022-05-31 0001641489 vtvt:G42InvestmentsMember us-gaap:RelatedPartyMember 2022-05-31 0001641489 vtvt:G42InvestmentsMember us-gaap:RelatedPartyMember 2023-02-28 2023-02-28 0001641489 vtvt:G42InvestmentsMember us-gaap:RelatedPartyMember 2023-02-28 0001641489 vtvt:MasterServiceAgreementMember us-gaap:RelatedPartyMember 2022-10-10 0001641489 vtvt:MasterServiceAgreementMember us-gaap:RelatedPartyMember us-gaap:CommonClassAMember vtvt:CinRxPharmaLLCMember 2023-09-30 0001641489 vtvt:MFTTPHoldingsLLCMember 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassBMember 2023-01-01 2023-09-30 0001641489 us-gaap:CommonClassBMember 2022-01-01 2022-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001641489 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001641489 us-gaap:WarrantMember 2023-01-01 2023-09-30 0001641489 us-gaap:WarrantMember 2022-01-01 2022-09-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2023-09-30 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2023-09-30 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2023-09-30 0001641489 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember vtvt:WarrantLiabilityRelatedPartyMember 2022-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2022-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2023-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2021-12-31 0001641489 us-gaap:FairValueInputsLevel3Member 2022-01-01 2022-09-30 0001641489 us-gaap:FairValueInputsLevel3Member 2022-09-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001641489 srt:MinimumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001641489 srt:MaximumMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001641489 srt:WeightedAverageMember vtvt:LetterAgreementWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputPriceVolatilityMember 2023-09-30 0001641489 vtvt:CinRxWarrantsMember 2023-09-30 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-09-30 0001641489 vtvt:CinRxWarrantsMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-09-30 shares iso4217:USD iso4217:USD shares pure 0001641489 --12-31 2023 Q3 false 0.5 10-Q true 2023-09-30 false 001-37524 vTv Therapeutics Inc. DE 47-3916571 3980 Premier Dr Suite 310 High Point NC 27265 336 841-0300 Class A common stock, par value $0.01 per share VTVT NASDAQ Yes Yes Non-accelerated Filer true false false 81483600 23093860 8238000 12126000 0 173000 0 12243000 1872000 2537000 15000 15000 10125000 27094000 140000 207000 272000 349000 4387000 5588000 14924000 33238000 9620000 7313000 165000 154000 17000 17000 473000 224000 10275000 7708000 18669000 18669000 213000 338000 278000 684000 29435000 27399000 10722000 16579000 0.01 0.01 200000000 200000000 81483600 81483600 815000 815000 0.01 0.01 100000000 100000000 23093860 23093860 232000 232000 254912000 253737000 -281192000 -265524000 -25233000 -10740000 14924000 33238000 0 0 0 2009000 2824000 3055000 11457000 8393000 2544000 2634000 9338000 9813000 5368000 5689000 20795000 18206000 -5368000 -5689000 -20795000 -16197000 -3640000 403000 -1514000 -2998000 341000 -324000 406000 221000 131000 150000 384000 200000 4000 8000 6000 9000 -8540000 -5468000 -21525000 -18783000 0 0 0 200000 -8540000 -5468000 -21525000 -18983000 -1886000 -1207000 -4753000 -4564000 -6654000 -4261000 -16772000 -14419000 -6654000 -4261000 -16772000 -14419000 -0.08 -0.08 -0.05 -0.05 -0.21 -0.21 -0.20 -0.20 81483600 81483600 80490121 80490121 81483600 81483600 72649531 72649531 18879000 81483600 815000 23093860 232000 254479000 -280809000 -25283000 -1886000 -6654000 -6654000 433000 433000 -6271000 6271000 6271000 10722000 81483600 815000 23093860 232000 254912000 -281192000 -25233000 15916000 77329051 773000 23093860 232000 0 243772000 -253303000 -8526000 -1207000 -4261000 -4261000 338000 338000 4154549 42000 -4000000 9336000 5378000 9498000 -9498000 -9498000 24207000 81483600 815000 23093860 232000 -4000000 253446000 -267062000 -16569000 16579000 81483600 815000 23093860 232000 253737000 -265524000 -10740000 -4753000 -16772000 -16772000 1175000 1175000 -1104000 1104000 1104000 10722000 81483600 815000 23093860 232000 254912000 -281192000 -25233000 24962000 66942777 669000 23093860 232000 0 238193000 -248834000 -9740000 -4564000 -14419000 -14419000 981000 981000 10386274 104000 4936000 5040000 4154549 42000 -4000000 9336000 5378000 3809000 -3809000 -3809000 24207000 81483600 815000 23093860 232000 -4000000 253446000 -267062000 -16569000 -21525000 -18983000 67000 69000 -313000 0 100000 200000 0 9000 1175000 981000 3044000 -2998000 4245000 0 -406000 -221000 -173000 0 -665000 -853000 2270000 -1417000 0 6769000 -16167000 -9142000 0 21000 0 -21000 12030000 0 0 5040000 0 5746000 566000 776000 317000 475000 12279000 11087000 -3888000 1924000 12126000 13415000 8238000 15339000 1104000 -3809000 0 11891000 0 4000000 Description of Business, Basis of Presentation and Going Concern<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. (the “Company,” the “Registrant,” “we” or “us”) was incorporated in the state of Delaware in April 2015. The Company is a clinical stage pharmaceutical company focused on treating metabolic and inflammatory diseases to minimize their long-term complications and improve the lives of patients.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vTv Therapeutics Inc. is a holding company, and its principal asset is a controlling equity interest in vTv Therapeutics LLC (“vTv LLC”), the Company’s principal operating subsidiary, which is a clinical stage pharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that vTv LLC is a variable-interest entity (“VIE”) for accounting purposes and that vTv Therapeutics Inc. is the primary beneficiary of vTv LLC because (through its managing member interest in vTv LLC and the fact that the senior management of vTv Therapeutics Inc. is also the senior management of vTv LLC) it has the power and benefits to direct all of the activities of vTv LLC, which include those that most significantly impact vTv LLC’s economic performance. vTv Therapeutics Inc. has therefore consolidated vTv LLC’s results pursuant to Accounting Standards Codification Topic 810, “Consolidation” in its Condensed Consolidated Financial Statements. Various holders own nonvoting interests in vTv LLC, representing a 22.1% economic interest in vTv LLC, effectively restricting vTv Therapeutics Inc.’s interest to 77.9% of vTv LLC’s economic results, subject to increase in the future, should vTv Therapeutics Inc. purchase additional nonvoting common units (“vTv Units”) of vTv LLC, or should the holders of vTv Units decide to exchange such units (together with shares of the Company’s Class B common stock, par value $0.01 (“Class B common stock”)) for shares of Class A common stock (or cash) pursuant to the Exchange Agreement (as defined in Note 9). vTv Therapeutics Inc. has provided financial and other support to vTv LLC in the form of its purchase of vTv Units with the net proceeds of the Company’s initial public offering (“IPO”) in 2015, its registered direct offering in March 2019, and its agreeing to be a co-borrower under the Venture Loan and Security Agreement (the “Loan Agreement”) with Horizon Technology Finance Corporation and Silicon Valley Bank (together, the “Lenders”) which was entered into in 2016. vTv Therapeutics Inc. entered into the letter agreements with MacAndrews and Forbes Group LLC (“M&amp;F Group”), a related party and an affiliate of MacAndrews &amp; Forbes Incorporated (together with its affiliates “MacAndrews”) in December 2017, July 2018, December 2018, March 2019, September 2019, and December 2019 (each a “Letter Agreement” and collectively, the “Letter Agreements”). In addition, vTv Therapeutics Inc. also entered into the Controlled Equity Offering</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald &amp; Co. (“Cantor Fitzgerald”) (the “ATM Offering”), the purchase agreement with Lincoln Park Capital Fund, LLC (“Lincoln Park”) (the “LPC Purchase Agreement”), the common stock purchase agreement with G42 Investments AI Holding RSC Ltd (“G42 Investments”) (the “G42 Purchase Agreement”) and the common stock and warrant purchase agreement with CinPax, LLC and CinRx, LLC, respectively (the “CinRx Purchase Agreement”). v</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Tv Therapeutics Inc. will not be required to provide financial or other support for vTv LLC. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, vTv Therapeutics Inc. will control its business and other activities through its managing member interest in vTv LLC, and its management is the management of vTv LLC. Nevertheless, because vTv Therapeutics Inc. will have no material assets other than its interests in vTv LLC, any financial difficulties at vTv LLC could result in vTv Therapeutics Inc. recognizing a loss.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Going Concern and Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any product revenue and has not achieved profitable operations. The continuing development of our drug candidates will require additional financing. From its inception through September 30, 2023, the Company has funded its operations primarily through a combination of private placements of common and preferred equity, research collaboration agreements, upfront and milestone payments for license agreements, debt and equity financings and the completion of its IPO in August 2015. As of September 30, 2023, the Company had an accumulated deficit of $281.2 million and has generated net losses in each year of its existence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2023, the Company’s liquidity sources included cash and cash equivalents of $8.2 million. Based on our current operating plan, we believe that our current cash and cash equivalents will allow us to meet our liquidity requirements into the first quarter of 2024. To meet our future funding requirements into the third quarter of 2024, including </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">funding the ongoing and future clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TTP399),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we are evaluating several financing strategies, including direct equity investments and the potential licensing and monetization of other Company programs. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company may also use its remaining availability of $37.3 million under its Sales Agreement with Cantor Fitzgerald pursuant to which the Company may offer and sell, from time to time shares of the Company’s Class A common stock and the ability to sell an additional 9,437,376 shares of Class A common stock under the LPC Purchase Agreement based on the remaining number of registered shares. However, the ability to use these sources of capital is dependent on a number of factors, including the prevailing market price of and the volume of trading in the Company’s Class A common stock. See Note 9 for further details. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to raise additional capital as and when needed, or upon acceptable terms, such failure would have a significant negative </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impact on our financial condition. As such, these conditions raise substantial doubt about the Company’s ability to continue as a going concern.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Condensed Consolidated Financial Statements do not include adjustments to reflect the possible future effects on the recoverability and classification of recorded assets or the amounts of liabilities that might be necessary should the Company be unable to continue as a going concern.</span></div> 0.221 0.779 0.01 -281200000 8200000 37300000 9437376 Summary of Significant Accounting Policies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One hundred percent (100%) of the revenue earned during the nine months ended September 30, 2022 was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). The accompanying Condensed Consolidated Balance Sheet as of September 30, 2023, Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2023 and 2022, Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders’ Deficit for the three and nine months ended September 30, 2023 and 2022 and Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2023 and 2022 are unaudited. These unaudited financial statements have been prepared in accordance with the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. These financial statements should be read in conjunction with the audited financial statements and the accompanying notes for the year ended December 31, 2022, contained in the Company’s Annual Report on Form 10-K. The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring adjustments) necessary to state fairly the Company’s financial position as of September 30, 2023, the results of operations for the three and nine months ended September 30, 2023 and 2022 and cash flows for the nine months ended September 30, 2023 and 2022. The December 31, 2022 Condensed Consolidated Balance Sheet included herein was derived from the audited financial statements but does not include all disclosures or notes required by GAAP for complete financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The financial data and other information disclosed in these notes to the financial statements related to the three and nine months ended September 30, 2023 and 2022 are unaudited. Interim results are not necessarily indicative of results for an entire year.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have any components of other comprehensive income recorded within its Condensed Consolidated Financial Statements, and, therefore, does not separately present a statement of comprehensive income in its Condensed Consolidated Financial Statements.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On an ongoing basis, the Company evaluates its estimates, including those related to the grant date fair value of equity awards, the fair value of warrants to purchase shares of its Class A common stock, the fair value of its Class B common stock, the useful lives of property and equipment and the fair value of the Company’s debt, among others. The Company bases its estimates on historical experience and on various other assumptions that it believes to be reasonable, the results of which form the basis for making judgments about the carrying value of assets and liabilities.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with one financial institution. The balance of the cash account frequently exceed insured limits. The associated risk of concentration for cash and cash equivalents is mitigated by transferring a majority of our cash to a AAA rated money market account with a creditworthy institution.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One hundred percent (100%) of the revenue earned during the nine months ended September 30, 2022 was attributable from the satisfaction of a development milestone from the First Huadong Amendment (as defined herein). The Company did not have any revenue during the three months ended September 30, 2022. The Company did not have any revenue during the three and nine months ended September 30, 2023.</span></div> 1 0 0 0 <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers any highly liquid investments with an original maturity of three months or less to be cash and cash equivalents.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments in entities in which the Company has no control or significant influence, is not the primary beneficiary, and have a readily determinable fair value are classified as equity investments with readily determinable fair value. The investments are measured at fair value based on a quoted market price per unit in active markets multiplied by the number of units held without consideration of transaction costs (Level 1). Gains and losses are recorded in other income (expense), net on the Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Equity investments without readily determinable fair value include ownership rights that do not provide the Company with control or significant influence and these investments do not have readily determinable fair values. The Company has elected to measure its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div> <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses the revenue recognition guidance established by ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue From Contracts With Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). When an agreement falls under the scope of other standards, such as ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 808”), the Company will apply the recognition, measurement, presentation, and disclosure guidance in ASC 606 to the performance obligations in the agreements if those performance obligations are with a customer. Revenue recognized by analogizing to ASC 606, is recorded as collaboration revenue on the statements of operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of the Company’s revenue results from its license and collaboration agreements associated with the development of investigational drug products. The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable. For each contract meeting these criteria, the Company identifies the performance obligations included within the contract. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer. The Company then recognizes revenue under each contract as the related performance obligations are satisfied. The Company will recognize collaboration revenue under ASC 808 as a stand-ready obligation under ASC 606 over time based on the estimated period of performance.</span></div>The transaction price under the contract is determined based on the value of the consideration expected to be received in exchange for the transferred assets or services. Development, regulatory and sales milestones included in the Company’s collaboration agreements are considered to be variable consideration. The amount of variable consideration expected to be received is included in the transaction price when it becomes probable that the milestone will be met. For contracts with multiple performance obligations, the contract’s transaction price is allocated to each performance obligation using the Company’s best estimate of the standalone selling price of each distinct good or service in the contract. The primary method used to estimate standalone selling price is the expected cost plus margin approach. Revenue is recognized over the related period over which the Company expects the services to be provided using a proportional performance model or a straight-line method of recognition if there is no discernible pattern over which the services will be provided. <div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Major components of research and development costs include cash compensation, depreciation expense on research and development property and equipment, costs of preclinical studies, clinical trials and related clinical manufacturing, costs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of drug development, costs of materials and supplies, facilities cost, overhead costs, regulatory and compliance costs, and fees paid to consultants and other entities that conduct certain research and development activities on the Company’s behalf. Research and development costs are expensed as incurred.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals based on estimates of the services received, efforts expended and amounts owed pursuant to contracts with numerous contract research and manufacturing organizations. In the normal course of business, the Company contracts with third parties to perform various clinical study activities in the ongoing development of potential products. The financial terms of these agreements are subject to negotiation and variation from contract to contract and may result in uneven payment flows. Payments under the contracts depend on factors such as the achievement of certain events and the completion of portions of the clinical study or similar conditions. The objective of the Company’s accrual policy is to match the recording of expenses in its financial statements to the actual services received and efforts expended. As such, expense accruals related to clinical studies are recognized based on the Company’s estimate of the degree of completion of the event or events specified in the specific clinical study.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records nonrefundable advance payments it makes for future research and development activities as prepaid expenses. Prepaid expenses are recognized as expenses in the Condensed Consolidated Statements of Operations as the Company receives the related goods or services.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs that are reimbursed under a cost-sharing arrangement are reflected as a reduction of research and development expense.</span></div> <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In June 2022, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2022-03 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This guidance is effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company has assessed ASU 2022-03 and early adopted the guidance during the second quarter of 2022. The adoption did not have a material impact on the Company's Condensed Consolidated Financial Statements.</span></div> Collaboration Agreements<div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Purchase Agreement and Cogna Collaborative and License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and G42 Investments AI Holding RSC Ltd, a private limited company (“G42 Investments”), entered into a Common Stock Purchase Agreement (the “G42 Purchase Agreement”) on May 31, 2022, pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at May 31, 2023 (the “G42 Promissory Note”). As part of the G42 Purchase Agreement, G42 Investments nominated a director as appointee and the Company’s board of directors approved appointing the new director to the Company’s board. On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">G42 Investments has agreed to certain transfer restrictions (including restrictions on short sales or similar transactions) and restrictions on further acquisitions of shares, in each case subject to specified exceptions. Following the expiration of a lock up period, from the period May 31, 2022 until December 31, 2024, (or if earlier, the date of receipt of U.S. Food and Drug Administration (“FDA”) approval in the U.S. for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company has granted to G42 Investments certain shelf and piggyback registration rights with respect to those shares of Class A common stock issued to G42 Investments pursuant to the G42 Purchase Agreement, including the ability to conduct an underwritten offering to resell such shares under certain circumstances. The registration rights include customary cooperation, cut-back, expense reimbursement, and indemnification provisions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contemporaneously with the G42 Purchase Agreement, effective on May 31, 2022, the Company entered into a collaboration and license agreement (the “Cogna Agreement”) with Cogna Technology Solutions LLC, an affiliate of G42 Investments (“Cogna”), which requires Cogna to work with the Company in performing clinical trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as jointly creating a global development plan to develop, market, and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in certain countries in the Middle East, Africa, and Central Asia (the “Partner Territory”). Under the terms of the Cogna Agreement, Cogna will obtain a license under certain intellectual property controlled by the Company to enable it to fulfill its obligations and exercise its rights under the Cogna agreement, including to develop and commercializ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Partner Territory, but will not have access to the various intellectual property (“IP”) related to the license and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Specifically, the Company will share various protocols with Cogna related to conducting the clinical trials and will provide the patient dosages and placebo of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">needed to conduct the trials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Cogna Agreement, Cogna has the right to develop and commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory at its own cost once restrictions on the use of the IP have been lifted by the Company. The Cogna Agreement determined which specific countries in the Partner Territory that Cogna may pursue development and commercialization and provides the Company with the ability to determine when Cogna can benefit from this IP through the powers granted to the Company to approve the global development plan. Further, the Company may supply at cost, or Cogna may manufacture, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for commercial sale under terms to be agreed upon by the parties at a later date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company will conduct its clinical trials for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> outside of the Partner Territory at its own cost. The results of each party’s clinical trials will be combined by the Company to seek FDA approval in the United States for </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On December 21, 2022, G42 Healthcare Technology Solutions LLC (formerly known as Cogna Technology Solutions LLC) novated its rights and obligation under the Cogna agreement to G42 Healthcare Research Technology Projects LLC (“G42 Healthcare”), an affiliate of G42 Investments. As a result of the novation, all reference to Cogna herein shall be deemed to refer to G42 Healthcare.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G42 Purchase Agreement also provides for, following the receipt of FDA approval of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, at the option of G42 Investments, either (a) the issuance of the Company’s Class A common stock (the “Milestone Shares”) having an aggregate value equal to $30.0 million or (b) the payment by the Company of $30.0 million in cash (the “Milestone Cash Payment”). The issuance of the Milestone Shares or the payment of the Milestone Cash Payment, as applicable, is conditioned upon receipt of the FDA approval and subject to certain limitations and conditions set forth in the G42 Purchase Agreement. There can be no assurance that the FDA approval will be granted or as to the timing thereof.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once commercialization takes place in the Partner Territory, the Company will receive royalties in the single digits from Cogna on the net sales of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a period of at least ten years after the first commercial sale of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the Partner Territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to G42 Investments, the Company considered the closing price of the common stock on the effective date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this quarterly report on Form 10-Q for details of the ASU. Accordingly, the Company determined that cash consideration of $5.7 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.55 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A premium was paid on the Class A common stock by G42 Investments of $18.7 million, net of a note receivable discount of $0.6 million. This premium is determined to be the transaction price for all remaining obligations under the agreements, which will be accounted for under ASC 808 or ASC 606 based on determination of the unit of account. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that certain commitments under the agreements are in the scope of ASC 808 as both the Company and Cogna are active participants in the clinical trials of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and both are exposed to significant risks and rewards based on the success of the clinical trials and subsequent FDA approval. Cogna is determined to be a vendor of the Company during the clinical trial phase, working on the Company’s behalf to complete R&amp;D activities, and not in a customer capacity. The Company accounted for the commitments related to the clinical trials, which includes transfer of trial protocols, supply of clinical trial dosages, and collaboration on the joint development committee (“JDC”) as an ASC 808 unit of account, applying the recognition and measurement principles of ASC 606 by analogy. The Company will recognize collaboration revenue for its development activities under ASC 808 over time based on the estimated period of performance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By applying the principals in ASC 606 by analogy, the Company identified the performance obligation and considered the timing of satisfaction of the obligation to account for the pattern of revenue recognition. In order to recognize collaboration revenue, generally, the Company would begin satisfying its performance obligation and Cogna would need to be able to use and benefit from delivery of the assets or services. The performance obligation under the agreements that fall within the ASC 808 unit of account are concentrated in the clinical trials. As of September 30, 2023, the clinical trials had not </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commenced. Accordingly, no collaboration revenue was recognized for the ASC 808 unit of account during the three and nine months ended September 30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company identified certain commitments that are in the scope of ASC 606 as Cogna’s relationship is that of a customer for these commitments. The significant performance obligations that are in the scope of ASC 606 are (1) the development, commercialization and manufacturing license of the IP once restrictions on the use of the IP have been lifted by the Company and (2) a potential material right to a commercial supply agreement. The Company will recognize revenue from the development, commercial and manufacturing license at a point in time when the Company releases the restrictions on the use of the IP, which is expected to be after </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is approved by the FDA. The Company will recognize revenue from the material right related to Cogna’s ability to purchase the commercial supply at cost as Cogna purchases the commercial supply from the Company, which will occur after the completion of the initial clinical trials (if Cogna decides to purchase the clinical supply from the Company). As a result, the Company has not recognized any revenue under the ASC 606 unit of account during the three and nine months ended September 30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company receive</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resulting in a loss of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The G42 Promissory Note receivable was classified and accounted for under ASC 310 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Receivables </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(“ASC 310”) and was initially measured at its fair value of $11.9 million. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded the $18.7 million as deferred revenue in the Condensed Consolidated Balance Sheets, as none of the underlying performance obligations had been satisfied as of and for the three and nine months ended September 30, 2023. </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Huadong License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a license agreement with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (“Huadong”) (the “Huadong License Agreement”), under which Huadong obtained an exclusive and sublicensable license to develop and commercialize the Company’s glucagon-like peptide-1 receptor agonist (“GLP-1r”) program, including the compound</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> TTP273</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for therapeutic uses in humans or animals, in China and certain other Pacific Rim countries, including Australia and South Korea (collectively, the “Huadong License Territory”). Additionally, under the Huadong License Agreement, the Company obtained a nonexclusive, sublicensable, royalty-free license to develop and commercialize certain Huadong patent rights and know-how related to the Company’s GLP-1r program for therapeutic uses in humans or animals outside of the Huadong License Territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2021, the Company entered into the first amendment to the Huadong License Agreement ( the “First Huadong Amendment”) which eliminated the Company’s obligation to sponsor a multi-region clinical trial (the “Phase 2 MRCT”), and corresponding obligation to contribute up to $3.0 million in support of such trial. The amendment also reduced the total potential development and regulatory milestone payments by $3.0 million.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the First Amendment, the Company had allocated a portion of the transaction price to the obligation to sponsor and conduct a portion of the Phase 2 MRCT. Upon the removal of this performance obligation, the Company evaluated the impact of the modification under the provisions of ASC 606 and performed a reallocation of the transaction price among the remaining performance obligations. The majority of the transaction price originally allocated to the Phase 2 MRCT performance obligation was reallocated to the license and technology transfer services combined performance obligation discussed below, which had already been completed. The reallocation of the purchase price in connection with the First Huadong Amendment was made based on the relative estimated selling prices of the remaining performance obligations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant performance obligations under the Huadong License Agreement, as amended, were determined to be (i) the exclusive license to develop and commercialize the Company’s GLP-1r program, (ii) technology transfer services related to the chemistry and manufacturing know-how for a defined period after the effective date, (iii) the Company’s obligation to participate on a joint development committee (the “JDC”), and (iv) other obligations considered to be immaterial in nature. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that the license and technology transfer services related to the chemistry and manufacturing know-how represent a combined performance obligation because they were not capable of being distinct on their own. The Company also determined that there was no discernible pattern in which the technology transfer services would be provided during the transfer service period. As such, the Company recognized the revenue related to this combined performance obligation using the straight-line method over the transfer service period. In the first quarter of 2022, the transaction price for this performance obligation was increased by $2.0 million due to the satisfaction of a development milestone under the license agreement. This amount was fully recognized as revenue during the nine months ended </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022 as the related performance obligation was fully satisfied. No revenue related to this combined performance obligation was recognized during the nine months ended September 30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the transaction price allocated to the obligation to participate in the JDC to oversee the development of products and the Phase 2 MRCT in accordance with the development plan remained deferred as of September 30, 2023, and revenue will be recognized using the proportional performance model over the period of the Company’s participation on the JDC. The unrecognized amount of the transaction price allocated to this performance obligation as of September 30, 2023 was immaterial. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An immaterial amount of revenue for this performance obligation was recognized during the nine months ended September 30, 2022. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No revenue for this performance obligation has been recognized during the nine months ended September 30, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anteris License Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 11, 2020, the Company entered into a license agreement with Anteris Bio, Inc. (“Anteris”) (the “Anteris License Agreement”), under which Anteris obtained a worldwide, exclusive and sublicensable license to develop and commercialize the Company’s Nrf2 activator, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">HPP971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Anteris License Agreement, Anteris paid the Company an initial license fee of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company is eligible to receive additional potential development, regulatory, and sales-based milestone payments totaling up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$151.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Anteris is also obligated to pay vTv royalty payments at a double-digit rate based on annual net sales of licensed products. Such royalties will be payable on a licensed product-by-licensed product basis until the latest of expiration of the licensed patents covering a licensed product in a country, expiration of data exclusivity rights for a licensed product in a country, or a specified number of years after the first commercial sale of a licensed product in a country. As additional consideration, the Company received preferred stock representing a minority ownership interest in Anteris.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Anteris License Agreement, the Company was required to provide technology transfer services for a 30 day period after the effective date. In accordance with ASC 606, the Company identified all of the performance obligations at the inception of the Anteris License Agreement. The significant obligations were determined to be the license and the technology transfer services. The Company has determined that the license and technology transfer services represent a single performance obligation because they were not capable of being distinct on their own. The transaction price has been fully allocated to this combined performance obligation and consisted of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2.0 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> initial license payment as well as the fair value of the equity interest received in Anteris of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$4.2 million</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The revenue related to this performance obligation was fully recognized during the year ended December 31, 2020, as the technology transfer services were considered complete as of that date. No revenue was recognized related to the Anteris License Agreement during the three and nine months ended September 30, 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2023, Anteris notified the Company that it was terminating the Anteris License Agreement. Under the terms of the Anteris License Agreement, the termination would become effective ninety days following the receipt of notice, or December 24, 2023. The Company has begun the process of winding up the license, including obtaining all regulatory, manufacturing and other records generated by Anteris during the term of the Anteris License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company received a Section228(e) notice from Anteris. that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). (See Note 14).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Liabilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10386274 2.41 25000000 12500000 12500000 12000000 0.0375 -300000 30000000 30000000 P10Y 5700000 0.55 18700000 600000 0 0 0 0 12000000 0.0375 -300000 11900000 18700000 3000000 3000000 2000000 0 0 0 2000000 151000000 2000000 4200000 0 0 0 0 <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities related to the Company’s collaboration agreements consisted of the following (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.221%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of contract liabilities</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,669 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,686 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 17000 17000 18669000 18669000 18686000 18686000 Share-Based CompensationThe Company has issued nonqualified stock option awards to management, other key employees, consultants, and nonemployee directors. These option awards generally vest ratably over a three-year period and the option awards expire after a term of ten years from the date of grant. As of September 30, 2023, the Company had total unrecognized stock-based compensation expense for its outstanding stock option awards of approximately $1.8 million, which is expected to be <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognized over a weighted average period of 2.2 years. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 and 2022 was $0.76 and $0.68 per option, respectively. The aggregate intrinsic value of the in-the-money awards outstanding at September 30, 2023 was immaterial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,418,571 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,000)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018,072 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,188,444 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P3Y P10Y 1800000 P2Y2M12D 0.76 0.68 <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the stock option awards for the nine months ended September 30, 2023:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted <br/>Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at December 31, 2022</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,418,571 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.17 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176,868 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.87 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50,000)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.29 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Awards outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.01 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,018,072 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04 </span></td><td style="background-color:#ebfeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options vested and expected to vest at September 30, 2023</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,188,444 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.21 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining contractual term</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5 Years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div> 8418571 2.17 1176868 0.87 50000 1.29 9545439 2.01 5018072 3.04 P6Y7M6D 8188444 2.21 P7Y6M <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense related to the grants of stock options is included in research and development and general and administrative expense as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">692 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,175 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 113000 109000 316000 289000 320000 229000 859000 692000 433000 338000 1175000 981000 Investments<div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the Reneo Pharmaceuticals, Inc. (“Reneo”) and Anteris License Agreements, the Company received equity ownership interests of less than 20% of the voting equity of the investees. Further, the Company does not have the ability to exercise significant influence over the investees. The investments are classified as long-term investments in the Company’s Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reneo completed its initial public offering in April 2021. Prior to Reneo becoming a publicly traded company, the Company’s investment in Reneo did not have a readily determinable fair value and was measured at cost less impairment, adjusted for any changes in observable prices, under the measurement alternative. Subsequent to Reneo’s initial public offering, the Company’s investment in Reneo is considered to have a readily determinable fair value and, as such, is adjusted to its fair value each period with changes in fair value recognized as a component of net loss. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment in Anteris does not have a readily determinable fair value and is measured at cost less impairment, adjusted for any changes in observable prices.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:68.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized an unrealized gain on its investment in Reneo of $0.6 million and $3.0 million for the three and nine months ended September 30, 2023, respectively. The Company recognized an unrealized gain on its investment in Reneo of $0.4 million and an unrealized loss of $3.0 million for the three and nine months ended September 30, 2022, </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respectively. These adjustments were recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 16, 2023, the Company received a Section228(e) notice from Anteris that the stockholders voted in favor of the dissolution of Anteris and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”). The Company determined the carrying value of this investment was not expected to be recoverable due to the Plan of Dissolution. As a result, the Company recorded a $4.2 million impairment charge during the three and nine months ended September 30, 2023. </span></div>On October 30, 2023, the Company entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with Reneo to purchase all of its common stock held by vTv LLC for total proceeds to vTv LLC of approximately $4.4 million. 0.20 <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investments consist of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:68.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.296%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.102%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment with readily determinable fair value:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reneo common stock</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investment without readily determinable fair values assessed under the measurement alternative:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anteris preferred stock</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,245 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,588 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4387000 1343000 0 4245000 4387000 5588000 600000 3000000 400000 -3000000 4200000 4200000 4400000 Commitments and Contingencies<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Matters</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company is involved in various legal proceedings arising in the normal course of business. If a specific contingent liability is determined to be probable and can be reasonably estimated, the Company accrues and discloses the amount. The Company is not currently a party to any material legal proceedings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novo Nordisk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2007, the Company entered into an Agreement (the “Novo License Agreement”) Concerning Glucokinase Activator Project with Novo Nordisk A/S (the “Novo Nordisk”) whereby the Company obtained an exclusive, worldwide, sublicensable license under certain Novo Nordisk intellectual property rights to discover, develop, manufacture, have manufactured, use and commercialize products for the prevention, treatment, control, mitigation or palliation of human or animal diseases or conditions. As part of this license grant, the Company obtained certain worldwide rights to Novo Nordisk’s GKA program, including rights to preclinical and clinical compounds such as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. This agreement was amended in May 2019 to create milestone payments applicable to certain specific and nonspecific areas of therapeutic use. Under the terms of the amended Novo License Agreement, the Company has potential developmental and regulatory milestone payments payable totaling up to $9.0 million for approval of a product for the treatment of type 1 diabetes, $50.5 million for approval of a product for the treatment of type 2 diabetes, or $115.0 million for approval of a product in any other indication. The Company may also be obligated to pay an additional $75.0 million in potential sales-based milestones, as well as royalty payments, at mid-single digit royalty rates, based on tiered sales of commercialized licensed products. During the fourth quarter of 2021, the Company made a payment of $2.0 million related to the satisfaction of the milestone to complete the phase 2 trials for </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> under this agreement.</span></div> 9000000 50500000 115000000 75000000 2000000 Leases<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company leased office space for its headquarters location under an operating lease. This lease commenced in November 2019 after the completion of certain tenant improvements made by the lessor. The lease includes an option to renew for a five-year term as well as an option to terminate after three years, neither of which have been recognized as part of its related right of use assets or lease liabilities as their election is not considered reasonably certain. In November 2022, the Company entered into a second amendment to the lease, (i) to reduce the square footage and (ii) to extend the lease term, which constituted a modification event under ASC 842 and, the lease classification for the asset remains as an operating lease. As a result of the remeasurement of the associated lease liabilities, the Company recognized additional right of use assets and corresponding lease liabilities</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Further, th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e second amendment to the lease does not include any material residual value guarantee or restrictive covenants. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At each of September 30, 2023 and December 31, 2022, the weighted average incremental borrowing rate for the operating leases held by the Company was 9.5%. At September 30, 2023 and December 31, 2022, the weighted average remaining lease terms for the operating leases held by the Company were 2.2 years and 2.9 years, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company’s operating leases as of September 30, 2023 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease cost and the related operating cash flows for the nine months ended September 30, 2023 and 2022 was $0.2 million and $0.1 million, respectively.</span></div> P5Y P3Y 100000 100000 0.095 0.095 P2Y2M12D P2Y10M24D <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities for the Company’s operating leases as of September 30, 2023 were as follows (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:85.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.082%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023 (remaining three months)</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">419 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 48000 194000 177000 0 0 0 419000 41000 378000 200000 100000 Redeemable Noncontrolling Interest<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to the Exchange Agreement with respect to the vTv Units representing the 22.1% noncontrolling interest in vTv LLC outstanding as of September 30, 2023 (see Note 9). The Exchange Agreement requires the surrender of an equal number of vTv Units and Class B common stock for (i) shares of Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. The exchange value is determined based on a 20-day volume weighted average price of the Class A common stock as defined in the Exchange Agreement, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable noncontrolling interest is recognized at the higher of (1) its initial fair value plus accumulated earnings/losses associated with the noncontrolling interest or (2) the redemption value as of the balance sheet date. At September 30, 2023 and December 31, 2022, the redeemable noncontrolling interest was recorded based on the redemption value as of the balance sheet date of $10.7 million and $16.6 million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company’s ownership interest in vTv LLC while the Company retains its controlling interest in vTv LLC are accounted for as equity transactions, and the Company is required to adjust noncontrolling interest and equity for such changes. The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,435)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,560)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0.221 1 P20D 10700000 16600000 The following is a summary of net income attributable to vTv Therapeutics Inc. and transfers to noncontrolling interest:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.542%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to vTv Therapeutics Inc. common shareholders</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,174)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,212 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(103)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,062)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,435)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,560)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,522)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -6654000 -4261000 -16772000 -14419000 1592000 -1174000 4212000 -103000 -5062000 -5435000 -12560000 -14522000 Stockholders’ DeficitOn May 4, 2021, the Company filed an amendment to its Amended and Restated Certificate of Incorporation (the “Charter Amendment”) to increase the number of shares of Class A common stock that the Company is authorized to issue from 100,000,000 shares of Class A common stock to 200,000,000 shares of Class A common stock, representing an increase of 100,000,000 shares of authorized Class A common stock, with a corresponding increase in the total authorized common stock, which includes Class A common stock and Class B common stock, from 200,000,000 to 300,000,000, and a corresponding increase in the total authorized capital stock, which includes common stock and preferred stock, from 250,000,000 shares to 350,000,000 shares.<div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company and G42 Investments entered in to the G42 Purchase Agreement (see Note 3), pursuant to which the Company agreed to sell to G42 Investments 10,386,274 shares of the Company's Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, consisting of (i) $12.5 million in cash at the closing of the transaction and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid at the one-year anniversary of the execution of the G42 Purchase Agreement (the “G42 Promissory Note”). On February 28, 2023, the Company and G42 Investments amended the G42 Purchase Agreement and modified the G42 Promissory Note to accelerate the payment due under the note. Pursuant to the amendment, on February 28, 2023, the Company received $12.0 million, which reflected the original amount due under the G42 Promissory Note less a 3.75% discount, in full satisfaction of the note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinPax and CinRx Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022 (the “Transaction Date”), the Company entered into the CinRx Purchase Agreement with CinPax, LLC (“CinPax”) and CinRx Pharma, LLC (“CinRx”), pursuant to which the Company agreed to sell to CinPax 4,154,549 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $10.0 million, which was paid (i) $6.0 million in cash at the closing of the transaction and (ii) $4.0 million in the form of a non-interest-bearing promissory note with CinPax and was paid to the Company on November 22, 2022. The CinRx Purchase Agreement provides CinPax the right to nominate a director to be approved to sit on the Company’s Board of Directors and a board observer, which was subsequently approved by the Company’s board.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Common stock is generally recorded at fair value at the date of issuance. In determining the fair value of the Class A common stock issued to CinPax, the Company considered the closing price of the common stock on the Transaction Date. The Company did not make an adjustment to the fair value for sale restrictions on the stock in accordance with guidance recently adopted in ASU 2022-03. See the “Recently Issued Accounting Guidance” in this quarterly report on Form 10-Q for details of the ASU.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, the Company determined that cash consideration of $3.0 million should be recorded as fair value of the Class A common stock at the effective date, utilizing the Class A common stock closing price of $0.72 at the effective date. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Purchase Agreement also provides CinRx warrants to purchase up to 1,200,000 shares of common stock at an initial exercise of price of approximately $0.72 per share (the “CinRx Warrants”). The CinRx Warrants were initially measured at fair value of $0.4 million using the Black-Scholes option model at the time of issuance and will be recorded in Warrant liability related party in the Condensed Consolidated Balance Sheets and will be subsequently remeasured at fair value through earnings on a recurring basis. (see Note 13)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CinRx Warrants will become exercisable by CinRx only if (i) the Company receives approval from the U.S. Food and Drug Administration (“FDA Approval”) to market and distribute the pharmaceutical product containing the Company’s proprietary candidate, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">cadisegliatin (TTP399)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the “Product”), or (ii) the Company is acquired by a third party, sells all or substantially all of its assets related to the Product to a third party or grants a third party an exclusive license to develop, commercialize and manufacture the Product in the United States. If neither of these events happen within five years of the date of the issuance of the CinRx Warrants, the CinRx Warrants will expire and not be exercisable by CinRx. The exercise price of the CinRx Warrants and the number of shares issuable upon exercise of the CinRx Warrants are subject to adjustments in accordance with the terms of the CinRx Warrants.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in conjunction with the CinRx Purchase Agreement the Company and CinRx entered into a Master Service Agreement (“CinRx MSA”) whereby CinRx provides the Company with consulting, preclinical and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. (see Note 10)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company did not identify any other promises in the CinRx Purchase Agreement (aside from the issuance of common shares and the CinRx Warrants) and determined since there is no value ascribed to the CinRx MSA, the right to appoint a member and observer to the board of directors, that the remaining unallocated amount meets the definition of contributed equity and represents the amount in excess of par.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">ATM Offering</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2020, the Company entered into the Sales Agreement with Cantor as the sales agent, pursuant to which the Company may offer and sell, from time to time, through Cantor, shares of its Class A common stock, par value $0.01 per share, having an aggregate offering price of up to $13.0 million by any method deemed to be an “at the market offering” as </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">defined in Rule 415(a)(4) under the Securities Act (the “ATM Offering”). The shares are offered and sold pursuant to the Company’s shelf registration statement on Form S-3. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2021 and June 25, 2021, the Company filed a prospectus supplement in connection with the ATM Offering to increase the size of the at-the-market offering pursuant to which the Company may offer and sell, from time to time, through or to Cantor, as sales agent or principal, shares of the Company’s Class A common stock, by an aggregate offering price of</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $5.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $50.0 million, respectively</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and nine months ended September 30, 2023 and 2022, the Company did not sell any shares under the ATM Offering. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lincoln Park Capital Transaction</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 24, 2020, the Company entered into the LPC Purchase Agreement and a registration rights agreement (the “Registration Rights Agreement”), pursuant to which the Company has the right to sell to Lincoln Park shares of the Company’s Class A common stock having an aggregate value of up to $47.0 million, subject to certain limitations and conditions set forth in the LPC Purchase Agreement. The Company will control the timing and amount of any sales of shares to Lincoln Park pursuant to the LPC Purchase Agreement. During the three and nine months ended September 30, 2023 and 2022, the Company did not sell any shares under the LPC Purchase Agreement.</span></div> 100000000 200000000 100000000 200000000 300000000 250000000 350000000 10386274 2.41 25000000 12500000 12500000 P1Y 12000000 0.0375 -300000 4154549 2.41 10000000 6000000 4000000 3000000 0.72 1200000 0.72 400000 P5Y 0.01 13000000 5500000 50000000 0 0 0 0 47000000 0 0 0 0 Related-Party Transactions<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MacAndrews &amp; Forbes Incorporated</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MacAndrews directly or indirectly controls 23,084,267 shares of Class B common stock. Further, as of September 30, 2023, MacAndrews directly or indirectly holds 36,519,212 shares of the Company’s Class A common stock. As a result, MacAndrews’ holdings represent approximately 57.0% of the combined voting power of the Company’s outstanding common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has entered into several agreements with MacAndrews or its affiliates as further detailed below:</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Letter Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had previously entered into the Letter Agreements with MacAndrews. Under the terms of the Letter Agreements, during the one year commitment period beginning on the date of each Letter Agreement, the Company had the right to sell to MacAndrews shares of its Class A common stock at a specified price per share, and MacAndrews had the right (exercisable up to three times) to require the Company to sell to it shares of Class A common stock at the same price. The commitment period of each of the Letter Agreements has now expired. In addition, in connection with and as a commitment fee for the entrance into certain of these Letter Agreements, the Company also issued MacAndrews warrants (the “Letter Agreement Warrants”) to purchase additional shares of the Company’s Class A common stock. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Letter Agreement Warrants have been recorded as warrant liability, related party within the Company’s Condensed Consolidated Balance Sheets based on their fair value. The issuance of the Letter Agreement Warrants was considered to be a cost of equity recorded as a reduction to additional paid-in capital. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exchange Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of the Exchange Agreement, but subject to the Amended and Restated LLC Agreement of vTv Therapeutics LLC, the vTv Units (along with a corresponding number of shares of the Class B common stock) are exchangeable for (i) shares of the Company’s Class A common stock on a one-for-one basis or (ii) cash (based on the fair market value of the Company’s Class A common stock as determined pursuant to the Exchange Agreement), at the Company’s option (as the managing member of vTv Therapeutics LLC), subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. Any decision to require an exchange for cash rather than shares of Class A common stock will ultimately be determined by the entire Board of Directors. As of September 30, 2023, MacAndrews had not exchanged any shares under the provisions of the Exchange Agreement.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Receivable Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and MacAndrews are party to a tax receivable agreement (the “Tax Receivable Agreement”), which provides for the payment by the Company to M&amp;F TTP Holdings Two LLC (“M&amp;F”), as successor in interest to vTv Therapeutics Holdings, LLC (“vTv Therapeutics Holdings”), and M&amp;F TTP Holdings LLC (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of (a) the exchange of Class B common stock, together with the corresponding number of vTv Units, for shares of the Company’s Class A common stock (or for cash), (b) tax benefits related to imputed interest deemed to be paid by the Company as a result of the Tax Receivable Agreement and (c) certain tax benefits attributable to payments under the Tax Receivable Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As no shares have been exchanged by MacAndrews pursuant to the Exchange Agreement (discussed above), the Company has not recognized any liability, nor has it made any payments pursuant to the Tax Receivable Agreement as of September 30, 2023.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investor Rights Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to an investor rights agreement with M&amp;F, as successor in interest to vTv Therapeutics Holdings (the “Investor Rights Agreement”). The Investor Rights Agreement provides M&amp;F with certain demand, shelf, and piggyback registration rights with respect to its shares of Class A common stock and also provides M&amp;F with certain governance rights, depending on the size of its holdings of Class A common stock. Under the Investor Rights Agreement, M&amp;F was initially entitled to nominate a majority of the members of the Board of Directors and designate the members of the committees of the Board of Directors.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">G42 Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 31, 2022, the Company entered into a common stock purchase agreement with G42 Investments pursuant to which the Company sold to G42 Investments 10,386,274 shares of the Company’s Class A common stock at a price per share of approximately $2.41, for an aggregate purchase price of $25.0 million, which was paid (i) $12.5 million in cash at the closing and (ii) $12.5 million in the form of a promissory note of G42 Investments to be paid on May 31, 2023 (the “G42 Promissory Note”). As part of the G42 Purchase Agreement, G42 Investments put forward a director as appointee and the Company’s board of directors appointed the new director to the Company’s board on July 11, 2022. On February 28, 2023, the Company and G42 Investments entered into an amendment of the common stock purchase agreement pursuant to which G42 Investments agreed to accelerate payment of the amount due under the G42 Promissory Note. On February 28, 2023, the Company received $12.0 million from G42 Investments, which represented a 3.75% discount to the full amount due under the G42 Promissory Note, in full and final satisfaction of the promissory note, resulting in a loss of $0.3 million and was recognized as a component of other income/(expense) in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CinRx Pharma, LLC</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Services Agreement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 22, 2022, the Company entered into the CinRx MSA with CinRx. Under the CinRx MSA, CinRx provides the Company with consulting and clinical trial services, as enumerated in project proposals negotiated between the Company and CinRx from time to time. As of October 10, 2022, the Company agreed to pay CinRx fees of up to $0.2 million per month until approximately December 2024 in respect of ongoing agreed project proposals under the CinRx MSA, plus out-of-pocket expenses incurred by CinRx on the Company’s behalf. Dr. Jonathan Isaacsohn, who was appointed as chair of the Company’s board of directors on August 9, 2022, is the President and Chief Executive Officer of CinRx. CinPax, a subsidiary of CinRx, currently holds 4,154,549 shares of the Company’s Class A common stock.</span></div> 23084267 36519212 0.570 0.85 10386274 2.41 25000000 12500000 12500000 12000000 0.0375 -300000 200000 4154549 Income Taxes<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to U.S. federal income taxes as well as state taxes. The Company did not record an income tax provision for the three and nine months ended September 30, 2023. The Company’s income tax provision for the nine months ended September 30, 2022 was $0.2 million representing foreign withholding taxes incurred in connection with payments received under license agreements with foreign entities. The Company did not record an income tax provision for the three months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has evaluated the positive and negative evidence surrounding the realization of its deferred tax assets, including the Company’s history of losses, and under the applicable accounting standards determined that it is more likely than not that the deferred tax assets will not be realized. The difference between the effective tax rate of the Company and the U.S. statutory tax rate of 21% on September 30, 2023 is due to the valuation allowance against the Company’s expected net operating losses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 10, the Company is party to a tax receivable agreement with a related party which provides for the payment by the Company to M&amp;F (or certain of its transferees or other assignees) of 85% of the amount of cash savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realizes (or, in some circumstances, the Company is deemed to realize) as a result of certain transactions. As no transactions have occurred which </span></div>would trigger a liability under this agreement, the Company has not recognized any liability related to this agreement as of September 30, 2023. 0 0 200000 0 0.85 Net Loss per Share<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share is computed by dividing net loss attributable to vTv Therapeutics Inc. by the weighted average number of shares of Class A common stock outstanding during the period. Diluted loss per share is computed giving effect to all potentially dilutive shares. Diluted loss per share for all periods presented is the same as basic loss per share as the inclusion of potentially issuable shares would be antidilutive. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,490,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,649,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,853,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,027,307 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div> <div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A common stock is as follows (amounts in thousands, except per share amounts):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.144%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.145%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,540)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,468)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,983)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Net loss attributable to noncontrolling interests</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,886)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,207)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,753)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,564)</span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common shareholders of vTv Therapeutics Inc., basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,654)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,261)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,772)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,419)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,490,121 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,483,600 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,649,531 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share of vTv Therapeutics Inc. Class A common stock, basic and diluted</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.08)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.05)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.20)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -8540000 -5468000 -21525000 -18983000 -1886000 -1207000 -4753000 -4564000 -6654000 -6654000 -4261000 -4261000 -16772000 -16772000 -14419000 -14419000 81483600 81483600 80490121 80490121 81483600 81483600 72649531 72649531 -0.08 -0.08 -0.05 -0.05 -0.21 -0.21 -0.20 -0.20 <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:72.372%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.865%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.396%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.867%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Class B common stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,093,860 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options granted under the Plan</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,545,439 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,718,944 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,214,503 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,853,802 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,027,307 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.720%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Shares of Class B common stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B common stock under the two-class method has not been provided. Each share of Class B common stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A common stock.</span></td></tr></table></div> 23093860 23093860 9545439 7718944 3214503 3214503 35853802 34027307 Fair Value of Financial Instruments<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of certain of the Company’s financial instruments, including cash and cash equivalents, net accounts receivable, note receivable, accounts payable and other accrued liabilities approximate fair value due to their short-term nature.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the value of its equity investments without readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or similar investment. During the year ended December 31, 2021, Reneo completed its initial public offering. As a result, the fair value of the Company’s investment in Reneo’s common stock now has a readily determinable market value and is no longer eligible for the practical expedient for investments without readily determinable fair market values.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Assets and Liabilities Measured at Fair Value on a Recurring Basis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company evaluates its financial assets and liabilities subject to fair value measurements on a recurring basis to determine the appropriate level in which to classify them for each reporting period. This determination requires significant </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">judgments. The Company determined that the G42 Promissory Note receivable was level 2 and the fair value measurement was based on the market yield curves. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2023 and December 31, 2022 (in thousands):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers into or out of level 3 instruments and/or between level 1 and level 2 instruments during the three and nine months ended September 30, 2023. Gains and losses recognized due to the change in fair value of the warrant liability, related party are recognized as a component of other income – related party in the Company’s Condensed Consolidated Statements of Operations. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Letter Agreement Warrants was determined using the Black-Scholes option pricing model or option pricing models based on the Company’s current capitalization. Expected volatility is based on the historical volatility </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2023 and December 31, 2022 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.37% - 77.01%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.06%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.94% - 85.88%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78% - 5.38%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11% - 4.43%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2023 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.38 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average expected volatility and risk-free interest rate was based on the relative fair values of the warrants.</span></div>Changes in the unobservable inputs noted above would impact the amount of the liability for the Letter Agreement Warrants and CinRx Warrants. Increases (decreases) in the estimates of the Company’s annual volatility would increase (decrease) the liability and an increase (decrease) in the annual risk-free rate would increase (decrease) the liability. The following table summarizes the conclusions reached regarding fair value measurements as of September 30, 2023 and December 31, 2022 (in thousands):<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,387 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.667%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.763%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted Prices in Active <br/>Markets for Identical Assets<br/>(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable <br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities with readily determinable fair value</span></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_____________________________</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:3.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:114%">(1)</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Fair value determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation.</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Changes in Level 3 instruments for the three months ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at January 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Change in<br/>fair value included in <br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchases /<br/>Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Sales /<br/>Repurchases</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at September 30,</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">684 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(406)</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278 </span></td><td style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrant liability, related party</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,262 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(221)</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,409 </span></td><td style="background-color:#ebfeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 4387000 4387000 0 0 4387000 4387000 0 0 278000 0 0 278000 278000 0 0 278000 1343000 1343000 0 0 1343000 1343000 0 0 684000 0 0 684000 684000 0 0 684000 684000 -406000 0 0 278000 684000 -406000 0 0 278000 1262000 -221000 368000 0 1409000 1262000 -221000 368000 0 1409000 Significant inputs utilized in the valuation of the Letter Agreement Warrants as of September 30, 2023 and December 31, 2022 were:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.553%"><tr><td style="width:1.0%"></td><td style="width:30.738%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.397%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.790%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.795%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68.37% - 77.01%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.06%</span></td><td colspan="3" style="background-color:#ebfeff;padding:0 1pt"></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.94% - 85.88%</span></div></td><td colspan="3" style="background-color:#ebfeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.17%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.78% - 5.38%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.88%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.11% - 4.43%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.19%</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the CinRx Warrants was determined using the Black-Scholes option pricing model. Expected volatility is based on the historical volatility of the Company’s common stock over the most recent period. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of valuation. Significant inputs utilized in the valuation of the CinRx Warrants as of September 30, 2023 were:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.329%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82.38 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life of options in years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75</span></td></tr><tr><td colspan="3" style="background-color:#ebfeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ebfeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.73 </span></td><td style="background-color:#ebfeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div> 0.6837 0.7701 0.7606 0.7694 0.8588 0.8217 0.0478 0.0538 0.0488 0.0411 0.0443 0.0419 0.8238 P3Y9M 0.0473 0 Subsequent EventsOn October 16, 2023, the Company received a Section 228(e) notice from Anteris that the stockholders voted in favor of the dissolution of the Company and the adoption of a plan of Liquidation and Dissolution (“Plan of Dissolution”) (See Note 5).On October 30, 2023, vTv LLC, entered into a Common Stock Repurchase Agreement (the “Repurchase Agreement”) with Reneo pursuant to which Reneo agreed to purchase all shares of common stock of Reneo that had been owned by vTv LLC. Pursuant to the Repurchase Agreement, Reneo agreed to pay vTv LLC gross proceeds of approximately $4.4 million, which was received by vTv LLC on October 30, 2023. vTv LLC had acquired the Reneo stock in connection with the December 21, 2017 License Agreement between vTv LLC and Reneo, which remains in effect. 4400000 false false false false EXCEL 65 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 66 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 67 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 68 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 219 237 1 false 65 0 false 4 false false R1.htm 0000001 - Document - Cover Sheet http://vtvtherapeutics.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited Condensed Consolidated Statements of Operations - Unaudited Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited Sheet http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows - Unaudited Statements 6 false false R7.htm 0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern Sheet http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern Description of Business, Basis of Presentation and Going Concern Notes 7 false false R8.htm 0000008 - Disclosure - Summary of Significant Accounting Policies Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Collaboration Agreements Sheet http://vtvtherapeutics.com/role/CollaborationAgreements Collaboration Agreements Notes 9 false false R10.htm 0000010 - Disclosure - Share-Based Compensation Sheet http://vtvtherapeutics.com/role/ShareBasedCompensation Share-Based Compensation Notes 10 false false R11.htm 0000011 - Disclosure - Investments Sheet http://vtvtherapeutics.com/role/Investments Investments Notes 11 false false R12.htm 0000012 - Disclosure - Commitments and Contingencies Sheet http://vtvtherapeutics.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 12 false false R13.htm 0000013 - Disclosure - Leases Sheet http://vtvtherapeutics.com/role/Leases Leases Notes 13 false false R14.htm 0000014 - Disclosure - Redeemable Noncontrolling Interest Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest Redeemable Noncontrolling Interest Notes 14 false false R15.htm 0000015 - Disclosure - Stockholders' Deficit Sheet http://vtvtherapeutics.com/role/StockholdersDeficit Stockholders' Deficit Notes 15 false false R16.htm 0000016 - Disclosure - Related-Party Transactions Sheet http://vtvtherapeutics.com/role/RelatedPartyTransactions Related-Party Transactions Notes 16 false false R17.htm 0000017 - Disclosure - Income Taxes Sheet http://vtvtherapeutics.com/role/IncomeTaxes Income Taxes Notes 17 false false R18.htm 0000018 - Disclosure - Net Loss per Share Sheet http://vtvtherapeutics.com/role/NetLossperShare Net Loss per Share Notes 18 false false R19.htm 0000019 - Disclosure - Fair Value of Financial Instruments Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstruments Fair Value of Financial Instruments Notes 19 false false R20.htm 0000020 - Disclosure - Subsequent Events Sheet http://vtvtherapeutics.com/role/SubsequentEvents Subsequent Events Notes 20 false false R21.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 21 false false R22.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 22 false false R23.htm 9954471 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies 23 false false R24.htm 9954472 - Disclosure - Collaboration Agreements (Tables) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsTables Collaboration Agreements (Tables) Tables http://vtvtherapeutics.com/role/CollaborationAgreements 24 false false R25.htm 9954473 - Disclosure - Share-Based Compensation (Tables) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationTables Share-Based Compensation (Tables) Tables http://vtvtherapeutics.com/role/ShareBasedCompensation 25 false false R26.htm 9954474 - Disclosure - Investments (Tables) Sheet http://vtvtherapeutics.com/role/InvestmentsTables Investments (Tables) Tables http://vtvtherapeutics.com/role/Investments 26 false false R27.htm 9954475 - Disclosure - Leases (Tables) Sheet http://vtvtherapeutics.com/role/LeasesTables Leases (Tables) Tables http://vtvtherapeutics.com/role/Leases 27 false false R28.htm 9954476 - Disclosure - Redeemable Noncontrolling Interest (Tables) Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables Redeemable Noncontrolling Interest (Tables) Tables http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest 28 false false R29.htm 9954477 - Disclosure - Net Loss per Share (Tables) Sheet http://vtvtherapeutics.com/role/NetLossperShareTables Net Loss per Share (Tables) Tables http://vtvtherapeutics.com/role/NetLossperShare 29 false false R30.htm 9954478 - Disclosure - Fair Value of Financial Instruments (Tables) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables Fair Value of Financial Instruments (Tables) Tables http://vtvtherapeutics.com/role/FairValueofFinancialInstruments 30 false false R31.htm 9954479 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail) Sheet http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail Description of Business, Basis of Presentation and Going Concern (Detail) Details http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern 31 false false R32.htm 9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail Summary of Significant Accounting Policies - Additional Information (Detail) Details 32 false false R33.htm 9954481 - Disclosure - Collaboration Agreements - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail Collaboration Agreements - Additional Information (Detail) Details 33 false false R34.htm 9954482 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details) Sheet http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details) Details 34 false false R35.htm 9954483 - Disclosure - Share-Based Compensation - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail Share-Based Compensation - Additional Information (Detail) Details 35 false false R36.htm 9954484 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail) Details 36 false false R37.htm 9954485 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) Sheet http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail) Details 37 false false R38.htm 9954486 - Disclosure - Investments - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail Investments - Additional Information (Detail) Details 38 false false R39.htm 9954487 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) Sheet http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail) Details 39 false false R40.htm 9954488 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 40 false false R41.htm 9954489 - Disclosure - Leases - Additional Information (Details) Sheet http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails Leases - Additional Information (Details) Details 41 false false R42.htm 9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) Sheet http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail) Details 42 false false R43.htm 9954491 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail Redeemable Noncontrolling Interest - Additional Information (Detail) Details 43 false false R44.htm 9954492 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) Sheet http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail) Details 44 false false R45.htm 9954493 - Disclosure - Stockholders' Deficit - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail Stockholders' Deficit - Additional Information (Detail) Details 45 false false R46.htm 9954494 - Disclosure - Related-Party Transactions - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail Related-Party Transactions - Additional Information (Detail) Details 46 false false R47.htm 9954495 - Disclosure - Income Taxes - Additional Information (Detail) Sheet http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail Income Taxes - Additional Information (Detail) Details 47 false false R48.htm 9954496 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) Sheet http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail) Details 48 false false R49.htm 9954497 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) Sheet http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail) Details 49 false false R50.htm 9954498 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail) Details 50 false false R51.htm 9954499 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) Sheet http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail) Details 51 false false R52.htm 9954500 - Disclosure - Subsequent Events (Details) Sheet http://vtvtherapeutics.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://vtvtherapeutics.com/role/SubsequentEvents 52 false false All Reports Book All Reports vtvt-20230930.htm vtvt-20230930.xsd vtvt-20230930_cal.xml vtvt-20230930_def.xml vtvt-20230930_lab.xml vtvt-20230930_pre.xml vtvt-20230930_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 71 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vtvt-20230930.htm": { "nsprefix": "vtvt", "nsuri": "http://vtvtherapeutics.com/20230930", "dts": { "inline": { "local": [ "vtvt-20230930.htm" ] }, "schema": { "local": [ "vtvt-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "vtvt-20230930_cal.xml" ] }, "definitionLink": { "local": [ "vtvt-20230930_def.xml" ] }, "labelLink": { "local": [ "vtvt-20230930_lab.xml" ] }, "presentationLink": { "local": [ "vtvt-20230930_pre.xml" ] } }, "keyStandard": 197, "keyCustom": 40, "axisStandard": 26, "axisCustom": 1, "memberStandard": 28, "memberCustom": 32, "hidden": { "total": 6, "http://xbrl.sec.gov/dei/2023": 5, "http://vtvtherapeutics.com/20230930": 1 }, "contextCount": 219, "entityCount": 1, "segmentCount": 65, "elementCount": 511, "unitCount": 4, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 574, "http://xbrl.sec.gov/dei/2023": 31, "http://xbrl.sec.gov/ecd/2023": 4 }, "report": { "R1": { "role": "http://vtvtherapeutics.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R2": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R3": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-9", "name": "us-gaap:CommonStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R4": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations - Unaudited", "shortName": "Condensed Consolidated Statements of Operations - Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R5": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "longName": "0000005 - Statement - Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited", "shortName": "Condensed Consolidated Statement of Changes in Redeemable Noncontrolling Interest and Stockholders' Deficit - Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-67", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-67", "name": "us-gaap:RedeemableNoncontrollingInterestEquityCarryingAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R6": { "role": "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows - Unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows - Unaudited", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R7": { "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern", "longName": "0000007 - Disclosure - Description of Business, Basis of Presentation and Going Concern", "shortName": "Description of Business, Basis of Presentation and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R8": { "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies", "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R9": { "role": "http://vtvtherapeutics.com/role/CollaborationAgreements", "longName": "0000009 - Disclosure - Collaboration Agreements", "shortName": "Collaboration Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R10": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensation", "longName": "0000010 - Disclosure - Share-Based Compensation", "shortName": "Share-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R11": { "role": "http://vtvtherapeutics.com/role/Investments", "longName": "0000011 - Disclosure - Investments", "shortName": "Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R12": { "role": "http://vtvtherapeutics.com/role/CommitmentsandContingencies", "longName": "0000012 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R13": { "role": "http://vtvtherapeutics.com/role/Leases", "longName": "0000013 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R14": { "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest", "longName": "0000014 - Disclosure - Redeemable Noncontrolling Interest", "shortName": "Redeemable Noncontrolling Interest", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:MinorityInterestDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R15": { "role": "http://vtvtherapeutics.com/role/StockholdersDeficit", "longName": "0000015 - Disclosure - Stockholders' Deficit", "shortName": "Stockholders' Deficit", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R16": { "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactions", "longName": "0000016 - Disclosure - Related-Party Transactions", "shortName": "Related-Party Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R17": { "role": "http://vtvtherapeutics.com/role/IncomeTaxes", "longName": "0000017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R18": { "role": "http://vtvtherapeutics.com/role/NetLossperShare", "longName": "0000018 - Disclosure - Net Loss per Share", "shortName": "Net Loss per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R19": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments", "longName": "0000019 - Disclosure - Fair Value of Financial Instruments", "shortName": "Fair Value of Financial Instruments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R20": { "role": "http://vtvtherapeutics.com/role/SubsequentEvents", "longName": "0000020 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R23": { "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "vtvt:UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R24": { "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsTables", "longName": "9954472 - Disclosure - Collaboration Agreements (Tables)", "shortName": "Collaboration Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R25": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationTables", "longName": "9954473 - Disclosure - Share-Based Compensation (Tables)", "shortName": "Share-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R26": { "role": "http://vtvtherapeutics.com/role/InvestmentsTables", "longName": "9954474 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R27": { "role": "http://vtvtherapeutics.com/role/LeasesTables", "longName": "9954475 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R28": { "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables", "longName": "9954476 - Disclosure - Redeemable Noncontrolling Interest (Tables)", "shortName": "Redeemable Noncontrolling Interest (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R29": { "role": "http://vtvtherapeutics.com/role/NetLossperShareTables", "longName": "9954477 - Disclosure - Net Loss per Share (Tables)", "shortName": "Net Loss per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R30": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables", "longName": "9954478 - Disclosure - Fair Value of Financial Instruments (Tables)", "shortName": "Fair Value of Financial Instruments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R31": { "role": "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "longName": "9954479 - Disclosure - Description of Business, Basis of Presentation and Going Concern (Detail)", "shortName": "Description of Business, Basis of Presentation and Going Concern (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-84", "name": "vtvt:RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R32": { "role": "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail", "longName": "9954480 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Detail)", "shortName": "Summary of Significant Accounting Policies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-86", "name": "us-gaap:ConcentrationRiskPercentage1", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "div", "us-gaap:ConcentrationRiskCreditRisk", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R33": { "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "longName": "9954481 - Disclosure - Collaboration Agreements - Additional Information (Detail)", "shortName": "Collaboration Agreements - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-89", "name": "vtvt:SaleOfStockConsiderationReceivedOnTransactionGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R34": { "role": "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails", "longName": "9954482 - Disclosure - Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)", "shortName": "Collaboration Agreements - Summary of Contract Liabilities Related to Company's Collaboration Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R35": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "longName": "9954483 - Disclosure - Share-Based Compensation - Additional Information (Detail)", "shortName": "Share-Based Compensation - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "c-113", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-113", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R36": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail", "longName": "9954484 - Disclosure - Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)", "shortName": "Share-Based Compensation - Summary of Stock Award Activity for the Period (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R37": { "role": "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail", "longName": "9954485 - Disclosure - Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)", "shortName": "Share-Based Compensation - Summary of Compensation Expense Related to Grants of Stock Options (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R38": { "role": "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "longName": "9954486 - Disclosure - Investments - Additional Information (Detail)", "shortName": "Investments - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrealizedGainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-129", "name": "us-gaap:UnrealizedGainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R39": { "role": "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "longName": "9954487 - Disclosure - Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)", "shortName": "Investments - Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "vtvt:EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R40": { "role": "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "longName": "9954488 - Disclosure - Commitments and Contingencies - Additional Information (Detail)", "shortName": "Commitments and Contingencies - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-134", "name": "vtvt:PotentialMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-134", "name": "vtvt:PotentialMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R41": { "role": "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails", "longName": "9954489 - Disclosure - Leases - Additional Information (Details)", "shortName": "Leases - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseRenewalTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R42": { "role": "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail", "longName": "9954490 - Disclosure - Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)", "shortName": "Leases - Schedule of Maturities of Lease Liabilities for Operating Leases (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R43": { "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "longName": "9954491 - Disclosure - Redeemable Noncontrolling Interest - Additional Information (Detail)", "shortName": "Redeemable Noncontrolling Interest - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-4", "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "vtvt:RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R44": { "role": "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail", "longName": "9954492 - Disclosure - Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)", "shortName": "Redeemable Noncontrolling Interest - Summary of Net Income Attributable to Vtv Therapeutics Inc (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "vtvt:ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R45": { "role": "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail", "longName": "9954493 - Disclosure - Stockholders' Deficit - Additional Information (Detail)", "shortName": "Stockholders' Deficit - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-147", "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-147", "name": "vtvt:CommonStockAndPreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R46": { "role": "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "longName": "9954494 - Disclosure - Related-Party Transactions - Additional Information (Detail)", "shortName": "Related-Party Transactions - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-168", "name": "vtvt:OwnershipPercentageOfMajorityOwner", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R47": { "role": "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "longName": "9954495 - Disclosure - Income Taxes - Additional Information (Detail)", "shortName": "Income Taxes - Additional Information (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-177", "name": "vtvt:PercentageOfAmountOfCashSavings", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R48": { "role": "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "longName": "9954496 - Disclosure - Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)", "shortName": "Net Loss per Share - Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-10", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-10", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "unique": true } }, "R49": { "role": "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "longName": "9954497 - Disclosure - Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)", "shortName": "Net Loss per Share - Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R50": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail", "longName": "9954498 - Disclosure - Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)", "shortName": "Fair Value of Financial Instruments - Summarizes the Conclusions Reached Regarding Fair Value Measurements (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-198", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-198", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R51": { "role": "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "longName": "9954499 - Disclosure - Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)", "shortName": "Fair Value of Financial Instruments - Fair Value Measurement Inputs and Valuation Techniques (Detail)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-217", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-217", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true, "unique": true } }, "R52": { "role": "http://vtvtherapeutics.com/role/SubsequentEventsDetails", "longName": "9954500 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-133", "name": "us-gaap:StockRepurchasedDuringPeriodValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vtvt-20230930.htm", "first": true }, "uniqueAnchor": null } }, "tag": { "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warranty liability, related party", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r62" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r125", "r135", "r136", "r137", "r153", "r176", "r177", "r184", "r186", "r192", "r193", "r250", "r269", "r271", "r272", "r273", "r276", "r277", "r282", "r283", "r286", "r289", "r296", "r408", "r515", "r516", "r517", "r518", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r549", "r570", "r594", "r614", "r615", "r616", "r617", "r618", "r742", "r759", "r766" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Domain]", "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "vtvt_PercentageOfNonVotingEconomicInterest": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PercentageOfNonVotingEconomicInterest", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Holdings LLC in vTv LLC", "verboseLabel": "Noncontrolling interest ownership percentage", "label": "Percentage Of Non Voting Economic Interest", "documentation": "Percentage of non voting economic interest." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-qualified stock option awards expiration term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r647" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchased during period", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r7", "r73", "r74", "r99", "r525", "r594", "r617", "r664" ] }, "vtvt_CommitmentsAndContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CommitmentsAndContingenciesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Line Items]", "label": "Commitments And Contingencies [Line Items]", "documentation": "Commitments and Contingencies." } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r62" ] }, "vtvt_OneCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "OneCustomerMember", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "One Customer", "label": "One Customer [Member]", "documentation": "One Customer" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average", "label": "Weighted Average [Member]" } } }, "auth_ref": [ "r622", "r623", "r795", "r797", "r800" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Axis]", "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r428", "r429", "r792" ] }, "vtvt_ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "ExchangeOfRedeemableNonControllingInterestToClassACommonStockMember", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exchange of Redeemable Non controlling Interest To Class A Common Stock", "label": "Exchange Of Redeemable Non Controlling Interest To Class A Common Stock [Member]", "documentation": "Exchange of redeemable non controlling interest to class A common stock." } } }, "auth_ref": [] }, "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisLineItems", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]", "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Line Items]", "documentation": "Fair value of assets and liabilities measured on recurring basis." } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r157", "r158", "r278", "r284", "r431", "r629", "r630" ] }, "vtvt_NovoLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "NovoLicenseAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Novo License Agreement", "label": "Novo License Agreement [Member]", "documentation": "Novo license agreement." } } }, "auth_ref": [] }, "vtvt_LicenseFeeReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LicenseFeeReceived", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License Fee Received", "label": "License Fee Received", "documentation": "License Fee Received" } } }, "auth_ref": [] }, "vtvt_CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CollaborativeArrangementContingentConsiderationTransferredAggregateShareValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, contingent consideration", "label": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value", "documentation": "Collaborative Arrangement, Contingent Consideration Transferred, Aggregate Share Value" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income tax provision", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r113", "r122", "r170", "r171", "r199", "r366", "r373", "r497" ] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r377" ] }, "vtvt_NotesReceivableDiscountRate": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "NotesReceivableDiscountRate", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Discount rate", "label": "Notes Receivable, Discount Rate", "documentation": "Notes Receivable, Discount Rate" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., diluted", "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r146", "r175", "r178", "r179", "r180", "r181", "r183", "r186" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Issued Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "vtvt_ReneoPharmaceuticalsIncMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "ReneoPharmaceuticalsIncMember", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reneo", "label": "Reneo Pharmaceuticals Inc [Member]", "documentation": "Reneo Pharmaceuticals Inc." } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease cost", "label": "Operating Lease, Cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r420", "r650" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investment without readily determinable fair values assessed under the measurement alternative:", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r245" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r336" ] }, "vtvt_AtTheMarketOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "AtTheMarketOfferingMember", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "ATM Offering", "label": "At The Market Offering [Member]", "documentation": "At the market offering." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Class A common stock and warrants, net of offering costs", "label": "Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants", "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price." } } }, "auth_ref": [ "r756" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r344" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/Leases" ], "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r417" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r55", "r56", "r324" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": [ "r54" ] }, "vtvt_CognaMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CognaMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cogna", "label": "Cogna [Member]", "documentation": "Cogna" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Awards outstanding, Beginning balance (in shares)", "periodEndLabel": "Awards outstanding, Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r330", "r331" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r467", "r758" ] }, "vtvt_ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "ConsolidationChangesWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Decrease/(Increase) in vTv Therapeutics Inc. accumulated deficit for purchase of vTv LLC Units as a result of common stock issuances", "label": "Consolidation Changes Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent", "documentation": "Consolidation changes wholly owned subsidiary parent ownership interest changes purchase of interest by parent." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r16", "r130", "r153", "r250", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r380", "r383", "r384", "r408", "r651", "r777", "r793", "r794" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Awards outstanding, Beginning balance (in usd per share)", "periodEndLabel": "Awards outstanding, Ending balance (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r330", "r331" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Accounts Payable and Accrued Liabilities, Current", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r14" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r332" ] }, "vtvt_LicenseAgreementObligationsAxis": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LicenseAgreementObligationsAxis", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement Obligations", "label": "License Agreement Obligations [Axis]", "documentation": "License agreement obligations." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r279", "r314", "r315", "r316", "r317", "r318", "r319", "r439", "r440", "r441", "r637", "r638", "r642", "r643", "r644" ] }, "us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue recognized", "label": "Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer", "documentation": "Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606." } } }, "auth_ref": [ "r114", "r784" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r332" ] }, "vtvt_RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "RemainingAvailabilityStockIssuedDuringPeriodValueNewIssues", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining available stock value", "label": "Remaining Availability Stock Issued During Period Value New Issues", "documentation": "Remaining availability under our controlled equity offering sales agreement" } } }, "auth_ref": [] }, "vtvt_G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "G2InvestmentsPurchaseAgreementAndCognaCollaborativeAndLicenseAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement", "label": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement [Member]", "documentation": "G2 Investments Purchase Agreement And Cogna Collaborative And License Agreement" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration Agreements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r115", "r117", "r124" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_MinorityInterestChangeInRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestChangeInRedemptionValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in redemption value of noncontrolling interest", "negatedTerseLabel": "Change in redemption value of noncontrolling interest", "label": "Noncontrolling Interest, Change in Redemption Value", "documentation": "Change in noncontrolling interest during the period as a result of a change in the redemption value of redeemable noncontrolling interest." } } }, "auth_ref": [ "r13", "r42", "r43", "r50" ] }, "vtvt_EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "EquitySecuritiesWithAndWithoutReadilyDeterminableFairValueTableTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Equity Investments with and without Readily Determinable Fair Values Assessed", "label": "Equity Securities With And Without Readily Determinable Fair Value Table [Table Text Block]", "documentation": "Tabular disclosure of investment in equity security with and without readily determinable fair value." } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders\u2019 deficit:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Contract with customer, liability, revenue recognized", "label": "Contract with Customer, Liability, Revenue Recognized", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r312" ] }, "vtvt_PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PeriodUsedToDetermineExchangeValueBasedOnWeightedAveragePriceOfClassCommonStock", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of days used to determine exchange value based on weighted average price of Class A common stock", "label": "Period Used To Determine Exchange Value Based On Weighted Average Price Of Class Common Stock", "documentation": "Period used to determine exchange value based on weighted average price of Class A common stock." } } }, "auth_ref": [] }, "us-gaap_ReceivablesFromStockholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesFromStockholderMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Note Receivable for Common Stock", "label": "Receivables from Stockholder [Member]", "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received." } } }, "auth_ref": [] }, "vtvt_RedeemableNonControllingInterestExchangeAgreementStockConversionRatio": { "xbrltype": "pureItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "RedeemableNonControllingInterestExchangeAgreementStockConversionRatio", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock conversion ratio", "label": "Redeemable Non Controlling Interest Exchange Agreement Stock Conversion Ratio", "documentation": "Redeemable non controlling interest exchange agreement stock conversion ratio." } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r154", "r365", "r367", "r368", "r369", "r372", "r374", "r375", "r376", "r520" ] }, "vtvt_UnauditedInterimFinancialInformationPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "UnauditedInterimFinancialInformationPolicyPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Unaudited Interim Financial Information", "label": "Unaudited Interim Financial Information Policy [Policy Text Block]", "documentation": "Unaudited interim financial information policy." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of securities called by warrants or rights (in shares)", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r297" ] }, "vtvt_LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LicenseAndTechnologyTransferServicesOfChemistryAndManufacturingKnowHowMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License and Technology Transfer Services of Chemistry and Manufacturing Know-How", "label": "License And Technology Transfer Services Of Chemistry And Manufacturing Know How [Member]", "documentation": "License and technology transfer services of chemistry and manufacturing know-how." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficit" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Deficit", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r96", "r152", "r281", "r283", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r295", "r298", "r392", "r597", "r599", "r619" ] }, "vtvt_CommitmentsAndContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CommitmentsAndContingenciesTable", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments And Contingencies [Table]", "label": "Commitments And Contingencies [Table]", "documentation": "Commitments And Contingencies [Table]" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeOperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeOperating", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Non-cash interest income", "label": "Interest Income, Operating", "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities." } } }, "auth_ref": [ "r83", "r571", "r612", "r613", "r662", "r663", "r808" ] }, "vtvt_TemporaryEquityChangeInRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "TemporaryEquityChangeInRedemptionValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in redemption value of noncontrolling interest", "label": "Temporary Equity, Change In Redemption Value", "documentation": "Temporary Equity, Change In Redemption Value" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r15", "r153", "r250", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r380", "r383", "r384", "r408", "r547", "r632", "r665", "r777", "r793", "r794" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r323", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r323", "r325", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r70", "r119" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales / Repurchases", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales", "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r63" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Purchases / Issuance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases", "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r63" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r399" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Unobservable Inputs (Level 3)", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r279", "r314", "r315", "r316", "r317", "r318", "r319", "r398", "r441", "r637", "r638", "r642", "r643", "r644" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Warrants, term", "terseLabel": "Expected life of options in years", "label": "Warrants and Rights Outstanding, Term", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r787" ] }, "us-gaap_RepaymentsOfNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfNotesPayable", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of notes payable", "label": "Repayments of Notes Payable", "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r23" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r3" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r654", "r655", "r656", "r658", "r659", "r660", "r661", "r763", "r764", "r785", "r804", "r806" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r87" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities, redeemable noncontrolling interest and stockholders\u2019 deficit", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r79", "r105", "r488", "r651", "r760", "r772", "r789" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities, Redeemable Noncontrolling Interest and Stockholders\u2019 Deficit", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalent", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r24", "r131", "r626" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r25" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r674", "r685", "r695", "r720" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r132" ] }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputExpectedDividendRateMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Measurement Input, Expected Dividend Rate [Member]", "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year." } } }, "auth_ref": [ "r786" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Compensation Expense Related to Grants of Stock Options", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r54" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r334" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Measurement Input, Price Volatility [Member]", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r786" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses:", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Exercise Price", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to vTv Therapeutics Inc.", "terseLabel": "Net loss", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r81", "r91", "r108", "r128", "r139", "r140", "r143", "r153", "r162", "r164", "r165", "r166", "r167", "r170", "r171", "r182", "r194", "r201", "r205", "r207", "r250", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r395", "r408", "r493", "r569", "r592", "r593", "r633", "r663", "r777" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in usd per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r336" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "parentTag": "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to vTv Therapeutics Inc. common shareholders", "totalLabel": "Net loss attributable to common shareholders of vTv Therapeutics Inc., basic", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r146", "r164", "r165", "r166", "r167", "r173", "r174", "r183", "r186", "r194", "r201", "r205", "r207", "r633" ] }, "us-gaap_GainsLossesOnExtinguishmentOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainsLossesOnExtinguishmentOfDebt", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Loss from G42 Promissory Note early redemption", "label": "Gain (Loss) on Extinguishment of Debt", "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity." } } }, "auth_ref": [ "r4", "r37", "r38" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r671", "r682", "r692", "r717" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r321", "r466", "r504", "r539", "r540", "r602", "r606", "r607", "r608", "r610", "r622", "r623", "r635", "r639", "r645", "r653", "r779", "r795", "r796", "r797", "r798", "r799", "r800" ] }, "us-gaap_ProceedsFromRepaymentOfLoansToPurchaseCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromRepaymentOfLoansToPurchaseCommonStock", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from G42 Promissory Note early redemption related to sale of Class A common stock to collaboration partner", "label": "Proceeds from Repayment of Loans to Purchase Common Stock", "documentation": "Cash inflow from repayment of loans for purchasing common stock." } } }, "auth_ref": [ "r22" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r313", "r321", "r349", "r350", "r351", "r442", "r466", "r504", "r539", "r540", "r602", "r606", "r607", "r608", "r610", "r622", "r623", "r635", "r639", "r645", "r653", "r656", "r773", "r779", "r796", "r797", "r798", "r799", "r800" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Measurement Input, Risk Free Interest Rate [Member]", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r786" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r29" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Total share-based compensation expense", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r353", "r361" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r104", "r133", "r153", "r194", "r202", "r206", "r250", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r379", "r383", "r408", "r484", "r561", "r651", "r665", "r777", "r778", "r793" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities not included in calculation of dilutive net loss per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r187" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r321", "r466", "r504", "r539", "r540", "r602", "r606", "r607", "r608", "r610", "r622", "r623", "r635", "r639", "r645", "r653", "r779", "r795", "r796", "r797", "r798", "r799", "r800" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r265", "r266", "r267", "r268", "r313", "r321", "r349", "r350", "r351", "r442", "r466", "r504", "r539", "r540", "r602", "r606", "r607", "r608", "r610", "r622", "r623", "r635", "r639", "r645", "r653", "r656", "r773", "r779", "r796", "r797", "r798", "r799", "r800" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sale of Class A common stock to collaboration partner, net of offering costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r2" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r358", "r359", "r360", "r525", "r763", "r764", "r765", "r785", "r806" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r729" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r714" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock par value (in usd per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r74" ] }, "vtvt_RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "RedeemableNoncontrollingInterestTemporaryEquityRedemptionValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Redemption amount of noncontrolling interest", "label": "Redeemable Noncontrolling Interest Temporary Equity Redemption Value", "documentation": "Redeemable noncontrolling interest temporary equity redemption value." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r127", "r159", "r160", "r161", "r163", "r169", "r171", "r251", "r252", "r358", "r359", "r360", "r370", "r371", "r385", "r387", "r388", "r390", "r393", "r505", "r507", "r525", "r806" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r731" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r713" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r4", "r36" ] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r57", "r298", "r763", "r764", "r765", "r806" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r734" ] }, "us-gaap_ProceedsFromInterestAndDividendsReceived": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromInterestAndDividendsReceived", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity interest received", "label": "Proceeds from Interest and Dividends Received", "documentation": "Cash received for dividends and interest on the entity's equity and debt investments during the current period." } } }, "auth_ref": [ "r112", "r149" ] }, "us-gaap_PreferredStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockMember", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred Stock", "label": "Preferred Stock [Member]", "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company." } } }, "auth_ref": [ "r654", "r655", "r658", "r659", "r660", "r661", "r804", "r806" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments", "label": "Other Commitments [Domain]", "documentation": "Other future obligation." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r415", "r434" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r714" ] }, "us-gaap_OtherCommitmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Commitments", "label": "Other Commitments [Axis]", "documentation": "Information by type of other commitment." } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r415", "r434" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r735" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r704" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r730" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r711" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r52" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r415", "r434" ] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r708" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r66", "r109", "r144", "r198", "r416", "r579", "r663", "r805" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r7", "r127", "r141", "r142", "r143", "r159", "r160", "r161", "r163", "r169", "r171", "r191", "r251", "r252", "r298", "r358", "r359", "r360", "r370", "r371", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r409", "r410", "r411", "r412", "r413", "r414", "r424", "r505", "r506", "r507", "r525", "r594" ] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Domain]", "label": "Investment, Name [Domain]" } } }, "auth_ref": [ "r247", "r248", "r249" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r735" ] }, "vtvt_SummaryOfSignificantAccountingPoliciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Line Items]", "label": "Summary Of Significant Accounting Policies [Line Items]", "documentation": "Summary of significant accounting policies." } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r704" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r712" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r732" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r704" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r708" ] }, "us-gaap_MinorityInterestDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterest" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Noncontrolling Interest Disclosure [Text Block]", "documentation": "The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r100" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r733" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r707" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r708" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r707" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r734" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r706" ] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Table]", "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r705" ] }, "us-gaap_MinorityInterestLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestLineItems", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Line Items]", "label": "Noncontrolling Interest [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "vtvt_PhaseTwoMultiRegionalClinicalTrialMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PhaseTwoMultiRegionalClinicalTrialMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Phase 2 MRCT", "label": "Phase Two Multi Regional Clinical Trial [Member]", "documentation": "Phase two multi-regional clinical trial." } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r734" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r705" ] }, "vtvt_CinRxMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CinRxMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CinRx", "label": "CinRx [Member]", "documentation": "CinRx" } } }, "auth_ref": [] }, "vtvt_IncreaseInCommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "IncreaseInCommonStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Increase in shares authorized (in shares)", "label": "Increase In Common Stock Shares Authorized", "documentation": "Increase in common stock shares authorized." } } }, "auth_ref": [] }, "us-gaap_MinorityInterestTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterestTable", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Minority Interest [Table]", "label": "Noncontrolling Interest [Table]", "documentation": "Schedule of noncontrolling interest disclosure which includes the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock." } } }, "auth_ref": [ "r20", "r58", "r59", "r84" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r706" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity securities with readily determinable fair value", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r134", "r407", "r627" ] }, "vtvt_MaximumFundingPercentageOfResearchAndDevelopmentMilestones": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "MaximumFundingPercentageOfResearchAndDevelopmentMilestones", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum funding percentage of research and development milestones", "label": "Maximum Funding Percentage Of Research And Development Milestones", "documentation": "Maximum funding percentage of research and development milestones." } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Information [Line Items]", "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r710" ] }, "vtvt_WarrantyLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "WarrantyLiability", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability, related party", "label": "Warranty Liability", "documentation": "Warranty Liability" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Schedule of Stock by Class [Table]", "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity." } } }, "auth_ref": [ "r39", "r44", "r45", "r46", "r47", "r48", "r49", "r97", "r98", "r99", "r135", "r136", "r137", "r192", "r282", "r283", "r284", "r286", "r289", "r294", "r296", "r515", "r516", "r517", "r518", "r639", "r742", "r759" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r735" ] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class Of Stock [Line Items]", "label": "Class of Stock [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r135", "r136", "r137", "r192", "r282", "r283", "r284", "r286", "r289", "r294", "r296", "r515", "r516", "r517", "r518", "r639", "r742", "r759" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensation" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r322", "r326", "r354", "r355", "r357", "r646" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r210", "r641", "r781", "r802", "r803" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r767" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueTable", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Table]", "label": "Equity Securities without Readily Determinable Fair Value [Table]", "documentation": "Disclosure of information about investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r769", "r770", "r771" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r707" ] }, "vtvt_CinRxWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CinRxWarrantsMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "CinRx Warrants", "label": "CinRx Warrants [Member]", "documentation": "CinRx Warrants" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueLineItems", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Securities Without Readily Determinable Fair Value [Line Items]", "label": "Equity Securities without Readily Determinable Fair Value [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r769", "r770", "r771" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r735" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r669" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r86", "r197" ] }, "vtvt_IncomeTaxesTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "IncomeTaxesTable", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Table]", "label": "Income Taxes [Table]", "documentation": "Income taxes." } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r709" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r362" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r735" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r707" ] }, "vtvt_MasterServiceAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "MasterServiceAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Master Service Agreement", "label": "Master Service Agreement [Member]", "documentation": "Master Service Agreement" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r708" ] }, "vtvt_StockIssuedDuringPeriodValuePurchaseAgreement": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "StockIssuedDuringPeriodValuePurchaseAgreement", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock under CinRx purchase agreement, net of offering costs", "label": "Stock Issued During Period, Value, Purchase Agreement", "documentation": "Stock Issued During Period, Value, Purchase Agreement" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r702" ] }, "vtvt_DueToRelatedPartiesMonthlyAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "DueToRelatedPartiesMonthlyAmount", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties, monthly amount", "label": "Due To Related Parties, Monthly Amount", "documentation": "Due To Related Parties, Monthly Amount" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Axis]", "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r51" ] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Stock", "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r125", "r135", "r136", "r137", "r153", "r176", "r177", "r184", "r186", "r192", "r193", "r250", "r269", "r271", "r272", "r273", "r276", "r277", "r282", "r283", "r286", "r289", "r296", "r408", "r515", "r516", "r517", "r518", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r549", "r570", "r594", "r614", "r615", "r616", "r617", "r618", "r742", "r759", "r766" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summarizes the Conclusions Reached Regarding Fair Value Measurements", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r397", "r398" ] }, "us-gaap_InvestmentOwnedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentOwnedBalanceShares", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares held by related party (in shares)", "label": "Investment Owned, Balance, Shares", "documentation": "Number of shares of investment owned." } } }, "auth_ref": [ "r537", "r538", "r603", "r609", "r611", "r656" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss before noncontrolling interest", "terseLabel": "Net loss before noncontrolling interest", "verboseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r128", "r139", "r140", "r147", "r153", "r162", "r170", "r171", "r194", "r201", "r205", "r207", "r250", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r378", "r381", "r382", "r395", "r408", "r482", "r491", "r524", "r569", "r592", "r593", "r633", "r648", "r649", "r664", "r755", "r777" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class of Warrant or Right [Domain]", "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r678", "r689", "r699", "r724" ] }, "us-gaap_NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossIncludingPortionAttributableToNonredeemableNoncontrollingInterest", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "label": "Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest", "documentation": "Amount after income tax of income (loss) including the portion attributable to nonredeemable noncontrolling interest. Excludes the portion attributable to redeemable noncontrolling interest recognized as temporary equity." } } }, "auth_ref": [ "r12", "r101", "r102" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r33", "r34", "r35", "r116", "r118", "r120", "r121" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r741" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r30", "r32", "r64", "r65", "r210", "r620" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r8" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 }, "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Less: net loss attributable to noncontrolling interest", "verboseLabel": "Less: Net loss attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r60", "r101", "r139", "r140", "r170", "r171", "r492", "r755" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r666" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r30", "r32", "r64", "r65", "r210", "r510", "r620" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Denominator:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r667" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r8" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average incremental borrowing rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r422", "r650" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of investments in Anteris Bio, Inc.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r246" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r667" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r678", "r689", "r699", "r724" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r678", "r689", "r699", "r724" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r667" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r75" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r668" ] }, "us-gaap_RedeemableNoncontrollingInterestEquityCarryingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RedeemableNoncontrollingInterestEquityCarryingAmount", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable noncontrolling interest", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Redeemable Noncontrolling Interest, Equity, Carrying Amount", "documentation": "As of the reporting date, the aggregate carrying amount of all noncontrolling interests which are redeemable by the (parent) entity (1) at a fixed or determinable price on a fixed or determinable date, (2) at the option of the holder of the noncontrolling interest, or (3) upon occurrence of an event that is not solely within the control of the (parent) entity. This item includes noncontrolling interest holder's ownership (or holders' ownership) regardless of the type of equity interest (common, preferred, other) including all potential organizational (legal) forms of the investee entity." } } }, "auth_ref": [ "r40", "r41", "r42", "r43" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r667" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Total lease payments", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r423" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r678", "r689", "r699", "r724" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r415", "r434" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r678", "r689", "r699", "r716", "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInTemporaryEquityRollForward", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]", "label": "Increase (Decrease) in Temporary Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A common stock, diluted (in usd per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r145", "r164", "r165", "r166", "r167", "r168", "r176", "r184", "r185", "r186", "r190", "r394", "r395", "r481", "r495", "r631" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]", "documentation": "Information by form of arrangement related to research and development." } } }, "auth_ref": [ "r364", "r783" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r678", "r689", "r699", "r724" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Quoted Prices in Active Markets for Identical Assets (Level 1)", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r279", "r314", "r319", "r398", "r439", "r642", "r643", "r644" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r423" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "2023 (remaining three months)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r791" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/LeasesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Maturities of Lease Liabilities for Operating Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r791" ] }, "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type", "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]", "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others." } } }, "auth_ref": [ "r364", "r783" ] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r433", "r435" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Significant Other Observable Inputs (Level 2)", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r279", "r314", "r319", "r398", "r440", "r637", "r638", "r642", "r643", "r644" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonClassAMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassAMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class A Common Stock", "label": "Common Class A [Member]", "documentation": "Classification of common stock representing ownership interest in a corporation." } } }, "auth_ref": [ "r806" ] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock value", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r74", "r486", "r651" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net Change in fair value included in earnings", "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r402", "r403" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r30", "r32", "r64", "r65", "r210", "r620" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r30", "r32", "r64", "r65", "r210", "r620", "r744" ] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price of warrants or rights (in usd per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r297" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r673", "r684", "r694", "r719" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r671", "r682", "r692", "r717" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A common stock, diluted (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r175", "r186" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 1.0 }, "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of contract liabilities", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r299", "r300", "r311" ] }, "us-gaap_ContractWithCustomerLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails": { "parentTag": "us-gaap_ContractWithCustomerLiability", "weight": 1.0, "order": 2.0 }, "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities, net of current portion", "label": "Contract with Customer, Liability, Noncurrent", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent." } } }, "auth_ref": [ "r299", "r300", "r311" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r790" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average number of vTv Therapeutics Inc. Class A common stock, basic (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r173", "r186" ] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsSummaryofContractLiabilitiesRelatedtoCompanysCollaborationAgreementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Contract liabilities, net of current portion", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r299", "r300", "r311" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining operating lease term", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r421", "r650" ] }, "us-gaap_InterestExpenseOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseOther", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Expense, Other", "documentation": "Amount of interest expense classified as other." } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock warrants", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r654", "r655", "r658", "r659", "r660", "r661" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails", "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of lease liabilities", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r419" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r159", "r160", "r161", "r191", "r468", "r511", "r536", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r563", "r564", "r565", "r566", "r568", "r572", "r573", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r594", "r657" ] }, "us-gaap_NoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestAbstract", "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling Interest [Abstract]", "label": "Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstruments" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value of Financial Instruments", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r396" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r419" ] }, "us-gaap_NetIncomeLossAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAbstract", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Numerator:", "label": "Net Income (Loss) Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShare" ], "lang": { "en-us": { "role": { "terseLabel": "Net Loss per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r172", "r187", "r188", "r189" ] }, "us-gaap_WarrantsAndRightsOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstanding", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants, fair value", "label": "Warrants and Rights Outstanding", "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price." } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r716" ] }, "us-gaap_DepositsAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositsAssetsCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current deposits", "label": "Deposits Assets, Current", "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter." } } }, "auth_ref": [ "r753" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r716" ] }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Contract Liabilities Related to Company's Collaboration Agreements", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": [ "r780" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r676", "r687", "r697", "r722" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r419" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r123", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r624" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements", "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r377" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShortTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestmentsAbstract", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Assets:", "label": "Short-Term Investments [Abstract]" } } }, "auth_ref": [] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r680", "r691", "r701", "r726" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r71", "r363", "r801" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning Balance", "periodEndLabel": "Ending Balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r9" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r728" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Stock Award Activity for the Period", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r10", "r11", "r53" ] }, "us-gaap_InvestmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentPolicyTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for investment in financial asset." } } }, "auth_ref": [ "r496", "r511", "r512", "r513", "r514", "r604", "r605" ] }, "us-gaap_ProceedsFromIssuanceOfDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfDebt", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from debt issuance", "label": "Proceeds from Issuance of Debt", "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt." } } }, "auth_ref": [ "r757" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk percentage", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r30", "r32", "r64", "r65", "r210" ] }, "us-gaap_ConversionOfStockNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of Stock, Name", "label": "Conversion of Stock, Name [Domain]", "documentation": "The unique name of a noncash or part noncash stock conversion." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Significant Accounting Policies", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r92", "r151" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r279", "r314", "r315", "r316", "r317", "r318", "r319", "r398", "r439", "r440", "r441", "r637", "r638", "r642", "r643", "r644" ] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock to collaboration partner, net of offering cost", "verboseLabel": "Stock issued during period", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r7", "r73", "r74", "r99", "r525", "r594", "r615", "r664" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r727" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r320", "r428", "r429", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r542", "r543", "r544", "r545", "r546", "r566", "r568", "r601", "r792" ] }, "us-gaap_ConversionOfStockByUniqueDescriptionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockByUniqueDescriptionAxis", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Conversion Description", "label": "Stock Conversion Description [Axis]", "documentation": "Information by description of stock conversions." } } }, "auth_ref": [ "r26", "r27", "r28" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r397", "r398", "r400", "r401", "r404" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/Investments" ], "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r103", "r110", "r111", "r126", "r213", "r214", "r405", "r406" ] }, "vtvt_CinRxPharmaLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CinRxPharmaLLCMember", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "CinRx Pharma, LLC", "label": "CinRx Pharma, LLC [Member]", "documentation": "CinRx Pharma, LLC" } } }, "auth_ref": [] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r148" ] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A Common Stock to Collaboration Partner (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r7", "r73", "r74", "r99", "r515", "r594", "r615" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r148" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r89", "r90", "r91" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r728" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r377" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r377" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Change in fair value of investments", "terseLabel": "Unrealized gain (loss) on investment", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r4" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r194", "r201", "r205", "r207", "r633" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest, weighted average remaining contractual term", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r347" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r727" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r7", "r19", "r127", "r141", "r142", "r143", "r159", "r160", "r161", "r163", "r169", "r171", "r191", "r251", "r252", "r298", "r358", "r359", "r360", "r370", "r371", "r385", "r386", "r387", "r388", "r389", "r390", "r393", "r409", "r410", "r411", "r412", "r413", "r414", "r424", "r505", "r506", "r507", "r525", "r594" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases [Abstract]", "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestTables" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of Net Income Attributable to Vtv Therapeutics Inc", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table Text Block]", "documentation": "The tabular disclosure of the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent if the ownership interests in a subsidiary changes during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary." } } }, "auth_ref": [ "r6", "r61" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r95", "r263", "r264", "r621", "r774" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r377" ] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Counterparty Name [Axis]", "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r157", "r158", "r278", "r284", "r431", "r628", "r630" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r261", "r262", "r578" ] }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangeDueToNetIncomeAttributableToParentAndEffectsOfChangesNet", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestSummaryofNetIncomeAttributabletoVtvTherapeuticsIncDetail" ], "lang": { "en-us": { "role": { "totalLabel": "Change from net loss attributable to vTv Therapeutics Inc. common shareholders and transfers to noncontrolling interest", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Change Due to Net Income Attributable to Parent and Effects of Changes, Net", "documentation": "This element represents the total net income attributable to the parent for the period and the effect of net changes during the period impacting the parent's ownership interest in a subsidiary as it relates to the total (consolidated) equity attributable to the parent. The changes to the parent's ownership interest in a subsidiary represented by this element did not result in a deconsolidation of the subsidiary from the consolidated financial statements." } } }, "auth_ref": [ "r6", "r50", "r61" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r262", "r578" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income taxes and noncontrolling interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r80", "r107", "r194", "r201", "r205", "r207", "r482", "r490", "r633" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r415", "r434" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r709" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r418" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r754" ] }, "us-gaap_NotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NotesPayableCurrent", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current portion of notes payable", "label": "Notes Payable, Current", "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer." } } }, "auth_ref": [ "r14" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r709" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r17", "r69", "r485", "r548" ] }, "vtvt_OperatingLeasesImputedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "OperatingLeasesImputedInterest", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: imputed interest", "label": "Operating Leases Imputed Interest", "documentation": "Operating leases imputed interest." } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r709" ] }, "us-gaap_NonfinancialLiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonfinancialLiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities:", "label": "Nonfinancial Liabilities Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "verboseLabel": "Inputs utilized in the valuation of warrants", "label": "Warrants and Rights Outstanding, Measurement Input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r401" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Non-qualified stock option awards vesting period", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r646" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "verboseLabel": "Retained earnings (accumulated deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r76", "r99", "r487", "r508", "r509", "r519", "r550", "r651" ] }, "us-gaap_SalesRevenueNetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SalesRevenueNetMember", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue Benchmark [Member]", "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r210", "r743" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average period to recognize unrecognized share-based compensation cost", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r356" ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r129", "r138", "r153", "r250", "r269", "r270", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r379", "r383", "r408", "r651", "r777", "r778", "r793" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r709" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r708" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Recurring", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r396", "r404" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r715" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r31", "r210" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r195", "r196", "r200", "r203", "r204", "r208", "r209", "r210", "r309", "r310", "r468" ] }, "us-gaap_CommonClassBMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonClassBMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/Cover", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Class B Common Stock", "label": "Common Class B [Member]", "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation." } } }, "auth_ref": [ "r806" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r709" ] }, "us-gaap_ProceedsFromCollectionOfNotesReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromCollectionOfNotesReceivable", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from collection of notes receivable", "label": "Proceeds from Collection of Notes Receivable", "documentation": "The cash inflow associated with principal collections from a borrowing supported by a written promise to pay an obligation." } } }, "auth_ref": [ "r21" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Shares sold (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r208", "r468", "r498", "r499", "r500", "r501", "r502", "r503", "r625", "r640", "r652", "r745", "r775", "r776", "r781", "r802" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r709" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r334" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r708" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Investment, Name [Axis]", "label": "Investment, Name [Axis]" } } }, "auth_ref": [ "r247", "r248", "r249" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 11.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r3" ] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, price per share (in usd per shares)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r74", "r549" ] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration received on transaction", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r208", "r468", "r498", "r499", "r500", "r501", "r502", "r503", "r625", "r640", "r652", "r745", "r775", "r776", "r781", "r802" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance, shares (in shares)", "periodEndLabel": "Ending balance, shares (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r7", "r74", "r549", "r567", "r806", "r807" ] }, "vtvt_JDRFInternationalMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "JDRFInternationalMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "JDRF", "label": "J D R F International [Member]", "documentation": "JDRF international." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Related Party Transactions [Abstract]", "label": "Related Party Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r85", "r573" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable and accrued expenses", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r3" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share [Abstract]", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r736" ] }, "us-gaap_CommonStockValueOutstanding": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValueOutstanding", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, value", "label": "Common Stock, Value, Outstanding", "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares." } } }, "auth_ref": [ "r74", "r549" ] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r320", "r428", "r429", "r542", "r543", "r544", "r545", "r546", "r566", "r568", "r601" ] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, capital shares reserved for future issuance (in shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r18" ] }, "vtvt_TypeOneDiabetesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "TypeOneDiabetesMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type 1 Diabetes", "label": "Type One Diabetes [Member]", "documentation": "Type 1 diabetes." } } }, "auth_ref": [] }, "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]", "label": "Organization Consolidation And Presentation Of Financial Statements [Table]", "documentation": "Organization Consolidation And Presentation Of Financial Statements [Table]" } } }, "auth_ref": [] }, "vtvt_NotesReceivableFromCollaborators": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "NotesReceivableFromCollaborators", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Notes receivable recorded at fair value from collaboration partner", "verboseLabel": "Notes receivable for common stock from CinRx purchase agreement", "label": "Notes Receivable from Collaborators", "documentation": "Notes Receivable from Collaborators" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r159", "r160", "r161", "r191", "r468", "r511", "r536", "r541", "r542", "r543", "r544", "r545", "r546", "r549", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r562", "r563", "r564", "r565", "r566", "r568", "r572", "r573", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r594", "r657" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r681", "r689", "r699", "r716", "r724", "r728", "r736" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r736" ] }, "vtvt_WarrantLiabilityRelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "WarrantLiabilityRelatedPartyMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant liability, related party", "label": "Warrant Liability Related Party [Member]", "documentation": "Warrant liability, related party." } } }, "auth_ref": [] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r88" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r3" ] }, "vtvt_VTvLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "VTvLLCMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "vTv Therapeutics LLC", "label": "V Tv L L C [Member]", "documentation": "vTv LLC." } } }, "auth_ref": [] }, "vtvt_SatisfactionOfMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "SatisfactionOfMilestonePaymentMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Satisfaction of Milestone Payment", "label": "Satisfaction Of Milestone Payment [Member]", "documentation": "Satisfaction of milestone payment." } } }, "auth_ref": [] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r716" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets", "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders\u2019 deficit attributable to vTv Therapeutics Inc.", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r74", "r77", "r78", "r94", "r551", "r567", "r595", "r596", "r651", "r665", "r760", "r772", "r789", "r806" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized compensation cost related to non-vested share-based compensation arrangements", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r782" ] }, "vtvt_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]", "documentation": "Organization consolidation and presentation of financial statements." } } }, "auth_ref": [] }, "vtvt_SummaryOfSignificantAccountingPoliciesTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "SummaryOfSignificantAccountingPoliciesTable", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Summary Of Significant Accounting Policies [Table]", "label": "Summary Of Significant Accounting Policies [Table]", "documentation": "Summary Of Significant Accounting Policies [Table]" } } }, "auth_ref": [] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r737" ] }, "vtvt_StockIssuedDuringPeriodSharesPurchaseAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "StockIssuedDuringPeriodSharesPurchaseAgreement", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of Class A common stock under CinRx purchase agreement, net of offering costs (in shares)", "label": "Stock Issued During Period, Shares, Purchase Agreement", "documentation": "Issuance of Class A Common Stock under LPC agreement shares.." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r5", "r483", "r489", "r651" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MajorCustomersAxis", "presentation": [ "http://vtvtherapeutics.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r210", "r641", "r781", "r802", "r803" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r667" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcern" ], "lang": { "en-us": { "role": { "terseLabel": "Description of Business, Basis of Presentation and Going Concern", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r72", "r92", "r93" ] }, "vtvt_DevelopmentalAndRegulatoryMilestonePaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "DevelopmentalAndRegulatoryMilestonePaymentMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Developmental and Regulatory Milestone Payment", "label": "Developmental And Regulatory Milestone Payment [Member]", "documentation": "Developmental and regulatory milestone payment." } } }, "auth_ref": [] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash activities:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "vtvt_LicenseAgreementObligationsDomain": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LicenseAgreementObligationsDomain", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "License Agreement Obligations", "label": "License Agreement Obligations [Domain]", "documentation": "License agreement obligations." } } }, "auth_ref": [] }, "vtvt_MaximumSponsoringContributionAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "MaximumSponsoringContributionAmount", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum contribution amount to clinical trial", "label": "Maximum Sponsoring Contribution Amount", "documentation": "Maximum sponsoring contribution amount." } } }, "auth_ref": [] }, "vtvt_CollaborativeArrangementNoteReceivableDiscountPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CollaborativeArrangementNoteReceivableDiscountPaid", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Discount on note receivable", "label": "Collaborative Arrangement, Note Receivable, Discount Paid", "documentation": "Collaborative Arrangement, Note Receivable, Discount Paid" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofCompensationExpenseRelatedtoGrantsofStockOptionsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "General and administrative", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r82" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r736" ] }, "vtvt_AnterisBioIncMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "AnterisBioIncMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Anteris Bio Inc", "label": "Anteris Bio Inc [Member]", "documentation": "Anteris Bio, Inc." } } }, "auth_ref": [] }, "vtvt_TypeTwoDiabetesMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "TypeTwoDiabetesMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Type 2 Diabetes", "label": "Type Two Diabetes [Member]", "documentation": "Type 2 diabetes." } } }, "auth_ref": [] }, "us-gaap_TransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionDomain", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction", "label": "Transaction [Domain]", "documentation": "Agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r630" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r681", "r689", "r699", "r716", "r724", "r728", "r736" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r738" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in usd per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r737" ] }, "us-gaap_AccountsNotesAndLoansReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableNetCurrent", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts and financing receivable, after allowance for credit loss", "label": "Accounts and Financing Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of accounts and financing receivables, classified as current. Includes, but is not limited to, notes and loan receivable." } } }, "auth_ref": [ "r211", "r634" ] }, "vtvt_AggregateOfferingPriceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "AggregateOfferingPriceOfShares", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate offering price", "label": "Aggregate Offering Price Of Shares", "documentation": "Aggregate offering price of shares." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "vtvt_MFTTPHoldingsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "MFTTPHoldingsLLCMember", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "M&F TTP Holdings LLC", "label": "M F T T P Holdings L L C [Member]", "documentation": "M&F TTP Holdings LLC." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss before noncontrolling interest to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "vtvt_FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "FairValueOfAssetsAndLiabilitiesMeasuredOnRecurringBasisTable", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]", "label": "Fair Value Of Assets And Liabilities Measured On Recurring Basis [Table]", "documentation": "Fair value of assets and liabilities measured on recurring basis table." } } }, "auth_ref": [] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r280", "r294", "r391", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r494", "r636", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r768", "r769", "r770", "r771" ] }, "vtvt_MacAndrewsAndForbesIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "MacAndrewsAndForbesIncorporatedMember", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "MacAndrews & Forbes Incorporated", "label": "Mac Andrews And Forbes Incorporated [Member]", "documentation": "MacAndrews and Forbes Incorporated." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail", "http://vtvtherapeutics.com/role/RedeemableNoncontrollingInterestAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_TransactionTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransactionTypeAxis", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Transaction Type", "label": "Transaction Type [Axis]", "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments." } } }, "auth_ref": [ "r630" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Subsequent Events [Abstract]", "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "vtvt_SaleOfStockConsiderationReceivableTerm": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "SaleOfStockConsiderationReceivableTerm", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration, receivables, payment term", "label": "Sale Of Stock, Consideration, Receivable, Term", "documentation": "Sale Of Stock, Consideration, Receivable, Term" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potentially Dilutive Securities not Included in Calculation of Diluted Net Loss per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r29" ] }, "vtvt_ScheduleOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "ScheduleOfEarningsPerShareLineItems", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share [Line Items]", "label": "Schedule Of Earnings Per Share [Line Items]", "documentation": "Schedule Of Earnings Per Share [Line Items]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r29" ] }, "vtvt_CinRxInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CinRxInvestmentMember", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "CinRx Investment", "label": "CinRx Investment [Member]", "documentation": "CinRx Investment" } } }, "auth_ref": [] }, "vtvt_PotentialMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PotentialMilestonePayment", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Potential milestone payment", "label": "Potential Milestone Payment", "documentation": "Potential milestone payment." } } }, "auth_ref": [] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r739" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r674", "r685", "r695", "r720" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r667" ] }, "vtvt_LPCPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LPCPurchaseAgreementMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "LPC Purchase Agreement", "label": "L P C Purchase Agreement [Member]", "documentation": "LPC purchase agreement." } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r670", "r740" ] }, "vtvt_NotesReceivableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "NotesReceivableCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "G42 Promissory Note receivable", "label": "Notes Receivable, Current", "documentation": "Notes Receivable, Current" } } }, "auth_ref": [] }, "vtvt_SalesBasedMilestonesPaymentMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "SalesBasedMilestonesPaymentMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sales-based Milestones Payment", "label": "Sales Based Milestones Payment [Member]", "documentation": "Sales-based milestones payment." } } }, "auth_ref": [] }, "vtvt_ChangeInFairValueOfWarrantsRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "ChangeInFairValueOfWarrantsRelatedParty", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value of warrants, related party", "label": "Change In Fair Value Of Warrants Related Party", "documentation": "Change in fair value of warrants related party." } } }, "auth_ref": [] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r211", "r212" ] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share of vTv Therapeutics Inc. Class A common stock, basic (in usd per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r145", "r164", "r165", "r166", "r167", "r168", "r173", "r176", "r184", "r185", "r186", "r190", "r394", "r395", "r481", "r495", "r631" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash and cash equivalents", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1", "r89" ] }, "vtvt_LetterAgreementWarrantsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LetterAgreementWarrantsMember", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsFairValueMeasurementInputsandValuationTechniquesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Letter Agreement Warrants", "label": "Letter Agreement Warrants [Member]", "documentation": "Letter agreement warrants." } } }, "auth_ref": [] }, "vtvt_PercentageOfNonVotingEconomicInterestByParent": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PercentageOfNonVotingEconomicInterestByParent", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of non-voting economic interest of vTv Therapeutics Inc in vTv LLC", "label": "Percentage Of Non Voting Economic Interest By Parent", "documentation": "Percentage of non voting economic interest by parent." } } }, "auth_ref": [] }, "vtvt_CollaborativeArrangementRoyaltiesReceivablePeriod": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CollaborativeArrangementRoyaltiesReceivablePeriod", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties receivable, period", "label": "Collaborative Arrangement, Royalties Receivable, Period", "documentation": "Collaborative Arrangement, Royalties Receivable, Period" } } }, "auth_ref": [] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r716" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r670", "r740" ] }, "vtvt_LesseeOperatingLeaseTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LesseeOperatingLeaseTerminationPeriod", "presentation": [ "http://vtvtherapeutics.com/role/LeasesAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, operating lease, termination period", "label": "Lessee, Operating Lease, Termination Period", "documentation": "Lessee, Operating Lease, Termination Period" } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" ], "lang": { "en-us": { "role": { "periodStartLabel": "Total cash and cash equivalents, beginning of period", "periodEndLabel": "Total cash and cash equivalents, end of period", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r24", "r89", "r150" ] }, "vtvt_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour", "crdr": "credit", "calculation": { "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail_1": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://vtvtherapeutics.com/role/LeasesScheduleofMaturitiesofLeaseLiabilitiesforOperatingLeasesDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four", "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r155", "r156", "r428", "r429", "r430", "r431", "r542", "r543", "r544", "r545", "r546", "r566", "r568", "r601" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r670", "r740" ] }, "vtvt_PercentageOfAmountOfCashSavings": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PercentageOfAmountOfCashSavings", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Amount of cash savings percentage", "label": "Percentage Of Amount Of Cash Savings", "documentation": "Percentage of amount of cash savings." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "vtvt_IncomeTaxesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "IncomeTaxesLineItems", "presentation": [ "http://vtvtherapeutics.com/role/IncomeTaxesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes [Line Items]", "label": "Income Taxes [Line Items]", "documentation": "Income taxes." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in usd per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r347" ] }, "vtvt_OwnershipPercentageOfMajorityOwner": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "OwnershipPercentageOfMajorityOwner", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage of majority owner", "label": "Ownership Percentage Of Majority Owner", "documentation": "Ownership percentage of majority owner." } } }, "auth_ref": [] }, "us-gaap_NonrelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonrelatedPartyMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementsofOperationsUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Nonrelated Party", "label": "Nonrelated Party [Member]", "documentation": "Party not related to reporting entity." } } }, "auth_ref": [ "r761", "r762" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r675", "r686", "r696", "r721" ] }, "vtvt_RedeemableNoncontrollingInterestsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "RedeemableNoncontrollingInterestsMember", "presentation": [ "http://vtvtherapeutics.com/role/CondensedConsolidatedStatementofChangesinRedeemableNoncontrollingInterestandStockholdersDeficitUnaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Redeemable Noncontrolling Interest", "label": "Redeemable Noncontrolling Interests [Member]", "documentation": "Redeemable noncontrolling interests." } } }, "auth_ref": [] }, "vtvt_HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "HangzhouZhongmeiHuadongPharmaceuticalCompanyLimitedMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.", "label": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited [Member]", "documentation": "Hangzhou Zhongmei Huadong Pharmaceutical Company Limited." } } }, "auth_ref": [] }, "vtvt_SaleOfStockConsiderationReceivedOnTransactionGross": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "SaleOfStockConsiderationReceivedOnTransactionGross", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of stock, consideration received on transaction, gross", "label": "Sale of Stock, Consideration Received on Transaction, Gross", "documentation": "Sale of Stock, Consideration Received on Transaction, Gross" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r67", "r68", "r574", "r575", "r578" ] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://vtvtherapeutics.com/role/FairValueofFinancialInstrumentsSummarizestheConclusionsReachedRegardingFairValueMeasurementsDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r280", "r294", "r391", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r494", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r768", "r769", "r770", "r771" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r667" ] }, "vtvt_EquityInvestmentsWithReadilyDeterminableFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "EquityInvestmentsWithReadilyDeterminableFairValue", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsScheduleofEquityInvestmentswithandwithoutReadilyDeterminableFairValuesAssessedDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity investment with readily determinable fair value:", "label": "Equity Investments With Readily Determinable Fair Value", "documentation": "Equity investments with readily determinable fair value." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail", "http://vtvtherapeutics.com/role/ShareBasedCompensationAdditionalInformationDetail", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Option", "verboseLabel": "Common stock options granted under the Plan", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "Related-Party Transactions", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r425", "r426", "r427", "r429", "r432", "r521", "r522", "r523", "r576", "r577", "r578", "r598", "r600" ] }, "vtvt_InvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "InvestmentOwnershipPercentage", "presentation": [ "http://vtvtherapeutics.com/role/InvestmentsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method investments, ownership percentage", "label": "Investment Ownership Percentage", "documentation": "Investment ownership percentage." } } }, "auth_ref": [] }, "vtvt_ScheduleOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "ScheduleOfEarningsPerShareTable", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareReconciliationoftheNumeratorandDenominatorUsedintheCalculationofBasicandDilutedNetLossperShareofClassACommonStockDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Earnings Per Share [Table]", "label": "Schedule Of Earnings Per Share [Table]", "documentation": "Schedule Of Earnings Per Share [Table]" } } }, "auth_ref": [] }, "vtvt_CommonStockAndPreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CommonStockAndPreferredStockSharesAuthorized", "presentation": [ "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Capital stock, shares authorized (in shares)", "label": "Common Stock And Preferred Stock Shares Authorized", "documentation": "Common stock and preferred stock shares authorized." } } }, "auth_ref": [] }, "vtvt_OtherIndicationMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "OtherIndicationMember", "presentation": [ "http://vtvtherapeutics.com/role/CommitmentsandContingenciesAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Other Indication", "label": "Other Indication [Member]", "documentation": "Other indication." } } }, "auth_ref": [] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "vtvt_PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "PotentialDevelopmentAndRegulatoryMilestonePaymentsReceivable", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Potential development and regulatory milestone payments", "label": "Potential Development And Regulatory Milestone Payments Receivable", "documentation": "Potential development and regulatory milestone payments receivable." } } }, "auth_ref": [] }, "vtvt_AdjustmentsToTransactionPriceForPerformanceObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "AdjustmentsToTransactionPriceForPerformanceObligations", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to transaction price for performance obligations", "label": "Adjustments To Transaction Price For Performance Obligations", "documentation": "Adjustments to transaction price for performance obligations." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party Transaction [Line Items]", "label": "Related Party Transaction [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r574", "r575", "r578" ] }, "us-gaap_ReceivablesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesFairValueDisclosure", "crdr": "debit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Receivables, fair value disclosure", "label": "Receivables, Fair Value Disclosure", "documentation": "Fair value portion of receivables, including, but not limited to, trade account receivables, note receivables, and loan receivables." } } }, "auth_ref": [ "r106", "r788" ] }, "vtvt_CantorFitzgeraldMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CantorFitzgeraldMember", "presentation": [ "http://vtvtherapeutics.com/role/DescriptionofBusinessBasisofPresentationandGoingConcernDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Cantor Fitzgerald", "label": "Cantor Fitzgerald [Member]", "documentation": "Cantor fitzgerald member." } } }, "auth_ref": [] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r703" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://vtvtherapeutics.com/role/ShareBasedCompensationSummaryofStockAwardActivityforthePeriodDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested and expected to vest (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r347" ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://vtvtherapeutics.com/role/NetLossperShareScheduleofPotentiallyDilutiveSecuritiesnotIncludedinCalculationofDilutedNetLossperShareDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r29" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r677", "r688", "r698", "r723" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://vtvtherapeutics.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "vtvt_G42InvestmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "G42InvestmentsMember", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/RelatedPartyTransactionsAdditionalInformationDetail", "http://vtvtherapeutics.com/role/StockholdersDeficitAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "G42 Investments", "label": "G42 Investments [Member]", "documentation": "G42 Investments" } } }, "auth_ref": [] }, "vtvt_CollaborateArrangementContingentConsiderationTransferredCash": { "xbrltype": "monetaryItemType", "nsuri": "http://vtvtherapeutics.com/20230930", "localname": "CollaborateArrangementContingentConsiderationTransferredCash", "crdr": "credit", "presentation": [ "http://vtvtherapeutics.com/role/CollaborationAgreementsAdditionalInformationDetail" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborate arrangement, contingent consideration transferred, cash", "label": "Collaborate Arrangement, Contingent Consideration Transferred, Cash", "documentation": "Collaborate Arrangement, Contingent Consideration Transferred, Cash" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "(3)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3A", "Subparagraph": "16(c)", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-2" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "50", "Section": "40", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481303/470-50-40-4" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(CFRR 211.02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(12)(c)", "Section": "S99", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "(16)(c)", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "14", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "480", "SubTopic": "10", "Subparagraph": "15", "Paragraph": "3A", "Section": "S99", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-3A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4M", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "940", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//940-320/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//942-320/tableOfContent" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//946-320/tableOfContent" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-16" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479428/808-10-45-3" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "(b)", "Publisher": "SEC" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(f)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "12", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "19", "Subparagraph": "(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "39", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480228/946-830-45-39" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r742": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 72 0001641489-23-000070-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001641489-23-000070-xbrl.zip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end

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